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Chapter 1
Introduction and outline of this thesis
Partly based on: Clinical applications of population pharmacokinetic 
models of antibiotics: challenges and perspectives 
F. de Velde
J.W. Mouton
B.C.M. de Winter
T. van Gelder
B.C.P. Koch
Pharmacological Research. 2018; 134: 280-288
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Bacterial infections, antibiotics and resistance
Infectious diseases are caused by pathogenic organisms, such as bacteria, viruses, 
fungi or parasites. Many of these organisms live in and on our bodies and are 
normally harmless, but may induce illness under certain conditions. Antibiotics 
can be used to treat infections caused by bacteria. Unfortunately, bacteria may 
become resistant to antibiotics that once could successfully treat the microbe. 
In case of antibiotic resistance, susceptible bacteria are killed while the resistant 
bacteria survive and selective pressure on resistance genes emerges [2]. Due a 
high selective pressure via overuse and misuse of antibiotics, antibiotic resistance 
is a growing problem worldwide [3]. The estimated number of deaths in Europe 
due to resistant bacteria was 33,000 in 2015 and this has more than doubled since 
2007 [4]. Resistant bacteria are more difficult to treat than non-resistant bacteria 
and require alternative antibiotics or higher doses [5]. There is an urgent need for 
novel antibiotic treatments to combat these resistant bacteria, but few new drugs 
make it to the market due to clinical trial hurdles such as an insufficient number of 
patients infected with the resistant bacterial species [6-8]. Another reason is that it 
is more difficult to bear the costs of antibacterial drug development compared to, 
for example, anticancer or orphan drugs, due to the low-price generic market of 
antibiotics [9]. Importantly, suboptimal dosing of antibiotics has an important part 
in several failures of antibiotic drug development programs, even in late phases of 
these programs [10]. Underdosing decreases clinical outcomes of infections [11-14] 
and promotes emergence of resistance [15].  A “one dose fits all” strategy in highly 
variable populations is one of the reasons for inadequate antibiotic therapy [16]. 
The increasing global resistance and difficulties experienced during antibiotic 
development  emphasize the importance of optimizing dosing regimens of old 
and new antibiotics in order to maximize clinical outcomes of infections and 
minimize emergence of resistance and toxicity [15]. Pharmacometric modelling of 
the pharmacokinetic and pharmacodynamic (PK/PD) characteristics of antibiotics 
can support the optimization of dosing regimens in drug development programs 
and can also be used for evaluation of dosing strategies of old antibiotics and 
individualisation of therapy [15]. In short, PK studies focus on the processes that 
describe what the body does to a drug (i.e. absorption, distribution, metabolism 
and excretion processes) and PD studies enclose what the drug does to the 
body (i.e. concentration-effect relationships). Population PK models describe 
concentration-time profiles of a specified population and explain PK variability. 
During new drug development, population PK models of antibiotics are recommended 
for optimizing dosing regimens, for example in European [17] and American 
[18] guidelines. However, these regulatory guidelines did not yet exist for many 
currently used antibiotics which were developed and approved decades ago when 
PK/PD principles were largely unknown and sophisticated population PK modelling 
techniques did not exist [19]. Nowadays, some of these old antibiotics are studied 
again and an increasing number of population PK models are published with new 
dosing recommendations for specific populations [20-25]. Because a coordinated 
redevelopment procedure for old drugs such as antibiotics does not yet exist [19], 
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1the methods used to establish these dosing strategies are highly variable and the evidence for clinical implementation can therefore be unclear.  
 
Aims of this thesis
This thesis is focused on dosing evaluation of old antibiotics using population PK 
models. More specifically, the aims of this thesis are:
1. Developing population PK models for two old beta-lactam antibiotics and 
one old beta-lactamase inhibitor, and subsequent evaluate dosing using these 
models. 
2. Comparing different population PK modelling approaches.
3. Identifying challenges in the process of antibiotic dosing evaluation using 
population PK models. 
4. Establishing recommendations for the use of population PK models in clinical 
practice. 
The introduction of this thesis continues with providing background information 
on PK/PD principles of antibiotics and PK modelling and simulation, followed by an 
outline of all chapters of the thesis. 
PK/PD principles of antibiotics
PK/PD of antibiotics describe the relationship between efficacy, the in vitro 
susceptibility of a drug to the microorganism (usually expressed as MIC, minimal 
inhibitory concentration) and the in vivo exposure to the drug, which relies on the 
PK and the dose (Figure 1) [15]. From this relationship follows that if the MIC is 
known, the microbiological and clinical outcome of treatment is determined by the 
individual PK profile and dose. To predict that exposure, population PK models can 
and are being used. The quality of the model used will determine the value of the 
estimated exposure.
Figure 1. Relationship between MIC, PK, dose and drug effects.
MIC
(susceptibility of a 
drug in vitro)
Microbiological cure
(antimicrobial efficacy of 
the drug)
Clinical cure
(effect on host)
PK
(exposure to the 
drug in vivo)
Dosing 
regimen
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PK/PD indices describe exposure-response relationships. A PK/PD index represents 
the relationship between a PK measure of exposure to the antibacterial agents (such 
as AUC, area under the concentration-time curve, or Cmax, maximal concentration) 
and a PD measure of bacterial susceptibility to the drug (usually the MIC). Only 
the non-protein-bound fraction of an antibiotic is microbiologically active and can 
penetrate into the extravascular space [26]. Therefore, PK/PD indices are based on 
unbound concentrations. 
For each antibiotic, different PK/PD indices (such as AUC/MIC, Cmax/MIC and T>MIC, 
Figure 2) are tested in preclinical studies to identify which PK/PD index is most 
likely to be associated with efficacy. PK/PD indices are different for each antibacterial 
class [27]. For example, the PK/PD index of beta-lactams is the percentage of the 
dosing interval that the unbound (free) antibiotic concentration is above the MIC 
(%fT>MIC) [27] and the PK/PD index of vancomycin is fAUC0-24/MIC [28].   
Figure 2. Concentration-time curve showing the pharmacokinetic parameters Cmax (maximal 
concentration) and AUC (shaded area) and the PK/PD index Time>MIC.
The PK/PD target is the minimal PK/PD index value that ensures a high probability of 
successful treatment [15]. There is no unique PK/PD target value per antibiotic. PK/
PD target values vary between the chosen endpoints such as stasis, maximal kill or 
resistance suppression (for preclinical studies) and microbiological or clinical cure 
(for clinical studies) [16, 29]. To attain a specific PK/PD target, the exposure of the 
microorganism to the antibacterial agent needs to be adequate. This exposure is 
dependent on the dose and PK properties of the drug. 
The optimal PK/PD target value is still not clearly defined for all antibiotics [19, 
30], in part because this depends on its clinical indication or use. For example, for 
beta-lactam antibiotics, used targets vary between 30-100% fT>MIC and 50-100% 
fT>4xMIC, dependent on several factors, such as the immune status/illness of the 
patient [16, 31, 32]. Small studies suggest that the required targets of the different 
beta-lactam subgroups are the highest in cephalosporines, followed by penicillins 
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1and then carbapenems [16, 27]. Importantly, preclinical derived PK/PD target values differ from clinical derived values in critically ill patients [16]. Currently, there is a 
trend towards the use of more conservative targets for critically ill patients than for 
the less critically ill, for example the use of a target belonging to stasis or 1-log10 
reduction in colony forming units for less severe infections or to a 2-log10 reduction 
for more severe infections [33]. 
Information about the PK/PD target, PK characteristics, exposure, variability and 
dosing regimens is needed to set clinical breakpoints. Clinical breakpoints are MICs 
that define microorganisms as susceptible or resistant to specific antibiotics [34]. 
Clinical breakpoints determine the antibacterial choice during empirical and culture-
driven therapy. The epidemiological cut-off value (ECOFF) is the highest MIC for 
“wild type” organisms devoid of phenotypically detectable resistance [35]. 
PK analyses and simulations
PK describes the behaviour of drugs and their metabolites in the body in terms of 
absorption, distribution, metabolism and elimination. Concentration-time courses 
are related to the dose received and subject characteristics. PK analysis methods 
can be distinguished between individual and population approaches, which can be 
further classified as parametric, nonparametric, maximum likelihood and Bayesian 
methods (Figure 3). Simulations of population PK models are used to evaluate these 
models (internal or external validation) or to evaluate dosing regimens. For the 
latter purpose, the probability of target attainment (PTA) can be calculated.
Individual PK methods
Individual PK methods analyse concentration-time courses per individual subject. 
Examples of individual PK methods are the non-compartmental analysis and the 
standard-two-stage method. Non-compartmental analysis (NCA) is the simplest 
individual PK method. NCA applies no model to the data but connects the observed 
individual concentrations by linear interpolation. The standard two-stage (STS) 
method fits the data of each individual separately into a compartmental model 
equation and then combines individual parameter estimates to generate mean 
(population) parameters and standard deviations [36]. 
Individual PK methods are relatively simple techniques and useful to explore datasets 
and calculate PK measures as AUC and Cmax. However, they don’t provide detailed 
information (e.g. covariates) on variation of PK parameters in a population. Another 
disadvantage is that these methods require intensive sampling. Examples of individual PK 
software packages are Phoenix WinNonlin and PKSolver [37]. In addition to NCA and/
or STS methods, some of the individual PK packages also offer population PK methods.
Population PK methods
Population PK methods analyse concentration-time courses of a population as a 
whole. During the modelling process, several models with different numbers of 
compartments, types of elimination and variability are evaluated. The final model 
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1provides mean population PK parameters (e.g. volume of distribution, clearance) and describes variability between subjects (inter-individual or between-subject variability, 
BSV) and variability between the doses of an individual subject (intra-individual or 
between-occasion variability, BOV). The observed variability is explained by 
covariates (subject characteristics as body weight, renal function or age). Residual 
variability (e.g. assay variance or sampling uncertainties) is also taken in account [36, 
38]. Thorough model evaluation and validation is important to deliver a robust and 
reliable model. Examples of model evaluation/validation methods and techniques are 
objective functions based on likelihood (e.g. AIC, Akaike Information Criterium), 
graphical plots, bootstrapping to estimate parameter precision, simulation-based 
diagnostics (e.g. VPC, Visual Predictive Check, or NPDE, Normalized Prediction 
Distribution Error) and external validation, when the developed model is applied to 
a new dataset [38, 39].  
Traditionally, population PK parameters were estimated by the standard two-stage 
“individual” approach, which cannot describe and explain the types of variability. 
More sophisticated population PK methods involve the development of nonlinear 
mixed-effect models. These models are called “nonlinear” because PK equations 
are nonlinear. “Mixed-effect” implies the description of fixed effects (which are the 
same for each individual) and random (individual-specific) effects. 
Population PK modelling methods can be statistically classified as either parametric 
or nonparametric. The parametric and nonparametric classifications can both be 
divided into maximum likelihood or Bayesian approaches [40, 41]. It is still unknown 
which population PK approach (e.g. parametric vs nonparametric) is most suitable 
for specific research questions. The different modelling approaches will be briefly 
described below.
Parametric maximum likelihood methods
Parametric maximum likelihood methods assume that the population parameter 
distribution is known with unknown population parameters [41]. These methods 
estimate the set of parameters that maximize the joint likelihood of observations. 
Most of the current software packages for population PK modelling are parametric 
maximum likelihood methods (e.g. Monolix, NONMEM and Phoenix NLME). Each 
package offers one or more mathematic algorithms to facilitate maximum likelihood 
modelling, such as FOCE, SAEM or QRPEM [42]. 
Nonparametric maximum likelihood methods
In contrast to parametric methods, nonparametric methods make no assumption 
about the shapes of the underlying parameter distributions, which is theoretically an 
advantage to detect subpopulations. Nonparametric methods use an exact likelihood 
function while most parametric methods use an approximation. A drawback of some 
nonparametric methods is that confidence intervals about parameter estimates are 
not easily determined [40, 41]. An example of a nonparametric maximum likelihood 
method is the NPAG algorithm in the software package Pmetrics (former MM-
USCPACK / USC*PACK, previously based on the NPEM algorithm) [43].
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Bayesian methods
The parametric iterative two-stage Bayesian (ITB) method uses mean parameter 
values and their standard deviations (obtained from a STS method or any reasonable 
initial guess) as Bayesian priors. Subsequently, individual patient data are examined 
to obtain Bayesian posterior parameter values based on the maximum a posteriori 
probability (MAP) Bayesian procedure. The mean parameter values can again be 
calculated and used as Bayesian priors to obtain new Bayesian posterior values. This 
iterative process is repeated until the difference between population and estimated 
values reaches a minimum value [44, 45]. Examples of software packages including 
the ITB method are the KinPop module in MW\PHARM [45] and the ITB algorithm 
in Pmetrics, which is mainly used to estimate parameter ranges to be passed to 
NPAG [43].  A nonparametric Bayesian approach is currently not available in a 
software package [40].
Simulations
For clinical applications, simulations using population PK models are generally 
performed for two purposes: 1) model evaluation and 2) dosing evaluation [36]. 
For model evaluation, concentration-time data are simulated and compared with a 
subset of the original dataset (internal validation) or new data (external validation). 
For dosing evaluation, concentration-time data are simulated for several dosing 
regimens to study the exposure and probability of target attainment, for example in 
specific subpopulations such as ICU-patients or patients with renal impairment [36, 
46], or during the process of setting breakpoints [34].
Stochastic simulating from population PK models with fixed-effect and random-effect 
parameters is more complex than non-stochastic simulating from simple fixed-effect 
models. The stochastic Monte Carlo simulation (MCS) can handle random variability 
and is therefore the most used simulation type for population PK models [46, 47]. 
Probability of target attainment (PTA)
MCS based on population PK models can be used to calculate the PTA of specific 
PK/PD targets for several dosing regimens and a range of MICs [34, 46]. Different 
methods are used to present the PTA results. One option is to plot (Figure 4a) or 
tabulate the PTA of a specific PK/PD target as a function of the MIC. Several dosing 
regimens can be included in such a graph (or table). A disadvantage of this approach 
is that only one PK/PD target value can be included per graph. Since the optimal PK/
PD target values are not defined for all antibiotics and indications, it may be useful 
to display several target values in one graph. The latter is possible in the graph 
shown in Figure 4b: the PK/PD target (here: %fT>MIC) is plotted as a function of 
the MIC for a specific dosing regimen. By including the mean (or median) of the 
population and the confidence interval (CI) estimations (percentiles) in the graph, 
the PTA’s for several PK/PD target values can be read. The lower boundary of a 
CI of 95% corresponds to a PTA of 97.5%. For example, in Figure 4b, the PTA for 
40% fT>MIC is 97.5% for 250mg q8h and an MIC of 0.25 mg/L. EUCAST (European 
committee on antimicrobial susceptibility testing) uses such graphs to determine 
breakpoints [34].  
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Figure 4a. PTA for various amoxicillin dosing regimens to reach the target 40% fT>MIC for 
a range of MICs. Modified from de Velde et al [48]. 
suspension data resulted in a time-constrainedMichaelis–Menten
absorption model with lag time followed by a storage compart-
ment and two disposition compartments.13,14 In our population
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the data better than models with first- or zero-order absorption,
as expected given previous studies.11–14 Similar to the two oral
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Figure 4b. %fT>MIC displayed as a function of the MIC for amoxicillin 250 mg q8h. The 
middle line represents the values for the median of the population and the surrounding lines 
indicate the 1st, 5th, 95th and 99th percentiles, obtained by 5000 Monte Carlo simulations. 
The arrows indicate the breakpoint that correspond to the 95% CI (97.5% PTA) for 40% 
fT>MIC. Modified from de Velde et al [48]. 
Current antibacterial drug development guidelines 
Until 1995, new medicinal products were approved by national authorities 
without centralized European guidelines, leading to different summary of product 
characteristics (SmPCs) in several European countries [49]. Since the start of 
the European Agency for the Evaluation of Medicinal Products (EMEA, currently 
known as the European Medicines Agency, EMA) in 1995, drugs are evaluated and 
authorized at a European level. The first EMEA notes to guidance on antibacterial drug 
suspension data re ulted in a time-constrainedMich elis–Menten
absorption model with lag time followed by a storage compart-
ment and two disposition compartments.13,14 In our opulation
PK analysis, models with Michaelis–M nten absorption described
the data better than models with fir t- or zero-order absorption,
as expected given previous studies.11–14 Similar to the two oral
0%
MIC (mg/L)
500 mg q12h
0.
01
5
0.
03
0.
06
0.
12
5
0.
25 0.
5 1 2 4 8 16 32 64
20%
fT
>M
IC
40%
60%
80%
100%
0%
MIC (mg/L)
250 mg q8h
0.99
0.95
0.5
0.05
0.01
0.
01
5
0.
03
0.
06
0.
12
5
0.
25 0.
5 1 2 4 8 16 32 64
20%
fT
>M
IC
40%
60%
80%
100%
0%
MIC (mg/L)
875 mg q12h
0.
01
5
0.
03
0.
06
0.
12
5
0.
25 0.
5 1 2 4 8 16 32 64
20%
fT
>M
IC
40%
60%
80%
100%
0%
MIC (mg/L)
500 mg q8h
0.
01
5
0.
03
0.
06
0.
12
5
0.
25 0.
5 1 2 4 8 16 32 64
20%
fT
>M
IC
40%
60%
80%
100%
0%
MIC (mg/L)
500 mg q6h
0.
01
5
0.
03
0.
06
0.
12
5
0.
25 0.
5 1 2 4 8 16 32 64
20%
fT
>M
IC
40%
60%
80%
100%
0%
MIC (mg/L)
750 mg q8h
0.
01
5
0.
03
0.
06
0.
12
5
0.
25 0.
5 1 2 4 8 16 32 64
20%
fT
>M
IC
40%
60%
80%
100%
0%
MIC (mg/L)
875 mg q8h
0.
01
5
0.
03
0.
06
0.
12
5
0.
25 0.
5 1 2 4 8 16 32 64
20%
fT
>M
IC
40%
60%
80%
100%
0%
MIC (mg/L)
1000 mg q8h
0.
01
5
0.
03
0.
06
0.
12
5
0.
25 0.
5 1 2 4 8 16 32 64
20%
fT
>M
IC
40%
60%
80%
100%
Figure 5. %fT.MIC display d as a function of the MIC for several dosing regimens.
de Velde et al.
2914
 at E
rasm
us U
niversiteit R
otterdam
 on O
ctober 18, 2016
http://jac.oxfordjournals.org/
D
ow
nloaded from
 
16 | Chapter 1
development [50] and on the role of pharmacodynamics in antibacterial SmPCs [51] 
were approved in 1997. These notes to guidance [50, 51] were further developed 
in the following years [52, 53] and subsequently evolved to EMA guidelines [17, 54]. 
The role of PK/PD in antibacterial development has been increased during the last 
two decades. The current guidelines [17, 54] state that PK/PD analyses may be used 
to select dose regimens and that it may be possible to omit clinical dose-finding 
studies in case of a clear PK/PD relationship and convincing PK/PD analyses. In short, 
the PK/PD characteristics of the antibiotic may be investigated during the different 
phases of drug development as follows [8, 17, 33]:
1. Nonclinical in vitro PK/PD studies. In vitro models (static concentration time-
kill assays, dynamic one-compartment models and dynamic two-compartment 
models such as a hollow fiber infection model) may be used to investigate 
PK/PD relationships, to assess multiple different PK profiles and to study the 
relationship between rates of emergent resistance, drug exposure and duration 
of therapy. 
2. Nonclinical in vivo PK/PD studies. Animal studies (such as the murine thigh 
model or murine lung infection model) are used to further characterize the PK/
PD in vivo. Population PK modelling and simulation may be used to calculate 
PTA’s for several dosing regimens. 
3. Clinical phase I studies. The PK is explored in healthy volunteers for several 
dosing regimens. Population PK modelling and simulation may be used to select 
one or two candidate dosing regimens with high PTA’s. 
4. Clinical phase II and III studies. The population PK models are further 
developed using PK data of the target population to confirm adequate drug 
exposure and to identify subpopulations with increased risk of toxicity or 
failure. 
Outline of this thesis
The majority of the research in this thesis was performed as part of the STAT-Net 
group of the Combatting Bacterial Resistance in Europe (COMBACTE) consortium 
(www.combacte.com), which was established by the European Innovative Medicines 
Initiative (IMI). The general objective of STAT-Net was to deliver strategies that may 
yield more efficient clinical trial programs while focusing on 3 pillars: improved PK/
PD modelling of old and new antibiotics, enhanced end points and innovative trial 
designs. 
Chapter 2 focuses on PK/PD of amoxicillin and amoxicillin/clavulanic acid. Both 
amoxicillin alone and amoxicillin/clavulanic acid were developed and approved more 
than 30 years ago when PK/PD principles were largely unknown. Amoxicillin is a 
beta-lactam antibiotic of the penicillin group which is frequently combined with the 
beta-lactamase inhibitor clavulanic acid to target beta-lactamase producing bacteria. 
Beta-lactamases are enzymes which make bacteria resistant against beta-lactam 
antibiotics. Population PK modelling and simulation of oral amoxicillin (Chapter 
2.1) and oral clavulanic acid (Chapter 2.2) were performed using data of a phase I 
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1trial in healthy volunteers. In the original study report of this phase I trial conducted in 1993, only individual (non-compartmental) PK methods were used to analyse 
the data. We reanalysed these data using population PK modelling and simulation 
methods with the objectives to estimate the exposure of amoxicillin and clavulanic 
acid and the variability in the population and to compare the probability of target 
attainment for several dosing regimens. Chapter 2.3 describes amoxicillin PK in 
patients with and without renal impairment treated with intravenous amoxicillin/
clavulanic acid. This analysis was conducted as an addendum to the EXPAT study, a 
prospective observational PK/PD study of several antibiotics in the Erasmus Medical 
Center. Our objectives were to determine if the predefined PK/PD target was 
achieved with local dosing guidelines in patients with and without renal impairment 
and to compare concentrations and half-life’s.
Chapter 3 is focused on the antibiotic imipenem, an intravenous beta-lactam 
antibiotic approved in the 1980s. Population PK modelling and simulation of 
imipenem in critically ill patients was performed using data of a prospective cohort 
study conducted by a Swiss STAT-Net partner. A parametric and a nonparametric 
PK model were build using the same data with the objective to investigate the 
advantages and disadvantages of both population PK modelling methods in practice 
(Chapter 3.1). In the second study (Chapter 3.2), the external validation and 
simulation results were compared using both population PK models described in 
Chapter 3.1. 
Chapter 4 includes STAT-Net’s white paper with recommendations about design 
and analysis strategies to support the evaluation of new and old antibiotics. The first 
2 recommendations were written by the author of this thesis. 
Chapter 5 describes the challenges of population PK models in clinical 
practise, which were noticed during the research of this thesis about dosing 
evaluation of old antibiotics, but are also applicable for other clinical applications 
such as settings clinical breakpoints and therapeutic drug monitoring. 
Chapter 5 is based on the second part of our review about challenges and 
perspectives of population PK models of antibiotics in clinical practise, while 
the first part of this review is implemented in the introduction of this thesis. 
Finally, the results and conclusions from the studies described in this thesis are 
summarized and discussed in Chapter 6 and the perspectives for future research 
and clinical recommendations are included in Chapter 7. 
18 | Chapter 1
References
[1] Jelliffe R, Van Guilder M, Leary R, Schumitzky A, Wang X, Vinks AA. Nonlinear parametric 
and nonparametric population pharmacokinetic modeling on a supercomputer, Technical 
Report 99-1. University of Southern California, School of Medicine, Laboratory of 
Applied Pharmacokinetics, http://www.lapk.org/pubsinfo/TechReports/TR99-1.pdf1999.
[2] Levy SB, Marshall B. Antibacterial resistance worldwide: causes, challenges and responses. 
Nature Medicine. 2004;10:S122-9.
[3] Davies J, Davies D. Origins and evolution of antibiotic resistance. Microbiology and 
molecular biology reviews : MMBR. 2010;74:417-33.
[4] Cassini A, Högberg LD, Plachouras D, Quattrocchi A, Hoxha A, Simonsen GS, Colomb-
Cotinat M, Kretzschmar ME, Devleesschauwer B, Cecchini M, Ouakrim DA, Oliveira 
TC, Struelens MJ, Suetens C, Monnet DL, Strauss R, Mertens K, Struyf T, Catry B, 
Latour K, Ivanov IN, Dobreva EG, Tambic Andraševic A, Soprek S, Budimir A, Paphitou 
N, Žemlicková H, Schytte Olsen S, Wolff Sönksen U, Märtin P, Ivanova M, Lyytikäinen 
O, Jalava J, Coignard B, Eckmanns T, Abu Sin M, Haller S, Daikos GL, Gikas A, Tsiodras 
S, Kontopidou F, Tóth Á, Hajdu Á, Guólaugsson Ó, Kristinsson KG, Murchan S, Burns 
K, Pezzotti P, Gagliotti C, Dumpis U, Liuimiene A, Perrin M, Borg MA, de Greeff SC, 
Monen JCM, Koek MBG, Elstrøm P, Zabicka D, Deptula A, Hryniewicz W, Caniça M, 
Nogueira PJ, Fernandes PA, Manageiro V, Popescu GA, Serban RI, Schréterová E, Litvová 
S, Štefkovicová M, Kolman J, Klavs I, Korošec A, Aracil B, Asensio A, Pérez-Vázquez 
M, Billström H, Larsson S, Reilly JS, Johnson A, Hopkins S. Attributable deaths and 
disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the 
EU and the European Economic Area in 2015: a population-level modelling analysis. The 
Lancet Infectious Diseases. 2019;19:56-66.
[5] Craig WA. Antimicrobial resistance issues of the future. Diagnostic Microbiology and 
Infectious Disease. 1996;25:213-7.
[6] Bettiol E, Rottier WC, Del Toro MD, Harbarth S, Bonten MJ, Rodriguez-Bano J, 
consortium C. Improved treatment of multidrug-resistant bacterial infections: utility of 
clinical studies. Future Microbiology. 2014;9:757-71.
[7] Theuretzbacher U, Gottwalt S, Beyer P, Butler M, Czaplewski L, Lienhardt C, Moja L, 
Paul M, Paulin S, Rex JH, Silver LL, Spigelman M, Thwaites GE, Paccaud JP, Harbarth 
S. Analysis of the clinical antibacterial and antituberculosis pipeline. Lancet Infectious 
Diseases. 2019;19:e40-e50.
[8] Rizk ML, Bhavnani SM, Drusano G, Dane A, Eakin AE, Guina T, Jang SH, Tomayko 
JF, Wang J, Zhuang L, Lodise TP. Considerations for Dose Selection and Clinical 
Pharmacokinetics/Pharmacodynamics for the Development of Antibacterial Agents. 
Antimicrobial Agents and Chemotherapy. 2019;63.
[9] Bax R, Green S. Antibiotics: the changing regulatory and pharmaceutical industry 
paradigm. Journal of Antimicrobial Chemotherapy. 2015;70:1281-4.
[10] Ambrose PG. Antibacterial drug development program successes and failures: a 
pharmacometric explanation. Current Opinion in Pharmacology. 2017;36:1-7.
19Introduction and outline of this thesis |
1[11] Duszynska W, Taccone FS, Switala M, Hurkacz M, Kowalska-Krochmal B, Kubler A. Continuous infusion of piperacillin/tazobactam in ventilator-associated pneumonia: 
a pilot study on efficacy and costs. International Journal of Antimicrobial Agents. 
2012;39:153-8.
[12] Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ. Pharmacodynamics 
of intravenous ciprofloxacin in seriously ill patients. Antimicrobial Agents and 
Chemotherapy. 1993;37:1073-81.
[13] Bhavnani SM, Rubino CM, Hammel JP, Forrest A, Dartois N, Cooper CA, Korth-Bradley 
J, Ambrose PG. Pharmacological and patient-specific response determinants in patients 
with hospital-acquired pneumonia treated with tigecycline. Antimicrobial Agents and 
Chemotherapy. 2012;56:1065-72.
[14] Rayner CR, Forrest A, Meagher AK, Birmingham MC, Schentag JJ. Clinical 
pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use 
programme. Clinical Pharmacokinetics. 2003;42:1411-23.
[15] Mouton JW, Ambrose PG, Canton R, Drusano GL, Harbarth S, MacGowan A, 
Theuretzbacher U, Turnidge J. Conserving antibiotics for the future: new ways to use 
old and new drugs from a pharmacokinetic and pharmacodynamic perspective. Drug 
Resist Updat. 2011;14:107-17.
[16] Roberts JA, Abdul-Aziz MH, Lipman J, Mouton JW, Vinks AA, Felton TW, Hope WW, 
Farkas A, Neely MN, Schentag JJ, Drusano G, Frey OR, Theuretzbacher U, Kuti JL, 
International Society of Anti-Infective P, the P, Pharmacodynamics Study Group of the 
European Society of Clinical M, Infectious D. Individualised antibiotic dosing for patients 
who are critically ill: challenges and potential solutions. Lancet Infectious Diseases. 
2014;14:498-509.
[17] European Medicines Agency. Guideline on the use of pharmacokinetics and 
pharmacodynamics in the development of antimicrobial medicinal products (EMA/
CHMP/594085/2015). https://www.ema.europa.eu/en/documents/scientific-guideline/
guideline-use-pharmacokinetics-pharmacodynamics-development-antimicrobial-
medicinal-products_en.pdf. 2016.
[18] Food and Drug Administration. Complicated Urinary Tract Infections: Developing Drugs 
for Treatment. Guidance for Industry. Silver Spring (MD); 2015. https://www.fda.gov/
downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070981.
pdf.
[19] Muller AE, Theuretzbacher U, Mouton JW. Use of old antibiotics now and in the future 
from a pharmacokinetic/pharmacodynamic perspective. Clinical Microbiology and 
Infection. 2015;21:881-5.
[20] Konig C, Braune S, Roberts JA, Nierhaus A, Steinmetz OM, Baehr M, Frey OR, Langebrake 
C, Kluge S. Population pharmacokinetics and dosing simulations of ceftazidime in 
critically ill patients receiving sustained low-efficiency dialysis. Journal of Antimicrobial 
Chemotherapy. 2017;72:1433-40.
[21] De Cock PA, Mulla H, Desmet S, De Somer F, McWhinney BC, Ungerer JP, Moerman 
A, Commeyne S, Vande Walle J, Francois K, Van Hasselt JG, De Paepe P. Population 
pharmacokinetics of cefazolin before, during and after cardiopulmonary bypass 
to optimize dosing regimens for children undergoing cardiac surgery. Journal of 
Antimicrobial Chemotherapy. 2017;72:791-800.
20 | Chapter 1
[22] Udy AA, Lipman J, Jarrett P, Klein K, Wallis SC, Patel K, Kirkpatrick CM, Kruger PS, 
Paterson DL, Roberts MS, Roberts JA. Are standard doses of piperacillin sufficient 
for critically ill patients with augmented creatinine clearance? Critical Care (London, 
England). 2015;19:28.
[23] Bos JC, Prins JM, Misticio MC, Nunguiane G, Lang CN, Beirao JC, Mathot RAA, van Hest 
RM. Pharmacokinetics and pharmacodynamic target attainment of ceftriaxone in adult 
severely ill sub-Saharan African patients: a population pharmacokinetic modelling study. 
Journal of Antimicrobial Chemotherapy. 2018.
[24] Hui K, Patel K, Kong DCM, Kirkpatrick CMJ. Impact of high-flux haemodialysis on the 
probability of target attainment for oral amoxicillin/clavulanic acid combination therapy. 
International Journal of Antimicrobial Agents. 2017.
[25] Goutelle S, Valour F, Gagnieu MC, Laurent F, Chidiac C, Ferry T, Lyon B, Joint Infection 
Study G. Population pharmacokinetics and probability of target attainment of ertapenem 
administered by subcutaneous or intravenous route in patients with bone and joint 
infection. Journal of Antimicrobial Chemotherapy. 2018;73:987-94.
[26] Zeitlinger MA, Derendorf H, Mouton JW, Cars O, Craig WA, Andes D, Theuretzbacher 
U. Protein binding: do we ever learn? Antimicrobial Agents and Chemotherapy. 
2011;55:3067-74.
[27] Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial 
dosing of mice and men. Clinical Infectious Diseases. 1998;26:1-10.
[28] Rybak MJ. The pharmacokinetic and pharmacodynamic properties of vancomycin. 
Clinical Infectious Diseases. 2006;42 Suppl 1:S35-9.
[29] Ambrose PG, Bhavnani SM, Rubino CM, Louie A, Gumbo T, Forrest A, Drusano GL. 
Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it’s not just for mice 
anymore. Clinical Infectious Diseases. 2007;44:79-86.
[30] Sime FB, Roberts MS, Peake SL, Lipman J, Roberts JA. Does Beta-lactam Pharmacokinetic 
Variability in Critically Ill Patients Justify Therapeutic Drug Monitoring? A Systematic 
Review. Ann Intensive Care. 2012;2:35.
[31] Huttner A, Harbarth S, Hope WW, Lipman J, Roberts JA. Therapeutic drug monitoring 
of the beta-lactam antibiotics: what is the evidence and which patients should we be 
using it for? Journal of Antimicrobial Chemotherapy. 2015.
[32] Sinnollareddy MG, Roberts MS, Lipman J, Roberts JA. beta-lactam pharmacokinetics 
and pharmacodynamics in critically ill patients and strategies for dose optimization: a 
structured review. Clinical and Experimental Pharmacology and Physiology. 2012;39:489-
96.
[33] Bulitta JB, Hope WW, Eakin AE, Guina T, Tam VH, Louie A, Drusano GL, Hoover JL. 
Generating Robust and Informative Nonclinical In Vitro and In Vivo Bacterial Infection 
Model Efficacy Data To Support Translation to Humans. Antimicrobial Agents and 
Chemotherapy. 2019;63.
[34] Mouton JW, Brown DF, Apfalter P, Canton R, Giske CG, Ivanova M, MacGowan 
AP, Rodloff A, Soussy CJ, Steinbakk M, Kahlmeter G. The role of pharmacokinetics/
pharmacodynamics in setting clinical MIC breakpoints: the EUCAST approach. Clinical 
Microbiology and Infection. 2012;18:E37-45.
[35] Mouton JW, Muller AE, Canton R, Giske CG, Kahlmeter G, Turnidge J. MIC-based dose 
adjustment: facts and fables. Journal of Antimicrobial Chemotherapy. 2018;73:564-8.
21Introduction and outline of this thesis |
1[36] Mould DR, Upton RN. Basic concepts in population modeling, simulation, and model-based drug development. CPT Pharmacometrics Syst Pharmacol. 2012;1:e6.
[37] Zhang Y, Huo M, Zhou J, Xie S. PKSolver: An add-in program for pharmacokinetic and 
pharmacodynamic data analysis in Microsoft Excel. Computer Methods and Programs in 
Biomedicine. 2010;99:306-14.
[38] Mould DR, Upton RN. Basic concepts in population modeling, simulation, and model-
based drug development-part 2: introduction to pharmacokinetic modeling methods. 
CPT Pharmacometrics Syst Pharmacol. 2013;2:e38.
[39] Sherwin CM, Kiang TK, Spigarelli MG, Ensom MH. Fundamentals of population 
pharmacokinetic modelling: validation methods. Clinical Pharmacokinetics. 2012;51:573-
90.
[40] Tatarinova T, Neely M, Bartroff J, van Guilder M, Yamada W, Bayard D, Jelliffe R, Leary 
R, Chubatiuk A, Schumitzky A. Two general methods for population pharmacokinetic 
modeling: non-parametric adaptive grid and non-parametric Bayesian. Journal of 
Pharmacokinetics and Pharmacodynamics. 2013;40:189-99.
[41] Racine-Poon A, Wakefield J. Statistical methods for population pharmacokinetic 
modelling. Statistical Methods in Medical Research. 1998;7:63-84.
[42] Liu X, Wang Y. Comparing the performance of FOCE and different expectation-
maximization methods in handling complex population physiologically-based 
pharmacokinetic models. Journal of Pharmacokinetics and Pharmacodynamics. 
2016;43:359-70.
[43] Neely MN, van Guilder MG, Yamada WM, Schumitzky A, Jelliffe RW. Accurate 
detection of outliers and subpopulations with Pmetrics, a nonparametric and parametric 
pharmacometric modeling and simulation package for R. Therapeutic Drug Monitoring. 
2012;34:467-76.
[44] Jelliffe RW, Schumitzky A, Bayard D, Milman M, Van Guilder M, Wang X, Jiang F, 
Barbaut X, Maire P. Model-based, goal-oriented, individualised drug therapy. Linkage 
of population modelling, new ‘multiple model’ dosage design, bayesian feedback and 
individualised target goals. Clinical Pharmacokinetics. 1998;34:57-77.
[45] Proost JH, Eleveld DJ. Performance of an iterative two-stage bayesian technique for 
population pharmacokinetic analysis of rich data sets. Pharmaceutical Research. 
2006;23:2748-59.
[46] Roberts JA, Kirkpatrick CM, Lipman J. Monte Carlo simulations: maximizing antibiotic 
pharmacokinetic data to optimize clinical practice for critically ill patients. Journal of 
Antimicrobial Chemotherapy. 2011;66:227-31.
[47] Bonate PL. A brief introduction to Monte Carlo simulation. Clinical Pharmacokinetics. 
2001;40:15-22.
[48] de Velde F, de Winter BCM, Koch BCP, van Gelder T, Mouton JW, Combacte-Net 
consortium. Non-linear absorption pharmacokinetics of amoxicillin: consequences 
for dosing regimens and clinical breakpoints. Journal of Antimicrobial Chemotherapy. 
2016;71:2909-17.
[49] Theuretzbacher U. Product information for parenteral colistin varies substantially across 
Europe. Journal of Antimicrobial Chemotherapy. 2014;69:1987-92.
[50] European Agency for the Evaluation of Medicinal Products. Note for guidance on 
evaluation of new antibacterial medicinal products (CPMP/EWP/558/95). 1997.
22 | Chapter 1
[51] European Agency for the Evaluation of Medicinal Products. Note for guidance on the 
pharmacodynamic section of the SPC for antibacterial medicinal products (CPMP/
EWP/520/96). 1997.
[52] European Agency for the Evaluation of Medicinal Products. Points to consider on 
pharmacokinetics and pharmacodynamics in the development of antibacterial medicinal 
products (CPMP/EWP/2655/99). 2000.
[53] European Agency for the Evaluation of Medicinal Products. Note for guidance on 
evaluation of medicinal products indicated for treatment of bacterial infections (CPMP/
EWP/558/95 rev 1). 2004.
[54] European Medicines Agency. Guideline on the evaluation of medicinal products indicated 
for treatment of bacterial infections (CPMP/EWP/558/95 rev 2). https://www.ema.
europa.eu/en/documents/scientific-guideline/guideline-evaluation-medicinal-products-
indicated-treatment-bacterial-infections-revision-2_en.pdf. 2011.
Chapter 2
Amoxicillin and clavulanic acid

Chapter 2.1
Population pharmacokinetics of oral 
amoxicillin in healthy volunteers
Nonlinear absorption pharmacokinetics of amoxicillin: consequences 
for dosing regimens and clinical breakpoints
F. de Velde
B.C.M. de Winter
B.C.P. Koch
T. van Gelder
J.W. Mouton
on behalf of Combacte-Net consortium. 
Journal of Antimicrobial Chemotherapy. 2016;71:2909-17.
26 | Chapter 2.1
Abstract
Objectives
To describe the population pharmacokinetics of oral amoxicillin and to compare the 
probability of target attainment of current dosing regimens.
Methods
Two groups of each 14 healthy male volunteers received oral amoxicillin/clavulanic 
acid tablets on two separate days one week apart. One group received 875/125 
mg twice daily and 500/125 mg three-times daily and the other group 500/125 mg 
twice daily and 250/125 mg three-times daily. 1428 amoxicillin blood samples were 
collected before and after administration. We analysed the concentration-time profiles 
using a non-compartmental pharmacokinetic method (PKSolver) and a population 
pharmacokinetic method (NONMEM). The probability of target attainment (PTA) 
was computed using Monte Carlo simulations for several dosing regimens.
Results
AUC0-24 and Cmax increased nonlinearly with dose. The final model included the following 
components: Savic’s transit compartment model, Michaelis-Menten absorption, two 
distribution compartments and first-order elimination. The mean central volume of 
distribution was 27.7 L and mean clearance was 21.3 L/h. We included variability for 
the central volume of distribution (34.4%), clearance (25.8%), transit compartment 
model parameters and Michaelis-Menten absorption parameters. For 40% fT>MIC and 
>97.5% PTA, the breakpoints were 0.125 mg/L (500 mg twice daily), 0.25 mg/L (250 
mg three-times daily, 875 mg twice daily), 0.5 mg/L (500 mg three-times daily),1 mg/L 
(750 mg, 875 mg or 1000 mg three-times daily, 500 mg four-times daily). 
Conclusions
The amoxicillin absorption rate appears to be saturable. The PTA’s of high dose as 
well as twice daily regimens are less favourable than regimens with lower doses and 
higher frequency. 
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Introduction 
Amoxicillin is an aminopenicillin that has been used to treat bacterial infections since 
the 1970s. It is frequently combined with the β-lactamase inhibitor clavulanic acid to 
target β-lactamase-producing strains. Either alone or in combination with clavulanic 
acid, amoxicillin was the most consumed antibacterial agent in primary care in two-
third of the EU/EEA countries in 2012 [1].
In an era of increasing antimicrobial resistance and with few new drugs making it to 
the market, antibiotic use must be optimized in order to improve clinical outcomes 
of infections [2]. These clinical outcomes are dependent on the relationship between 
MIC, efficacy and exposure [2]. For β-lactams, the pharmacokinetic-pharmacodynamic 
(PK/PD) index that best correlates with efficacy is the duration that the unbound 
concentration exceeds the MIC, expressed as a percentage of the dosing interval 
(%fT>MIC) [3]. The minimal PK/PD index value that ensures a high probability of 
successful treatment is the pharmacodynamic target [4]. The pharmacodynamic 
target appears to be different for each β-lactam group (penicillins, cephalosporins 
and carbapenems) [5]. For penicillins, the pharmacodynamic target is >30-50% fT>MIC, 
dependent on the microbial species and the choice of the antibacterial endpoint (i.e. 
the necessary %fT>MIC is larger for a 1 or 2-log bacterial kill than for a static effect) 
[3, 5-8]. While a high %fT>MIC is related to increased bacterial efficacy, an inadequate 
%fT>MIC is associated with emergence of resistance and selection of resistant strains 
[5, 8]. To attain a specific pharmacodynamic target, the exposure of the microorganism 
to the antibacterial agent needs to be adequate. This exposure is dependent on the 
dose and pharmacokinetic properties of the drug. 
Despite the abundant use of oral amoxicillin, the drug’s pharmacokinetics has been 
described in only a few studies. While small-scale pharmacokinetic studies have 
shown amoxicillin to have a nonlinear absorption profile [9-14], it remains unclear 
how such nonlinear absorption might influence the exposure of the various dosing 
regimens. At present, standard dosing regimens of oral amoxicillin in adults and 
children ≥ 40 kg vary between 750 and 3000 mg/day, divided into 2 to 4 doses (e.g. 
250 mg, 500 mg or 1000 mg three-times daily, 500 mg twice daily, 500 mg four-times 
daily). For oral amoxicillin/clavulanic acid, standard dosing regimens are 500/125 mg 
three-times daily or 875/125 mg twice or three-times daily. 
A population pharmacokinetic model can be used to estimate the exposure of various 
dosing regimens and variability of the antibiotic in the population. Yet, such a model is 
currently not available for oral amoxicillin in the literature. Monte Carlo simulations 
based on a population pharmacokinetic model can support recommendations for 
more appropriate dosing regimens with a reduced likelihood of ineffectiveness and 
resistance (with too low doses) and adverse events (with too high doses).
Information about the pharmacodynamic target, pharmacokinetics, exposure, 
variability and dosing regimens is needed to set clinical breakpoints. Clinical 
breakpoints are MICs that define microorganisms as susceptible, intermediate or 
resistant to specific antibiotics [4]. 
The purposes of this study were to estimate the exposure of various oral amoxicillin 
dosing regimens and the variability in the population, to compare the probability of 
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pharmacodynamic target attainment of these dosing regimens, and to suggest which 
clinical breakpoints would be justified for oral dosing. We therefore developed a 
population pharmacokinetic model using NONMEM and performed Monte Carlo 
simulations. 
Methods 
Study design and population
The study was designed as an open label, randomized two part-crossover investigation 
to study the pharmacokinetics of oral amoxicillin/clavulanic acid. Male volunteers 
were enrolled into the study if they were aged between 18 and 50 years and in good 
general health. Exclusion criteria were more than 20% deviation from ideal weight 
for height, use of prescribed medication in the 2 weeks prior to the study (antibiotics: 
4 weeks), use of any medication during the study without consent, alcohol intake 
more than 3 units/day, participation in a trial within 2 months prior to the start of 
this study, prior hypersensitivity to the trial drug or to drugs with a similar chemical 
structure, diseases known to interfere with the drug pharmacokinetics, or blood 
donation of more than 1500 mL within the previous year.
Ethics
The study was conducted in accordance with the Declaration of Helsinki. The study 
protocol was approved by the Freiburger Ethics Committee (Freiburg, Germany). 
All volunteers gave written informed consent prior to the study. The study 
(reference number 25000/360) [15] was conducted in 1993 at FOCUS Clinical 
Drug Development GmbH (Neuss, Germany) in commission of SmithKline Beecham 
Pharmaceuticals (Harlow, UK). 
Study procedures
The study consisted of two parts, each with two dosing regimens given for 1 day. The 
order of the dosing regimens was randomized and treatment days were separated 
by 6 or 7 days. In part 1, 16 subjects were allocated to amoxicillin/clavulanic acid 
875/125 mg twice daily and 500/125 mg three-times daily. In part 2, 16 other subjects 
were assigned to 500/125 mg twice daily and 250/125 mg three-times daily. Each dose 
was provided as a single tablet amoxicillin/clavulanic acid (Augmentin®, SmithKline 
Beecham Pharmaceuticals, Bristol, TN, USA). Doses were administered with 200 mL 
water at the start of a standard meal. The first dose of each day was administered at 
8:00h after having fasted from food and fluids from 22:00h the night before.
Blood samples were collected just before administration and after 0.5, 1, 1.5, 2, 2.5, 3, 
4, 6, 8, 10 and 12h (three-times daily regimens until 8h). Samples were frozen at -70 
°C within 1h of sampling and were assayed within 6 weeks of collection. Amoxicillin 
plasma concentrations were determined by Hazleton Laboratories (UK) using the 
ASTED (Automated Sequential Trace Enrichment of Dialysates) system coupled to 
high pressure liquid chromatography (HPLC) with ultraviolet absorbance detection. 
The lower limit of quantification was 0.1 mg/L. 
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Pharmacokinetic analysis
Non-compartmental pharmacokinetic analysis of the plasma concentration-time data 
was performed using PKSolver [16] (version 2.0, China Pharmaceutical University, 
Nanjing, China). Population pharmacokinetic analysis was performed using nonlinear 
mixed effects modelling (NONMEM version 7.2, ICON Development Solutions, 
Ellicott City, MD, USA). The Intel Visual Fortran Compiler XE 14.0 (Santa Clara, CA, 
USA) was used. The first-order conditional estimation method with interaction was 
used throughout the model building process. Tools used to evaluate and visualise 
the model were RStudio (version 0.98.1028), R (version 3.1.1), XPose (version 
4.5.0) and PsN (version 4.2.0), all with the graphical interface Pirana [17] (version 
2.9.0). Different absorption models (first-order, zero-order, Michaelis-Menten) with 
and without lag-time or Savic’s transit compartment model [18] were evaluated in 
combination with one- and two-compartment distribution models and an absorption 
storage compartment. Model selection criteria were decrease in the NONMEM 
objective function value (OFV), goodness-of-fit plots and visual predictive checks 
(VPC). A decrease in the OFV of 3.84 units was considered statistically significant 
(p<0.05) in a nested model [19]. For each VPC, a set of 200 simulated datasets 
was created to compare the observed concentrations with the distribution of the 
simulated concentrations (using the final model and parameter estimates). Between-
subject variability was tested using an exponential variance model. Residual variability 
was evaluated with a combined (additive and proportional) error model. 
From the available subject characteristics (age, height and weight), weight was selected 
to evaluate as a covariate. Dose was also evaluated as covariate. One covariate at a 
time was included using the likelihood ratio test. The covariate effect was considered 
significant at p<0.05 (decrease in the OFV of 3.84 units).
The 95% CI of each parameter in the final model was determined from a nonparametric 
bootstrap analysis, in which the dataset was resampled 500 times.
Monte Carlo simulations
Monte Carlo simulations were performed using the final model in NONMEM. Eight 
amoxicillin dosing regimens were evaluated: 250 mg three-times daily, 500 mg twice 
daily, 500 mg three-times daily, 500 mg four-times daily, 750 mg three-times daily, 
875 mg twice daily, 875 mg three-times daily and 1000 mg three-times daily. 5000 
subjects were simulated for each dosing regimen. For each simulated concentration-
time profile, %fT>MIC was calculated for MICs from 0.015 to 64 mg/L. The unbound 
amoxicillin concentration was calculated from the total concentration using a fixed 
value for protein binding of 20% [20-22]. The probability of target attainment (PTA) 
was assessed for MICs from 0.015 to 64 mg/L.   
Results 
Study population
32 healthy male volunteers (16 per part) entered the study. After 2 withdrawals 
(one because of diarrhoea and one due to personal reasons), amoxicillin plasma 
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concentrations were determined in 30 volunteers (15 per part) completing both 
dosing regimens. Pharmacokinetics could not be evaluated in one subject in part 
1 due to very low plasma concentrations and in one subject in part 2 because 
of analytical interference. The characteristics of the 28 pharmacokinetic evaluable 
subjects are shown in Table 1.
Table 1. Characteristics of study population (values expressed as mean ± s.d.)
Characteristic Total (n=28) Part 1 (n=14) Part 2 (n=14)
Age (years) 33 ± 7 35 ± 8 31 ± 6
Height (cm) 179 ± 6 179 ± 6 179 ± 7
Weight (kg) 77 ± 8 78 ± 5 77 ± 10
BMI (kg/m2) 24 ± 2 24 ± 2 24 ± 2
  
Adverse events
Mild to moderate diarrhoea was the most frequently reported drug related adverse 
event. The number of these events increased with total daily doses (1750/250 mg/
day: 5 events, 1500/375 mg/day: 4, 1000/250 mg/day and 750/375 mg/day: 2 each). In 
addition, mild abdominal pain and mild nausea were both once reported.
Pharmacokinetic analysis
140 amoxicillin concentration-time profiles (5 profiles per subject) with in total 
1428 samples were analysed. The results of the non-compartmental pharmacokinetic 
analysis are shown in Table 2.
The increase in mean Cmax and AUC0-24 was proportional to the daily dose for 750, 
1000 and 1500 mg/day amoxicillin, but the mean AUC0-24 of 1500 mg/day was equal 
to 1750 mg/day and the mean Cmax of 875 mg was lower than expected. Tmax increased 
with rising doses. t1/2 was comparable for the 4 doses.
Population pharmacokinetic analysis showed that amoxicillin pharmacokinetics was 
best described by Savic’s transit compartment model [18] followed by Michaelis-
Menten absorption, two distribution compartments and first-order elimination 
(NONMEM subroutine ADVAN6 and TOL=5). A literature-based [20] fixed value of 
70% for bioavailability was used because no pharmacokinetic data with intravenous 
administration were collected in this study. With each concentration-time profile 
analysed separately, variability was included for central volume of distribution, 
clearance, the parameters belonging to the transit compartment model and the 
Michaelis-Menten absorption parameters. Weight and dose didn’t improve the 
model as a covariate and, therefore, was not included in the final model. A schematic 
representation of the final model is shown in Figure 1.
As shown in Table 3, the model-based parameter estimates were similar to the 
values computed from the bootstrap analysis, indicating the stability of the model.
The goodness-of-fit plots in Figure 2 show that the model adequately described 
the observed concentrations. The VPC plot, presented in Figure 3, indicate a good 
predictive performance for each of the used doses of 250, 500 and 875 mg amoxicillin.
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Table 2. Results of the non-compartmental pharmacokinetic analysis of amoxicillin (values 
expressed as mean ± s.d.) 
Dosing regimen 
amoxicillin/ 
clavulanic acid
Cmax 
(mg/L)
Dose 
normalised 
Cmax 
(mg/L)/g
Tmax (h) AUC0-24 
(mg.h/L)
Dose 
normalised 
AUC0-24 
(mg.h/L)/g
t1/2 (h)
250/125 mg 
three-times daily
3.93 ± 
1.13
15.74 ± 
4.53
1.31 ± 
0.33
27.29 ± 
4.72
36.39 ± 
6.29
1.13 ± 
0.38
500/125 mg 
twice daily
7.17 ± 
1.63
14.34 ± 
3.26
1.40 ±
0.44
34.33 ± 
7.12
34.33 ± 
7.12
1.23 ± 
0.33
500/125 mg 
three-times daily
8.12 ± 
2.71
16.25 ± 
5.43
1.33 ± 
0.38
54.67 ± 
8.98
36.44 ± 
5.99
1.11 ± 
0.22
875/125 mg 
twice daily
11.21 ± 
3.42
12.81 ± 
3.91
1.52 ± 
0.40
55.04 ± 
12.68
31.45 ± 
7.24
1.14 ± 
0.21
Table 3. Model-based population pharmacokinetic parameter estimates and values obtained 
after bootstrap analysis
Final model 
estimate 
Bootstrap 
median
Bootstrap 
95%CI
Fixed effects
BIO (-) 0.7 (fixed) 0.7 (fixed) –
MTT (h) 0.524 0.521 0.455 – 0.591
N (-) 4.41 4.43 3.29 – 8.20
Vm (mg/h) 1220 1222 960 – 2036
Km (mg) 287 289 191 – 572 
Vc (L) 27.7 27.2 25.0 – 29.6 
CL (L/h) 21.3 21.2 20.1 – 22.2 
Q (L/h) 1.70 1.75 1.07 – 3.03
Vp (L) 3.02 3.12 2.48 – 3.89
Between-subject variability (% CV)
BIO 35.1 39.0 29.2 – 71.6 
MTT 46.8 46.2 38.1 – 55.9 
N 113 107 73.5 – 130
Vm 31.9 44.9 21.5 – 120
Km 98.7 110 78.5 – 164 
Vc 34.4 36.5 26.4 – 70.9 
CL 25.8 29.4 17.0 – 66.7 
Residual variability
Additive 0.0524 0.0525 0.0406 – 0.700
Proportional 0.0824 0.0809 0.0680 – 0.0931
BIO, bioavailability; MTT, mean transit time to depot; N, number of transit compartments; 
Vm, maximal absorption rate; Km, amount corresponding to 50% Vm; Vc, central volume 
of distribution; CL, clearance; Q, intercompartmental clearance; Vp, peripheral volume of 
distribution
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Monte Carlo simulations
The results of the simulations, presented in Figure 4, showed that 100% of the 
population reached the pharmacodynamic target 40% fT>MIC for MICs up to 0.125 
mg/L with all dosing regimens. For >95% PTA, breakpoints were 0.125 mg/L (500 mg 
twice daily), 0.25 mg/L (250 mg three-times daily and 875 mg twice daily), 0.5 mg/L 
(500 mg three-times daily), 1 mg/L (750 mg, 875 mg or 1000 mg three-times daily 
and 500 mg four-times daily). Figure 5 shows the %fT>MIC as a function of the MIC for 
several dosing regimens. The breakpoints that correspond to the 95% CI (= 97.5% 
PTA) are the same as the aforementioned breakpoints for >95% PTA.
Transit
N=4.41 VpDepot Vc
QVm,
KmBIO
dose
Ktr =(N+1)/MTT CL
Figure 1. Schematic representation of the final model
BIO, bioavailability; MTT, mean transit time to depot; N, number of transit compartments; Ktr, 
transit rate constant; Vm, maximal absorption rate; Km, amount corresponding to 50% Vm; Vc, 
central volume of distribution; CL, clearance; Q, intercompartmental clearance; Vp, peripheral 
volume of distribution
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Figure 2. Goodness-of-fit plots for the final model. (a) Observed versus population 
predicted amoxicillin concentrations. (b) Observed versus individual predicted amoxicillin 
concentrations. (c) Weighted residuals versus time. 
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Figure 3. Visual predictive check stratified on dose (TDOSE). The solid circles are observed 
concentrations. The upper, middle and lower lines indicate the 95th, 50th and 5th percentile 
of observations, respectively. The shaded areas represent the 95%CI of the corresponding 
percentiles of predictions.
Figure 4. Probability of target attainment (PTA) for various amoxicillin dosing regimens to 
reach the pharmacodynamic target 40% fT>MIC for a range of MICs. 
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Figure 5. %fT>MIC displayed as a function of the MIC for several dosing regimens. 
suspension data resulted in a time-constrainedMichaelis–Menten
absorption model with lag time followed by a storage compart-
ment and two disposition compartments.13,14 In our population
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Discussion 
Our population pharmacokinetic model includes a saturable absorption rate for 
amoxicillin, which corresponds to the nonlinear and delayed absorption found in the 
non-compartmental analysis.
The findings of our non-compartmental and population pharmacokinetic analyses 
with rich data are similar to the smaller studies that previously reported the 
absorption pharmacokinetics of amoxicillin to be nonlinear [9-14], mostly based 
on non-compartmental analysis and standard-two-stage methods [9-13]. Evidence 
for nonlinear pharmacokinetics was provided by the fact that Cmax and AUC were 
relatively low and Tmax was later for increasing single doses up to 3000 mg [9, 10, 12]. 
Spyker and colleagues showed a reduction in absorption rate for increasing single 
doses up to 1000 mg [9]. In two studies with single doses up to 3100 mg, Michaelis-
Menten parameters were used to describe the nonlinear relationship between dose 
and the amount absorbed [11, 12]. Two analyses that studied oral suspension data 
resulted in a time-constrained Michaelis-Menten absorption model with lag time 
followed by a storage compartment and two disposition compartments [13, 14]. In 
our population pharmacokinetic analysis, models with Michaelis-Menten absorption 
described the data better than models with first-order or zero-order absorption, 
as expected given the previous studies [11-14]. Similar to the two oral suspension 
studies [13, 14], our model became better when we added a storage compartment. 
The absorption phase of our model further improved when we replaced the lag time 
with Savic’s transit compartment model, which describes the absorption delay as a 
multiple step process represented by a chain of presystemic compartments [18]. 
Because the model with a combination of Savic’s transit compartment model and a 
storage compartment was similar to the model with the transit compartment model 
alone, the final model only included the transit compartment model.
The nonlinearity in Cmax and AUC that we found in our study and those of others may 
potentially be explained by several factors other than absorption, such as disposition 
or clearance. However, a proportional increase in AUC for increasing intravenous 
doses of 250 to 1000 mg [9, 23] excludes the probability of nonlinear disposition. 
Dose-dependent renal drug clearance is unlikely because of the finding in our study 
that t1/2 was stable throughout the dose range of our study as well as in another 
study with oral doses of 375 to 3000 mg [12].
Regarding the influence of fasting/non-fasting on amoxicillin Cmax and AUC, previous 
studies have shown results that contradict our results. SmithKline Beecham performed 
a study similar to ours in which oral amoxicillin/clavulanic acid was administered to 
fasting subjects [24], and which also demonstrated a nonlinear increase in Cmax and 
AUC0-24. In this study with fasting subjects [24], the amoxicillin Cmax and AUC0-24 were 
lower than those in the here presented SmithKline Beecham study in which the 
subjects were non-fasting. Indeed, the current instructions for use recommend that 
amoxicillin/clavulanic acid be taken at the start of a meal [20]. In contrast, Welling 
and colleagues revealed that fasting subjects had higher amoxicillin serum levels than 
non-fasting subjects [25]. These contrary results may be explained by the differences 
in the amounts of water with which the drug was administered, which could affect 
37Population pharmacokinetics of oral amoxicillin in healthy volunteers |
2.1
the dissolution of amoxicillin. The here presented SmithKline Beecham study used 
200 mL water for 250-875 mg amoxicillin, compared with 120 mL for 250-875 mg 
in the other SmithKline Beecham study [24], and 25-250 mL for 500 mg in the study 
of Welling et al [25]. This is evidenced by the fact that fasting subjects given a 500 
mg dose had significantly lower amoxicillin serum levels when the water volume was 
reduced from 250 to 25 mL [25]. An in vitro study showed that the solubility curve 
of amoxicillin is U-shaped with a minimum of 5.5 mg/L at pH 5 and 37 °C [26]. Since 
in our study the highest concentration was below 5.5 mg/L (875 mg amoxicillin 
administered with 200 mL water results in a concentration of 4.4 mg/L), we do not 
expect that the amoxicillin solubility influenced drug absorption.
Nonlinear absorption in human subjects has also been demonstrated for other 
aminopenicillins, such as ampicillin and bacampicillin [12, 27]. Penicillins can be 
regarded as a dipeptide derived from cysteine and valine [12] and a rat model 
suggest that aminopenicillins are absorbed via intestinal dipeptide carrier-mediated 
transport [28]. The amoxicillin absorption percentage from rat small intestine 
decreased with increasing concentrations, which indicates a saturable rate-limiting 
step in the absorption process [29]. 
Our final population pharmacokinetic model includes a Michaelis-Menten 
equation for absorption, which indicates that the absorption rate is saturable. This 
finding corresponds to the nonlinear and delayed absorption shown in the non-
compartmental analysis. Despite the non-proportional increase in Cmax, the dosing 
simulations demonstrate that increasing the dose results in a larger %fT>MIC, which is 
explained by the delayed absorption. However, high doses may increase the risk of 
adverse events and of disturbances in the intestinal microflora [30]. In our study, the 
frequency of diarrhoea tend to increase at higher daily doses of amoxicillin, which 
may be explained by the higher amount of unabsorbed antibiotic [30]. Sjövall and 
colleagues described an increased number of adverse events at higher single doses 
of amoxicillin [12]. In another study [31], high doses of clavulanic acid were related 
to upper digestive adverse events, but the amounts used (750 mg/day) were much 
higher than currently used (maximal 500 mg/day). The daily clavulanic dose in our 
study seems to be such low (250-375 mg/day) that it is not likely to be the cause 
of the diarrhoea. We did not found any correlation between diarrhoea and daily 
clavulanic acid amounts. 
The %fT>MIC becomes also larger when the frequency of dosing increases. On the 
other side, less frequent dosing can lead to a too low %fT>MIC which reduces the 
probability of antimicrobial efficacy and may contribute to the development of 
resistance. The balance between dose and frequency should be optimal to maximize 
the antimicrobial efficacy and to minimize the risk of adverse events. For example, 
the breakpoint of 250 mg three-times daily is similar (0.25 mg/L) to that of 875 mg 
twice daily, based on a 95% CI and 40% fT>MIC. The first regimen with a lower dose 
and a higher frequency is preferred to the second regimen with a higher dose and a 
lower frequency, because both the daily dose and the dose taken at one time of the 
first regimen are lower which appears to reduce the risk of adverse events. In case 
of regimens with a high dose and a low frequency which have the same breakpoint 
as regimens with a lower dose and higher frequency, high doses are wasteful. It is not 
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possible to recommend a maximal dose using the current data of 1750 mg/day and 
875 mg/dose, because the non-proportional increase in Cmax didn’t reach a plateau.
The view that amoxicillin/clavulanic acid 500/125 mg three-times daily is 
interchangeable with 875/125 mg twice daily should be reconsidered, because the 
target attainment and therefore the breakpoint of the twice daily regimen is lower 
than the three-times daily regimen (0.25 mg/L vs 0.5 mg/L based on a 95% CI and 
40% fT>MIC).  
The current EUCAST PK/PD non-species related breakpoints for amoxicillin are 
based on a fT>MIC target of 30-40% and a PTA >90% which resulted in S ≤2 mg/L (500 
mg three-times daily) and R >8 mg/L (1000 mg three-times daily) [6]. These amoxicillin 
breakpoints are based on intravenous administration. The acceptance level of PTA 
is still under debate and PTA values of 99%, 95% and 90% have all been used. In the 
majority of the present rationale documents for EUCAST breakpoints, the %fT>MIC as 
a function of the MIC is displayed with CIs. CIs of 99%, 95%, 90% and 80% correspond 
to PTAs of 99.5%, 97.5%, 95% and 90%, respectively [4]. Most current EUCAST PK/
PD breakpoints for β-lactams (e.g. piperacillin/tazobactam, ceftazidime, meropenem) 
are based on the 95% CI (= 97.5% PTA). In this paper we use a 40% fT>MIC target 
and a 95% CI to simplify the comparison of dosing regimens. Obviously, the PK/PD 
breakpoint for oral amoxicillin is lower than that for intravenous administration due 
to a bioavailability of approximately 70% [20]. A 95% CI of 500 mg three-times daily 
results in a breakpoint of 0.5 mg/L for 40% fT>MIC.
While our study describes the population pharmacokinetics of amoxicillin 
administered with clavulanic acid, we expect that the results of amoxicillin alone are 
similar, as others have shown [32]. 
This paper has a number of limitations. First, only a few covariates were available 
and creatinine data were lacking. However, the participants were healthy volunteers 
with normal renal function. Since oral amoxicillin or amoxicillin/clavulanic acid is 
mostly prescribed to patients with only relatively mild infections and normal renal 
function, the results of our study can be extrapolated to such patients. A second 
limitation is that the current model is only suitable for single doses, because we 
analysed each concentration-time profile separately. Incorporation of between 
occasion variability was not successful. If a multiple dose model will be developed, 
an output from the depot compartment should be considered to prevent possible 
accumulation of non-absorbed amoxicillin. Our population pharmacokinetic model 
is based on single doses up to 875 mg for which concentrations are measured 12 
hours after administration. Because the maximum simulated dose of 1000 mg is just 
slightly higher than 875 mg and the interval between doses never exceed 12 hours, 
we assume that the extrapolation is justified. 
In conclusion, the amoxicillin absorption rate appears to be saturable which results 
in a nonlinear increase in Cmax and a later Tmax for higher doses. Increasing the dose 
results in a larger %fT>MIC due to this delayed absorption, despite the non-proportional 
increase in Cmax. However, a higher dose increases the risk of adverse events. A smaller 
interval between doses leads to a larger fT>MIC as well. The balance between dose 
and frequency should be optimal to maximize the antimicrobial efficacy (fT>MIC) and 
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to minimize the risk of adverse events. Clinicians should take care when prescribing 
oral amoxicillin regimens with high doses as well as those involving twice daily doses. 
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Abstract
Objectives
To calculate the clavulanic acid exposure of oral amoxicillin/clavulanic acid dosing 
regimens, to investigate variability using a population pharmacokinetic model and to 
explore target attainment using Monte Carlo simulations. 
Methods
Two groups of healthy male volunteers received amoxicillin/clavulanic acid tablets 
at the start of a standard meal on two separate days one week apart. One group 
(n=14) received 875/125 mg q12h and 500/125 mg q8h and the other group (n=15) 
500/125 mg q12h and 250/125 mg q8h. 1479 blood samples were collected until 
8-12h after administration. Concentrations were analysed using non-compartmental 
(WinNonLin) and population pharmacokinetic methods (NONMEM). 
Results
Median Cmax and AUC0-8 were 2.21 mg/L (0.21-4.35) and 4.99 mg*h/L (0.44-8.31), 
respectively. In 40/58 daily concentration-time profiles, Cmax and AUC0-8 of the 
morning dose were higher than later doses. The final population model included a lag 
time (0.447 h), first-order absorption (3.99 h-1 at 8:00h, Between-Subject Variability 
52.8%, Between-Occasion Variability 48.5%), one distribution compartment (33.0 L, 
BSV 23.9%) and first-order elimination (24.6 L/h, BSV 26.7%). Bioavailability (fixed at 
1 at 8:00h, BOV 28.2%) and absorption rate decreased over the day. For 97.5% of 
the simulated population after 125 mg q12h or q8h, %fT>Ct at 0.5 mg/L was 8.33% 
(q12h) and 15.2% (q8h), at 1 mg/L 0% (q12h+q8h) and fAUC0-24 3.61 (q12h) and 5.56 
(q8h) mg*h/L.
Conclusions
Clavulanic acid absorption in healthy volunteers is highly variable. Bioavailability and 
absorption rate decrease over the day. The model developed may serve to suggest 
clavulanic acid dosing regimens to optimize efficacy and prevent under-dosing.
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Introduction 
Clavulanic acid is a beta-lactamase inhibitor that is combined with beta-lactam 
antibiotics such as amoxicillin to target beta-lactamase-producing strains. Amoxicillin 
alone or in combination with clavulanic acid was the most consumed antibacterial 
agent in primary care in two-third of the EU/EEA countries in 2012 [1]. However, 
despite its ample use since for 30 years, the pharmacokinetics of oral clavulanic acid 
have received little attention. 
Several non-compartmental pharmacokinetic (PK) studies showed highly variable 
pharmacokinetics [2-4] but it still remains unclear how the variable pharmacokinetics 
influences the exposure and thereby the efficacy of the drug. It is plausible that 
activity against beta-lactamase-producing strains will not be attained if the exposure 
of clavulanic acid is inadequate. A population PK model can be used to further 
investigate variability and exposure in the population. Currently, only 1 population 
PK model for oral amoxicillin/clavulanic acid suspension is available in a thesis [5].
The exposure of an antimicrobial to the microorganism in vivo (dependent on dose 
and PK) and the potency of a drug in vitro (usually expressed as a MIC) determine 
the antimicrobial efficacy [6]. For antimicrobials, pharmacokinetic-pharmacodynamic 
(PK/PD) indices, such as AUC0-24/MIC, Cmax/MIC and T>MIC, describe exposure-
response relationships of antimicrobial agents [6]. The pharmacodynamic target 
is the minimal PK/PD index value that ensures a high probability of successful 
treatment [6]. However, clavulanic acid has very weak antimicrobial activity when 
used alone [7]. For beta-lactamase inhibitors the time that the free concentration 
exceeds a threshold concentration (%fT>Ct) and the total daily dose and fAUC 
have been described to be important for inhibitory activity [8-12]. For tazobactam, 
sulbactam and avibactam, the PK/PD index seems to be %fT>Ct [8-11]. In contrast, 
for relebactam (MK-7655), the total daily dose and fAUC were linked to effect 
[12]. Clavulanic acid is an irreversible suicide inhibitor similar to tazobactam and 
sulbactam, but has a unique chemical structure and different affinities for beta-
lactamase enzymes than the other inhibitors [7]. Its pharmacodynamic properties 
can therefore not be extrapolated. For lack of preclinical data, the PKPD index best 
describing its activity is currently not known. 
The purposes of this study were therefore twofold. The first was to build a 
population pharmacokinetic model using NONMEM to determine the clavulanic acid 
exposure and variability of various oral amoxicillin/clavulanic acid dosing regimens 
and to investigate whether PK interactions occur between the two agents [13].  A 
population pharmacokinetic model for oral amoxicillin using the same amoxicillin/
clavulanic acid data was previously published by the authors [14]. The second purpose 
was to explore the variability of clavulanic acid exposure and its effects on target 
attainment for standard dosing regimens of 125 mg twice daily (q12h) and 125 mg 
three times daily (q8h) clavulanic acid. Because the PK/PD index and PD target of 
clavulanic acid are still unknown, both %fT>Ct and fAUC were calculated. 
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Methods 
Study design and population
The study was designed as an open label, randomized two part crossover investigation 
to study the pharmacokinetics of oral amoxicillin/clavulanic acid. Male volunteers 
were enrolled into the study if they were aged between 18 and 50 years and in good 
general health. Exclusion criteria were more than 20% deviation from ideal weight 
for height, use of prescribed medication in the 2 weeks prior to the study (antibiotics: 
4 weeks), use of any medication during the study without consent, alcohol intake 
more than 3 units/day, participation in a trial within 2 months prior to the start of 
this study, prior hypersensitivity to the trial drug or to drugs with a similar chemical 
structure, diseases known to interfere with the drug pharmacokinetics, or blood 
donation of more than 1500 mL within the previous year.
The study (reference number 25000/360) [15] was conducted in 1993 at FOCUS 
Clinical Drug Development GmbH (Neuss, Germany) in commission of SmithKline 
Beecham Pharmaceuticals (Harlow, UK). 
Ethics
The study was conducted in accordance with the Declaration of Helsinki. The study 
protocol was approved by the Freiburger Ethics Committee (Freiburg, Germany). All 
volunteers gave written informed consent prior to the study. 
Study procedures
The study consisted of 2 parts. Each part included a separate group of subjects 
that each received 2 dosing regimens of one day. The order of the dosing regimens 
was randomized and treatment days were separated by a washout period of 6 or 
7 days. In part 1, 16 subjects were allocated to amoxicillin/clavulanic acid 875/125 
mg q12h (2 doses) and 500/125 mg q8h (3 doses). In part 2, 16 other subjects 
were assigned to 500/125 mg q12h (2 doses) and 250/125 mg q8h (3 doses). Each 
dose was provided as a single tablet amoxicillin as trihydrate and clavulanic acid as 
potassium clavulanate (Augmentin®, SmithKline Beecham Pharmaceuticals, Bristol, 
TN, USA). Doses were administered with 200 mL water at the start of a standard 
meal. Each meal (approximately 800 kcal and 30% fat content) consisted of 4 slices 
of pork, slices of cucumber, 250 g of pasta-salad and a half slice of coarse wholemeal 
bread. Dosing times were 8:00h, 16:00h and 24:00h for three times daily regimens 
and 8:00h and 20:00h for twice daily regimens. For twice daily regimens, a second 
standard meal was provided at 12:00h. The first dose of each day was administered at 
8:00h after having fasted from food and fluids from 22:00h the night before. 
Blood samples were collected just before administration and after 0.5, 1, 1.5, 2, 2.5, 3, 
4, 6, 8, 10 and 12 h (three times daily regimens until 8 h). Samples were frozen at -70 
°C within 1 h of sampling and were assayed within 6 weeks of collection. Clavulanic 
acid plasma concentrations were determined by Hazleton Laboratories (UK) 
using the ASTED (Automated Sequential Trace Enrichment of Dialysates) system 
coupled to high pressure liquid chromatography (HPLC) with ultraviolet absorbance 
detection. The lower limit of quantification was 0.05 mg/L [15]. 
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Pharmacokinetic analysis
Non-compartmental pharmacokinetic analysis of the plasma concentration-time 
data was performed using WinNonLin (version 7.0, Certara, Princeton, NJ, USA). 
Population pharmacokinetic analysis was performed using nonlinear mixed effects 
modelling (NONMEM version 7.2, ICON Development Solutions, Ellicott City, MD, 
USA). The Intel Visual Fortran Compiler XE 14.0 (Santa Clara, CA, USA) was used. The 
first-order conditional estimation method with interaction was used throughout the 
model building process. Tools used to evaluate and visualise the model were RStudio 
(version 0.98.1028), R (version 3.1.1), XPose (version 4.5.0) and PsN (version 4.6.0), 
all with the graphical interface Pirana [16] (version 2.9.4). 
First-order, zero-order and Michaelis–Menten absorption models with and without 
lag time were evaluated in combination with one- and two-compartment distribution 
models. Between-subject variability (BSV, variability between individual subjects) and 
between-occasion variability (BOV, variability between the doses of an individual 
subject) were tested using an exponential variance model. Residual unexplained 
variability (RUV) was evaluated with a combined (additive and proportional) error 
model. A stepwise covariate model building was performed with forward addition 
at p<0.05 (decrease in the Objective Function Value, OFV, of 3.84 units) followed by 
backward elimination at p<0.001 (decrease in the OFV of 10.88 units). Evaluated 
covariates were body weight, dosing time, amoxicillin time dose and amoxicillin daily 
dose (dosing time and dose were evaluated as continuous and categorical covariates). 
Model selection criteria were decrease in OFV, goodness-of-fit plots and visual 
predictive checks (VPC). A decrease in the OFV of 3.84 units was considered 
statistically significant (p<0.05) in a nested model [17]. For each VPC, a set of 1000 
simulated datasets was created to compare the observed concentrations with the 
distribution of the simulated concentrations. 
The 95% CI of each parameter in the final model was determined from a nonparametric 
bootstrap analysis, in which the dataset was resampled 1000 times.
Monte Carlo simulations
Monte Carlo simulations were performed using the final model in NONMEM. 
Two clavulanic acid dosing regimens were evaluated: 125 mg q12h (at 8:00h and 
20:00h) and 125 mg q8h (at 8:00h, 16:00h and 24:00h). Five thousand subjects 
were simulated for each dosing regimen. For each simulated concentration-
time profile, the fAUC0-24 was calculated as well as the %fT>Ct (the percentage 
of the dosing period 24 h that the free clavulanic acid concentration exceeds 
the threshold concentration Ct) for threshold concentrations of 0.015–64 
mg/L. The unbound clavulanic acid concentration was calculated from the 
total concentration using a fixed value for protein binding of 25% [18, 19].
Results 
Study population
32 healthy male volunteers (16 per part) entered the study. After 2 withdrawals 
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(one because of diarrhoea and one due to personal reasons), clavulanic acid plasma 
concentrations were determined in 30 volunteers (15 per part) completing both 
dosing regimens. Pharmacokinetics could not be evaluated in one subject in part 1 due 
to very low plasma clavulanic acid and amoxicillin concentrations. The characteristics 
of the 29 pharmacokinetic evaluable subjects are shown in Supplementary Table 1. 
The average ± SD values were: age 33 ± 7 years, height 179 ± 6 cm, weight 78 ± 9 
kg and BMI 24 ± 2 kg/m2.
Pharmacokinetic analysis
One hundred and forty-five clavulanic acid concentration-time profiles (5 profiles 
per subject) with in total 1479 samples were analysed. The concentrations in twice 
daily regimens with sampling until 12 h after administration were detectable for 
maximal 8 h. 
A summary of the results of the non-compartmental pharmacokinetic analysis is 
shown in Table 1. Considering the ranges of Cmax and AUC0-8, the ratio between 
the maximum and minimum values is circa 20 for both parameters (Cmax 4.35/0.21 
and AUC0-8 8.31/0.44). The individual concentration-time profiles illustrate that this 
high variability in Cmax and AUC0-8 not only exists between the individual subjects 
but also between the different doses in one dosing regimen of a subject. In 40/58 
daily concentration-time profiles, the Cmax and AUC0-8 of the first dose were higher 
than the Cmax and AUC0-8 of the second or third dose. A summary of the individual 
concentration-time profiles is displayed in Figure 1.
Population PK analysis showed that the clavulanic acid data were best described by a 
model with a lag time and first-order absorption, one distribution compartment and 
first-order elimination. A second distribution compartment didn’t further improve 
the model. Implementation of BSV was significant for volume of distribution (Vd), 
clearance (CL) and first-order absorption rate constant (Ka). Implementation of 
BOV was significant for bioavailability (F) and Ka. BSV for F and lag time and BOV for 
Vd, CL and lag time was not significant and were therefore not implemented. 
The covariate analysis resulted in two significant covariates: dosing time (8:00h, 
16:00h, 20:00h, 24:00h) was proportionally correlated with F and Ka. The effect 
of dosing time was further studied by implementation of a cosine function [20]. 
Replacing the covariate dosing time with cosine functions on Ka and F didn’t improve 
the model and therefore the proportional effects of dosing time on Ka and F were 
implemented in the model. For example, at dosing time 8:00, the population value 
of Ka was 3.99 h-1 (fixed proportional effect of 1) and at 16:00 the population value 
was 3.60 h-1 (estimated proportional effect of 0.903). A model with combined dosing 
times 20:00h and 24:00h was also tested because the proportional effects on Ka and 
F looked similar at these dosing times, but this combination didn’t improve the model 
further and was therefore not implemented. 
The population PK parameter estimates of the final model are displayed in Table 2. 
Since no data with intravenous administration were collected in this study, F could 
not be quantified and was fixed to 1. Consequently, Vd/F and CL/F values are displayed 
instead of Vd and CL values. 
As shown in Table 2, the model-based parameter estimates were similar to the 
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values computed from the bootstrap analysis, indicating the stability of the model. 
The goodness-of-fit plots in Figure 2 and Supplementary Figure 1 show that the 
model adequately described the observed concentrations. The VPC plots, presented 
in Supplementary Figure 2, indicate a good predictive performance. 
Monte Carlo simulations
The results of the simulations with 125 mg q12h and 125 mg q8h are presented 
in Table 3 (fAUC0-24) and Figure 3 (%fT>Ct). Table 3 shows that 97.5% of the 
population reached an fAUC0-24 of 3.61 mg*h/L with 125 mg q12h and 5.56 mg*h/L 
with 125 mg q8h. For 97.5% of the population, the %fT>Ct at 1 mg/L was 0% for 
both regimens and the %fT>Ct at 0.5 mg/L was 8.33% (125 mg q12h) and 15.2% (125 
mg q8h). Half of the population (q12h: 46%, q8h: 53%) attained a concentration of 2 
mg/L, but the average %fT>Ct values at 2 mg/L were low: 2.09% with 125 mg q12h 
and 3.05% with 125 mg q8h. 
Figure 1. Clavulanic acid concentration-time curves for 4 dosing regimens: amoxicillin/
clavulanic acid 875/125 mg q12h (n=14), 500/125 mg q8h (n=14), 500/125 mg q12h (n=15) and 
250/125 mg q8h (n=15). The average concentration and standard deviation at each time point 
is displayed as a filled circle with error bars.
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Figure 2. Observed versus population predicted concentrations (a) and observed versus 
individual predicted concentrations (b). 
Table 1. Results of the non-compartmental pharmacokinetic analysis of clavulanic acid (values 
expressed as mean ± SD and median [minimum – maximum])
Dosing regimen
amoxicillin/
clavulanic acid
Pharmacokinetic parameters of clavulanic acid
Cmax (mg/L) Tmax (h) AUC0-8 
(mg*h/L)
AUC0-24 
(mg.h/L)
t1/2 (h)
250/125 mg q8h
mean ± SD 1.91 ± 0.68 1.30 ± 0.31 4.33 ± 1.54 12.98 ± 3.33 1.07 ± 0.28
median 
[range]
1.99 
[0.21-2.97]
1.50 
[1.00-2.00]
4.60 
[0.44-6.76]
13.45 
[4.63-18.26]
0.98 
[0.46-1.69]
500/125 mg q12h
mean ± SD 1.99 ± 0.61 1.33 ± 0.40 4.45 ± 1.15 8.90 ± 1.92 1.05 ± 0.19
median 
[range]
1.91 
[0.56-3.00]
1.25 
[1.00-2.50]
4.63 
[1.08-6.41]
9.26 
[4.86-11.55]
0.99 
[0.72-1.41]
500/125 mg q8h
mean ± SD 2.54 ± 0.76 1.26 ± 0.28 5.39 ± 1.38 16.17 ± 3.89 1.09 ± 0.41
median 
[range]
2.59 
[1.09-4.35]
1.25 
[1.00-2.00]
5.39 
[2.58-8.31]
17.17 
[8.23-21.75]
0.99 
[0.66-3.37a]
875/125 mg q12h
mean ± SD 2.41 ± 0.90 1.29 ± 0.32 5.25 ± 1.79 10.51 ± 3.07 1.02 ± 0.17
median 
[range]
2.62 
[0.23-4.02]
1.25 
[1.00-2.00]
5.63 
[0.50-7.78]
10.85 
[3.51-13.87]
1.00 
[0.73-1.47]
All regimens
mean ± SD 2.21 ± 0.78 1.29 ± 0.32 4.82 ± 1.53 12.10 ± 4.10 1.06 ± 0.30
median 
[range]
2.21
[0.21-4.35]
1.50 
[1.00-2.50]
4.99 
[0.44-8.31]
11.95 
[3.51-21.75]
0.99 
[0.46-3.37a]
q12h, every 12 h; q8h, every 8 h; range, minimum-maximum; Cmax , maximum concentration; Tmax, 
time to maximum concentration; AUC0-8, Area Under the concentration-time Curve for 0-8 h, 
AUC0-24, Area Under the concentration-time Curve for 0-24 h (q12h: 2 doses, q8h: 3 doses); 
t1/2, half-life. 
a Outlier (penultimate t1/2 was 1.53 for 500/125 mg q8h).
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Figure 3. %fT>Ct (the percentage of the dosing period 24 h that the free clavulanic acid 
concentration exceeds the threshold concentration Ct) displayed as a function of Ct for two 
dosing regimens 125 mg q12h (a) and 125 mg q8h (b). The middle line represents the values 
for the median of the population and the surrounding lines indicate the 1st, 5th, 95th and 99th 
percentiles, obtained by 5000 Monte Carlo simulations.
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Table 2. Model-based population PK parameter estimates and values obtained after bootstrap 
analysis. 
Parameter Final model 
estimate
RSE (%) Bootstrap 
median
Bootstrap
95% CI
Fixed effects
Vd/F (L) 33.0 3.8 33.0 30.3 – 35.6
CL/F (L/h) 24.6 3.8 24.7 22.6 – 26.6
F (-) 1 (fixed) - 1 (fixed) -
Ka (h-1) 3.99 14.1 3.95 3.07 – 5.20
Lag time (h) 0.447 1.3 0.447 0.436 – 0.456
Covariate: proportional effect on Ka
Dosing time 8:00 1 (fixed) - 1 (fixed) -
Dosing time 16:00 0.903 9.9 0.904 0.737 – 1.08
Dosing time 20:00 0.610 15.1 0.617 0.442 – 0.801
Dosing time 24:00 0.636 14.8 0.638 0.476 – 0.843
Covariate: proportional effect on F
Dosing time 8:00 1 (fixed) - 1 (fixed) -
Dosing time 16:00 0.873 5.6 0.876 0.765 – 0.949
Dosing time 20:00 0.799 7.4 0.802 0.688 – 0.904
Dosing time 24:00 0.801 8.8 0.806 0.663 – 0.944
Between-subject variability (BSV)
Vd (%CV) 23.9 23.2 23.4 12.9 – 33.3
CL (%CV) 26.7 17.1 26.1 17.8 – 34.8
Ka (%CV) 52.8 15.8 51.7 34.4 – 67.8
Between-occasion variability (BOV)
Ka (%CV) 48.5 12.8 47.3 37.8 – 60.2
F (%CV) 28.2 21.4 27.2 16.7 – 38.6
Residual unexplained variability (RUV)
Additive (mg/L) 0.0533 8.2 0.0530 0.0450 – 0.0625
Proportional 0.142 8.2 0.141 0.119 – 0.165
Vd, volume of distribution; F, bioavailability; CL, clearance; Ka, first-order absorption rate 
constant; RSE, relative standard error; CV, coefficient of variation
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Table 3. fAUC0-24 distribution obtained by 5000 Monte Carlo simulations for two dosing 
regimens 125 mg q12h and 125 mg q8h.
fAUC0-24 (mg*h/L)
125 mg q12h 125 mg q8h
Minimum 2.10 3.43
1st percentile 3.17 4.86
2.5th percentile 3.61 5.56
5th percentile 4.07 6.15
50th percentile 6.94 10.4
95th percentile 12.2 17.5
97.5th percentile 13.7 19.2
99th percentile 15.4 21.2
Maximum 28.0 36.1
Discussion 
Our non-compartmental pharmacokinetic analysis showed that clavulanic acid Cmax 
and AUC0-8 in healthy volunteers were highly variable, whereas t1/2 had a limited 
variability. In two-third of the subjects, the Cmax and AUC0-8 of the morning dose were 
higher than later doses. Our population PK model indicated that most variability was 
present on the first-order absorption rate constant (Ka). Ka and bioavailability (F) 
were estimated to be higher in the morning than in the afternoon and evening. 
Similar to the present study, other non-compartmental PK studies with oral clavulanic 
acid demonstrated a more variable Cmax and AUC than t1/2 [2-4]. A population PK 
model for oral amoxicillin/clavulanic suspension [5] also included a high between-
subject variability and between-occasion variability of absorption parameters rather 
than on Vd and CL. Another study in 10 volunteers receiving a single oral and a single 
intravenous dose of clavulanic acid also found a wide bioavailability range (31.4-
98.8%) [2]. 
In our population PK model, we could explain part of the observed variability by 
the effect of dosing time on Ka and F. To our knowledge, time-varying absorption 
and bioavailability of oral clavulanic acid has not previously been described. For two 
other beta-lactams, meropenem and ceftazidime, it has been shown that morning 
concentrations were higher than afternoon concentrations [21-23]. However, 
since those antibiotics were both given intravenously, the varying concentrations 
were explained by renal clearance variation rather than absorption differences as 
in our study. Our finding of the inversely proportional effect of dosing time on 
Ka may be caused by nonlinear processes, such as saturation of Ka. However, this 
seems to be unlikely since implementation of Michaelis-Menten absorption didn’t 
improve the model. Unfortunately, it is impossible to predict the results for second 
and later dosing days, because our data only included dosing regimens of 24 hours. 
Differences in meal composition can be excluded as a reason for variation in Ka and 
F, because each dose was taken at the start of a standardized meal which was the 
same for each moment of the day. Administration without food does not eliminate 
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the variable pharmacokinetics, since fasting studies with oral clavulanic acid also 
showed a high variation in Cmax and AUC [2, 4]. In a chronopharmacokinetic study 
with oral midazolam [20], the daily variation in Ka was described by a time-varying 
covariate and F was parameterized as a cosine function. The Ka and F differences 
were explained by 24-hour variation in gastric emptying, gastrointestinal mobility 
and splanchnic blood flow [20], which may be the most reliable explanation for the 
findings in our study as well. Possible clinical implications of time-varying Ka and F 
for dosing regimens, such as higher afternoon and evening doses than morning doses, 
should be further studied. 
The results of our non-compartmental analysis seem to suggest that the amoxicillin 
dose influences the clavulanic acid PK. However, we tested several covariate types 
of amoxicillin dose (e.g. time dose, daily dose, categorical covariate, continuous 
covariate) during the modelling process and none was significant. The literature is not 
conclusive about the effect of amoxicillin on clavulanic acid PK. It has been reported 
that the Cmax and AUC of oral clavulanic acid in presence of amoxicillin were higher 
than clavulanic acid alone and that the AUC ratio of amoxicillin/clavulanic acid was 
lower (2.55) than expected (500/125=4) [24]. These findings suggest an interaction 
between the absorption of amoxicillin and clavulanic acid. However, these AUC 
ratios differ enormously between studies. For oral 500/125 mg, the AUC ratios in 
our study were 3.4 (500/125 mg q12h) and 3.9 (500/125 mg q8h) whereas other 
studies found ratios of 2.0 [25] and 4.3 [4]. We found an AUC ratio of 2.1 for oral 
250/125 mg which was the same as found by another study [4]. However, a third 
study found a ratio of 1.4 [26]. The AUC ratios for oral 875/125 mg were 5.3 (our 
study) and 5.7 [4]. It is possible that the saturable absorption rate of amoxicillin 
influences the AUC ratio [14]. However, for intravenous amoxicillin/clavulanic acid 
too, the AUC ratios were not as expected: 2.8 (500/100 mg) [27], 2.7 (1000/200 mg) 
[27], 3.2 (500/100 mg) [25], 7.1 (625/125 mg) [2] and 6.5 (2000/200 mg) [27]. These 
findings indicate that also other factors than absorption influence the interaction 
between the two drugs. Although we were not able to find a significant effect of the 
amoxicillin dose on clavulanic acid pharmacokinetics, the influence of the interaction 
between both compounds is not yet clear. The EMA guideline on the use of PK/PD 
in the development of antimicrobials recommends to study the PK interaction of 
beta-lactams and beta-lactam inhibitors [13]. Future research should elucidate the 
influence of amoxicillin on clavulanic acid PK.
Similar to a study with oral amoxicillin/clavulanic suspension in healthy volunteers 
[5], the between-subject variability and between-occasion variability magnitude 
of the absorption parameter was comparable. We hypothesize that in a patient 
population the BSV will be higher than the BOV. Due to highly variable clavulanic 
acid concentrations, the risk of ineffectiveness (with too low concentrations) and 
adverse events (with too high concentrations) should be attended.
When the PD target is known, dosing regimens can be optimized to attain a high 
probability of successful treatment. However, it is still unknown which PK/PD index 
and PD target should be taken into account for clavulanic acid. Since clavulanic acid 
has a unique structure in the group of beta-lactamase inhibitors [7], it is difficult 
to simply extrapolate a PK/PD index from another inhibitor. Clavulanic acid is a 
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clavam isolated from Streptomyces clavuligeres whereas tazobactam and sulbactam 
are synthetic penicillinate sulfones [7, 28]. The different chemical structures possibly 
explain the differences in enzyme activities of these inhibitors [7]. The beta-
lactamase inhibitors avibactam and relebactam are diazabicyclooctane derivatives 
that don’t have structural similarity with beta-lactams [28]. These two compounds 
have different pharmacodynamic properties, although they are both from the same 
group. Avibactam activity is primarily dependent on %fT>Ct [10, 11] and relibactam 
on fAUC [12]. 
Since the PD target for clavulanic acid is unclear, optimization of treatment by 
ensuring a high probability of attainment is not well possible. However, we do 
present simulations and attainment for different targets and these will be useful 
once the PD target of clavulanic acid becomes available. Current EUCAST guidelines 
use a fixed clavulanic acid concentration of 2 mg/L for susceptibility testing purposes 
[29]. Our Monte Carlo simulations show that with 125 mg q12h or q8h half of the 
population attains concentrations of 2 mg/L and the average %fT>Ct is only 2-3%. 
Similarly, assuming a fAUC0-18 of 36 mg*h/L in vitro (based on using the same 2 
mg/L concentration and an incubation time of 18 hours) the probability of target 
attainment is 0% with 125 mg q12h or q8h. However, the in vivo effect of clavulanic 
acid is thereby far underestimated. Ultimately, the susceptibility in vitro has to be 
correlated to efficacy in vivo and there is at present - in contrast to antimicrobials 
- no clear consensus for inhibitors. For example, the EUCAST fixed concentration 
for tazobactam is 4 mg/L [29], which is much higher than the PD target %fT>Ct at 
0.5 mg/L [8]. Pharmacodynamic studies providing data on the clavulanic acid target 
are clearly required. 
A limitation of this study is that only a few covariates were available and unfortunately, 
creatinine data were lacking. This prohibited an analysis of the impact of renal function 
on clavulanic acid exposure. However, the participants were healthy volunteers with 
normal renal function and a clear relationship would likely not have been found in this 
population. Since oral amoxicillin/clavulanic acid is mostly prescribed to patients with 
only relatively mild infections and normal renal function, the results of our study can 
therefore be extrapolated to such patients. Second, it was not possible to evaluate 
different clavulanic acid doses in the population pharmacokinetic analysis, because 
only one dose of clavulanic acid (125 mg) was included in this study. However, 125 mg 
is the dose most generally used for oral dosing. This study included 3 different tablets 
and 4 dosing regimens for amoxicillin/clavulanic acid. It is impossible to extrapolate 
these results to other oral formulations (e.g. the extended release (XR) tablet or 
the suspension). However, because the clavulanic acid formulation and the dosing 
frequency of the XR tablet are the same as used in our study, we expect that the 
timing problem may also exist with the XR tablet. A third limitation is that our data 
only included dosing regimens of 24 hours, which makes it impossible to predict the 
results for second and later dosing days.
In conclusion, clavulanic acid concentrations in healthy volunteers are highly variable 
after oral administration. Bioavailability and absorption rate decrease over the day. 
The consequences of the variable concentrations for underdosing and adverse 
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events should be further studied for multiple day dosing and dosing regimens should 
be optimized. Studies on the PK/PD index and PD target are needed.
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Supplementary Table 1. Characteristics of study population (values expressed as mean ± 
SD)
Characteristic Total (n=29) Part 1 (n=14) Part 2 (n=15)
Age (years) 33 ± 7 35 ± 8 30 ± 5
Height (cm) 179 ± 6 179 ± 6 179 ± 7
Weight (kg) 78 ± 9 78 ± 5 78 ± 11
BMI (kg/m2) 24 ± 2 24 ± 2 24 ± 3
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Supplementary Figure 1. CWRES (Conditional Weighted Residuals) plots: CWRES versus 
PRED (population predicted concentrations) (a) and CWRES versus time (b).
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Supplementary Figure 2. Visual predictive 
checks (VPC), stratified on dosing time: 
125 mg q8h at 8:00 (a), 16:00 (b) and 24:00 
(c) and 125 mg q12h at 8:00 (d) and 20:00 
(e). The open circles represent observed 
concentrations. The upper, middle and 
lower lines indicate the 95th, 50th and 5th 
percentile of observations, respectively. The 
shaded areas represent the 95%CI of the 
corresponding percentiles of predictions.
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Abstract
Background
Population pharmacokinetic (popPK) models for antibiotics are used to improve 
dosing strategies and individualize dosing by therapeutic drug monitoring. Little is 
known about the differences in results of parametric versus nonparametric popPK 
models and their potential consequences in clinical practice. We developed both 
parametric and nonparametric models of imipenem using data from critically ill 
patients and compared their results.  
Methods
Twenty-six critically ill patients treated with intravenous imipenem/cilastatin were 
included. Median estimated glomerular filtration rate (eGFR) measured by the CKD-
EPI equation was 116 ml/min/1.73 m2 (interquartile range, 104-124) at inclusion. The 
usual dosing regimen was 500mg/500mg four times daily. On average, 5 imipenem 
levels per patient (138 levels in total) were drawn as peak, intermediate and trough 
levels. Imipenem concentration-time profiles were analyzed using parametric 
(NONMEM 7.2) and nonparametric (Pmetrics 1.5.2) popPK software. 
Results
For both methods, data were best described by a model with 2 distribution 
compartments and the CKD-EPI eGFR equation unadjusted for body surface area 
as a covariate on the elimination rate constant (Ke). The parametric population 
parameter estimates were: Ke 0.637 h
-1 (between-subject variability [BSV]: 19.0% 
CV) and central distribution volume (Vc) 29.6 L (without BSV). The nonparametric 
values were: Ke 0.681 h
-1 (34.0% CV) and Vc 31.1 L (42.6% CV). 
Conclusions
Both models described imipenem popPK well, the parameter estimates were 
comparable and the included covariate was identical. Estimated BSV was higher, 
however, in the nonparametric model. This may have consequences for estimated 
exposure during dosing simulations and should be further investigated in simulation 
studies. 
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Introduction
Because of increased antimicrobial resistance and few new antibiotics making it to 
market, optimization of antibiotic dosing regimens remains an important challenge to 
improve clinical outcomes of infections. Antimicrobial efficacy is determined by the 
susceptibility of a drug in vitro (usually expressed as the minimal inhibitory concentration, 
MIC) and exposure to the drug in vivo, which relies on the pharmacokinetics and 
the dose [1]. Population pharmacokinetic (popPK) models describe the variability 
of exposure to a drug and are therefore used to support the optimization of 
dosing regimens with the objective to improve antimicrobial efficacy. During the 
development of new antibiotics, popPK models are recommended to support dose 
regimen identification and selection [2]. For already marketed antibiotics, popPK 
models are used in different ways to improve antibiotic dosing: individualization of 
dosing via therapeutic drug monitoring (TDM) software by Bayesian estimation and 
control, optimization of dosing regimens described in the package insert (especially 
for specific subpopulations), and setting clinical breakpoints [3]. Clinical breakpoints 
are MICs that define microorganisms as susceptible, intermediate or resistant to 
specific antibiotics [4]. 
While individual PK methods analyze the concentration-time profiles per individual 
subject, popPK methods analyze these profiles of a population as a whole. PopPK 
models describe and explain different types of PK variability, such as between-subject 
variability (BSV) and residual variability. PopPK modelling methods are classified as 
either parametric or nonparametric methods, which can each be divided in maximum 
likelihood or Bayesian approaches [3]. Bayesian popPK methods are used much less 
often than maximum likelihood popPK methods. Most published popPK models 
are based on parametric maximum likelihood methods (e.g. Monolix, NONMEM 
and Phoenix NLME), which estimate the set of PK parameters that maximize the 
joint likelihood of observations. Parametric methods assume that the population 
parameter distribution is known with population parameters to be estimated [5]. 
An example of nonparametric maximum likelihood software is the NPAG algorithm 
in the R package Pmetrics [6]. Nonparametric methods make no assumption about 
the shapes of the underlying parameter distributions. Another difference is that 
nonparametric methods use an exact likelihood function while most parametric 
methods use an approximation. A disadvantage of nonparametric methods in the 
past was that confidence intervals about parameter estimates could not be easily 
determined [5, 7]. However, Pmetrics can estimate credibility intervals around 
median parameter estimates using a bootstrap method. 
Some studies comparing parametric and nonparametric models are available in the 
literature. Precluding studies with currently outdated modelling software [8-11], we 
found eight comparison studies [12-19]. Four of these studies showed comparable 
parameter estimates of both models [12-15], one study showed different estimates 
[16], for two studies the estimates were incomparable due to a different model 
structure [17, 18] and in one study no parameter estimates were reported [19]. 
However, less similarity among methods was noticed for the BSV of parameters. The 
BSV is defined as the percent coefficient of variation (CV%), which is the standard 
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deviation (SD) divided by the parameter mean. Three studies showed a higher BSV 
for the nonparametric model [12, 13, 16], one study showed similar BSV [14] and, for 
another study, the BSV of the nonparametric model was not reported [15]. Only one 
comparison study [18] presented goodness-of-fit (GOF) plots and visual predictive 
checks (VPCs) of both models. The other studies [12-17, 19] showed either GOF or 
VPC plots of both models, displayed the plots of only one method or did not show 
any GOF or VPC plots.
Many parametric and nonparametric popPK models have been published in the 
literature and are often accompanied by dosing recommendations based on 
simulations of the model [3]. Differences in modelling results between these methods 
may have consequences for simulation findings and may therefore also influence 
dosing recommendations. Different parameter value probability distributions may 
influence dosing recommendations based on popPK models in TDM software. 
To investigate the advantages and disadvantages of both modelling methods in 
practice, we developed both parametric and nonparametric popPK models using 
the same data and compared the results. We used imipenem PK data from critically 
ill patients given this population’s known PK variability for several antibiotics [20]. 
Imipenem is a carbapenem antibiotic administered in combination with cilastatin 
to prevent degradation by dehydropeptidase-I in the kidneys. When combined with 
cilastatin, approximately 70% of imipenem is recovered in the urine within 10 hours 
and the rest is excreted as inactive metabolites via the urine [21]. The half-life is 1 
hour in patients with normal renal function but is extended in patients with renal 
dysfunction [21]. Protein binding is reported as 10 to 20% [22]. 
Although it is known that the correlation between measured creatinine clearance (CLcr) 
and estimated glomerular filtration rate (eGFR) equations is weak [23], these equations 
are used in daily practice in many intensive care units (ICU). In our study population, 
measured CLcr was unavailable. Therefore, we decided to test several eGFR equations 
during covariate model building, to find the most suitable one in our population. 
Methods
Study population
Imipenem PK data from a previously published prospective cohort study [24] 
conducted between 2010 and 2013 in the ICU of the Geneva University Hospitals 
(Geneva, Switzerland) were used for this popPK study. The usual dosing regimen for 
imipenem/cilastatin was 500mg/500mg four times daily, administered by intermittent 
intravenous infusion of 30 minutes. Inclusion criteria were suspected or documented 
severe bacterial infection and age 18-60 years. Exclusion criteria were estimated 
glomerular filtration rate (eGFR) <60 ml/min (measured by the Cockcroft-Gault 
equation [25]), Body Mass Index <18 or >30 kg/m2 and pregnancy. The study protocol 
was approved by the University Hospital’s Ethics Committee (NAC 09-117). Given 
its observational nature, the Committee waived the requirement for informed 
consent from patients who were unconscious or otherwise unable to understand 
the study protocol.
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Among the 54 critically ill patients from the Swiss study who were receiving 
imipenem therapy, the last 27 patients could be included because exact dosing and 
blood sampling times were known, in contrast to the first 27 patients, for whom 
levels were labeled only as trough, intermediate or peak. After excluding one subject 
because of missing height [26], data from the remaining 26 patients were included in 
the popPK study. None of these patients received probenecid, the only drug known 
to influence imipenem concentrations [21]. 
Study procedures
Patients were included on their first or second day of imipenem therapy. Blood 
samples were planned on days 1, 2, 3, 4 and 6 of therapy, although in some patients 
not all planned samples were realized, e.g. due to discontinuation of therapy or 
problems with blood drawing. Imipenem TDM included peak (approximately 15-
30 minutes after end of infusion), intermediate (midway between two sequential 
administrations, approximately 30 minutes) and trough (approximately 15 minutes 
before the next dose) concentrations. Creatinine was monitored daily. 
Imipenem blood samples were drawn and immediately placed on ice and transported 
to the laboratory for centrifugation. MOPS [3-(N-morpholino)propanesulfonic acid], 
a stabilizing buffer that protects imipenem from degradation [27], was added to an 
equivalent volume of plasma. Stabilized imipenem samples were subsequently stored 
at −80 ºC for maximally 1 month.
Imipenem plasma concentrations were analysed by high-performance liquid 
chromatography (HPLC) with ultraviolet (UV) detection at 298 nm. Ceftazidime was 
used as an internal standard in the HPLC-UV analysis. Acetonitrile was added to the 
stabilized plasma for deproteinisation. The calibration curve was linear from 0.5 to 
80 mg/L. Limit of detection (LOD) and limit of quantification (LOQ) were 0.2 mg/L 
and 0.5 mg/L, respectively [24].
Parametric population PK analysis (NONMEM)
Parametric population PK analyses were performed using nonlinear mixed effects 
modelling (NONMEM version 7.2, ICON Development Solutions, Ellicott City, MD, 
USA). The Intel Visual Fortran Compiler XE 14.0 (Santa Clara, CA, USA) was used. 
The first-order conditional estimation method with interaction (FOCE-I) was used 
throughout the model building process. Tools used to evaluate and visualize the 
model were RStudio (version 1.1.456), R (version 3.5.1), XPose (version 4.6.1) and 
PsN (version 4.6.0), all with the graphical interface Pirana [28] (version 2.9.4). 
General model selection criteria were decrease in objective function value (ΔOFV), 
GOF plots and VPCs. A decrease in the OFV of 3.84 units was considered statistically 
significant (p<0.05, df=1) in a nested model [29]. For each VPC, a set of 1000 simulated 
datasets was created to compare the observed concentrations with the distribution 
of the simulated concentrations. A numerical predictive check (NPC) of the final 
model was created to compare with the NPC of the final nonparametric model. 
During modelling, only lower bounds (of 0) and no upper bounds were set for 
each parameter [29]. One-, two- and three-compartment distribution models 
were evaluated [30]. Databases with untransformed and logarithmic transformed 
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concentrations were compared by assessing GOF plots and parameter estimates. 
For both databases, residual unexplained variability was tested with proportional 
and combined (additive and proportional) error models [31]. The proportional 
(exponential) error model of the final NONMEM model with log-transformed data is 
shown in equation 1. The observed concentration (OBS) consists of the individually 
predicted concentration IPRED with added residual unexplained variability ε (epsilon, 
fixed to 1 in our model) weighted by an estimated error parameter.  
OBS = IPRED + √(error2) * ε          (1)
Variability of a population PK parameter was estimated using an exponential variance 
model (individual popPK parameter = population popPK value * eη). Eta (η) is a 
random variable drawn from a normal distribution with a mean of 0 and a variance of 
omega (ω2) [32]. The BSV (CV%) of a population parameter is calculated by equation 
2 [33]. The SD is subsequently calculated by multiplying the CV% with the population 
parameter estimate. 
CV% (eη ) = √(eω2- 1) * 100%              (2)
First, models with BSV on Ke and BSV on V were compared by assessing ΔOFV and 
GOF plots. Subsequently, one-by-one addition of BSV on the other parameters was 
studied. A stepwise covariate model building was performed with forward addition 
at p<0.05 (ΔOFV of 3.84 units, df=1) followed by backward elimination at p<0.001 
(ΔOFV of 10.83 units, df=1) [34]. Covariates were tested on parameters with BSV. 
The tested covariates are described in the Methods section “Covariates”. 
The 95% CI of each parameter in the final model was determined from a nonparametric 
bootstrap analysis, in which the dataset was resampled 1000 times.
Nonparametric population PK analysis (Pmetrics)
Nonparametric population PK analysis was performed using Pmetrics version 1.5.2 
(Laboratory of Applied Pharmacokinetics and Bioinformatics, Los Angeles, CA, USA) [6] 
in RStudio (version 1.1.456) as a wrapper for R (version 3.5.1). The Intel Visual Fortran 
Compiler XE 14.0 (Santa Clara, CA, USA) was used. The Non-Parametric Adaptive Grid 
(NPAG) program was used throughout the model building process. The Iterative 2-stage 
Bayesian (IT2B) program was used to estimate parameter ranges to pass to NPAG.
An NPAG will create a nonparametric popPK model consisting of discrete support 
points, each with a set of estimates for all parameters in the model plus an associated 
probability of that set of estimates (see Figure 1 for an illustration of the distribution 
of a parameter) [6]. The sum of all probabilities is 1. There can be a maximum of 1 
point for each subject in the study population [6]. Besides an overview of support 
points with corresponding parameter estimates, the NPAG output contains also the 
mean, SD and CV% of each parameter. The reported means are weighted means which 
are calculated by multiplying the estimate of each support point by the probability of 
that point and then summing up the resulting numbers. The SD is calculated from the 
parameter distribution. The BSV (CV%) of each parameter estimate is calculated by 
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dividing the SD by the weighted mean.  
One-, two- and three-compartment distribution models were evaluated. A stepwise 
covariate model building was performed with forward addition at p<0.05 (decrease 
in the -2 times the log-likelihood, Δ-2LL, of 3.84 units, df=1) followed by backward 
elimination at p<0.001 (Δ-2LL of 10.83 units, df=1) [34]. Covariates were tested on 
parameters selected after a graphical examination of possible covariate-parameter 
relationships. The tested covariates are described in the Methods section “Covariates”. 
Each observation in Pmetrics is weighted by 1/error2. Both gamma and lambda error 
models were tested (see equation 3 and 4). The SD of an observation is based on 
the assay error polynomial (see equation 5) [6]. However, because the assay error 
polynomial was unavailable in our study, we estimated the error coefficients with C0 
= 0.5 * LOQ, C1 = 0.1, C2=0 and C3=0 as a starting point. 
error = SD * gamma            (3)
error = √(SD2 + lambda2)             (4)
SD = C
0 
+ C
1 
* OBS + C
2 
* OBS2 + C
3 
* OBS3           (5)
Model selection criteria were decrease in -2LL, bias, imprecision, GOF plots and 
VPCs. A decrease in the -2LL of 3.84 units was considered statistically significant 
(p<0.05, df=1) in a nested model. For each VPC, a set of 1000 simulated datasets 
was created to compare the observed concentrations with the distribution of the 
simulated concentrations. An NPC of the final model was created to compare with 
the NPC of the final parametric model. The raw VPC and NPC data were imported 
into PsN (version 4.6.0) using the Pirana interface [28] to generate plots with a 
similar layout as the parametric plots. VPC and NPC plots were created using XPose 
(version 4.6.1) within RStudio (version 1.1.456). Bias (mean weighted prediction 
error) and imprecision (bias-adjusted mean weighted squared prediction error) are 
automatically calculated by Pmetrics according to equations 6 and 7, both population 
and posterior predictions. 
           
Bias =          
           
(6)
           
Imprecision =                   - bias2           (7)
The 95% CI of each parameter in the final model was determined using a Monte Carlo 
simulation approach by creating 1000 samples with replacement for each support 
point [35], resulting in the 2.5th, 50th and 97.5th percentiles of the weighed median 
and  the median absolute weighted deviation (MAWD). The SD was estimated by 
multiplying MAWD by 1.4826 [36]. The CV% was calculated by dividing the SD by 
the 50th percentile of the weighted median. 
Covariates
The tested covariates for both modelling approaches were: total body weight (TBW), 
ideal body weight (IBW) [37], lean body weight (LBW) [37], Cockcroft-Gault (CG) 
(PRED
1 
- OBS
1
)/(error2)
1 
+ ... + (PRED
n 
- OBS
n
)/(error2)
n
(PRED
1 
- OBS
1
)2
 + ... +
(PRED
n 
- OBS
n
)2
((error2)
1
)2                                ((error2)
n
)2
n
n
∑ (
∑ 
)
)(
82 | Chapter 3.1
eGFR [25], 4-variable Modification of Diet in Renal Disease (MDRD) Study eGFR 
[38], Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) eGFR [39], 
and Jelliffe’s eGFR equation for patients with unstable renal function [40]. Per patient, 
one body weight measure was available, while a median of 3 creatinine samples per 
patient was drawn (see also Table 1). The MDRD, CKD-EPI and Jelliffe’s equations 
provide eGFR values adjusted for body surface area, BSA, (ml/min/1.73 m2). The BSA-
unadjusted (absolute) values (ml/min) were also calculated by multiplying the original 
eGFR by the individual BSA [41] and evaluated as covariates: MDRD-abs, CKD-EPI-
abs and Jelliffe-abs. The CG eGFR equation is unadjusted for BSA (ml/min) and no 
adjustment was made.   
All covariates were evaluated by power models with normalized covariates where 
the median covariate value was taken as the reference value (see equation 8). 
Because multiple creatinine samples per patient were collected, which are each used 
to calculate CG, MDRD and CKD-EPI eGFR values, eGFR was tested as a time-
varying covariate. We also tested the possible situation of reaching a maximum value 
of the elimination constant Ke for high (adjusted or unadjusted) eGFR values from 
150, 120 and 90. For total, lean and ideal body weight, both fixed (-0.25 for Ke and 1 
for V) and estimated values of the power exponent were evaluated [42].
           
Par
ind
 = Par *                    
power
 * en             (8)
Parind: individual PK parameter estimate, Par: population PK parameter estimate (for 
NONMEM) or weighted median value of the Bayesian posterior distribution (for 
Pmetrics), Covind: individual covariate value, Covmedian: median covariate value, power: 
covariate effect, eη: individual variability (eη only for NONMEM). See equation 9 
and 10 in the Results section for further clarification of the differences between 
equations in the final parametric and nonparametric models. 
Default covariate settings were used for each modelling approach. In NONMEM, 
by default, the next observation is carried backward (NOCB) until the time point 
of the previous covariate observation. For Pmetrics, covariates are applied at each 
dose event. By default, for missing covariate values, the last observation is carried 
forward (LOCF) until the last dose before the next covariate observation, when the 
last observation is linearly interpolated to the next observation.
Model development and comparison
Both models were developed by a medium-experienced NONMEM and Pmetrics 
modeler (FdV) supervised by highly experienced NONMEM (BdW) and Pmetrics 
(WY, MN) modelers. The development of both models occurred independently 
from each other according to a predefined study procedure, where the modelling 
workflow (e.g. model selection criteria, building of the structural model and covariate 
evaluation) was described. During model development, the GOF plots and VPCs were 
assessed in the layout of the separate programmes. During writing of the manuscript, 
the raw data of the GOF plots were transferred to GraphPad Prism (version 8.1.1) 
and the raw VPC and NPC data of Pmetrics were transferred to PsN (see Methods 
Covind
Covmedian(
(
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section about Pmetrics) to create plots with the same layout. The R2 of nonlinear 
regression was calculated within GraphPad Prism by the 4th equation of Willett and 
Singer [43] for the GOF plots as a description of the graphical fit. R2 was not used 
during model selection.
Results 
Study population
Demographic and clinical characteristics of the 26 included patients are summarized in 
Table 1. None of the patients received continuous renal replacement therapy (CRRT).
Table 1. Demographic and clinical characteristics of study population (n=26). 
Parameter Value
Male, n (%) 18 (69)
APACHE II score, median (IQR) 22 (17-27)
Age (years), median (IQR) 51 (39-54)
Creatinine at inclusion (μmol/L), median (IQR) 59 (46-70)
Creatinine samples per patient, median (IQR) 3.0 (2.0-4.0)
Creatinine samples per patient per day, median (IQR) 1.5 (1.2-1.8)
eGFR at inclusion
CG (ml/min), median (IQR) 146 (123-170)
CKD-EPI (ml/min/1.73 m2), median (IQR) 116 (104-124)
CKD-EPI-abs (ml/min), median (IQR) 119 (110-139)
MDRD (ml/min/1.73 m2), median (IQR) 121 (104-159)
MDRD-abs (ml/min), median (IQR) 127 (118-162)
Jelliffe (ml/min/1.73 m2), median (IQR) 156 (132-183)
Jelliffe-abs (ml/min), median (IQR) 168 (141-202)
Height (cm), median (IQR) 175 (168-179)
Total bodyweight (kg), median (IQR) 75 (66-85)
Ideal bodyweight (kg), median (IQR) 70 (59-73)
Lean bodyweight (kg), median (IQR) 58 (46-64)
BMI (kg/m2), median (IQR) 25 (22-27)
BSA (m2), median (IQR) 1.89 (1.72-2.04)
Presumed infection, n (%)
Lower respiratory tract infection 16 (62)
Intra-abdominal infection 4 (15)
Bloodstream infection 3 (12)
Surgical site infection 1 (4)
Meningitis 1 (4)
Gynecological infection 1 (4)
APACHE, Acute Physiology and Chronic Health Evaluation; IQR, Interquartile Range, eGFR, 
estimated Glomerular Filtration Range; CG, Cockcroft-Gault; CKD-EPI, Chronic Kidney 
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Disease Epidemiology Collaboration; CKD-EPI-abs, absolute CKD-EPI (= CKD-EPI multiplied 
by BSA); MDRD, 4-variable Modification of Diet in Renal Disease; MDRD-abs, absolute MDRD 
(= MDRD multiplied by BSA); Jelliffe-abs, absolute Jelliffe (= Jelliffe multiplied by BSA); BMI, 
Body Mass Index; BSA, Body Surface Area.
Imipenem samples 
In total, 138 imipenem blood samples were collected from 26 patients and were 
subsequently analyzed. Fewer than 10% [30] of all concentrations (13/138 = 9.4%) 
were below the limit of quantification (0.5 mg/L) and were excluded from the popPK 
analysis. The average number of levels per patient was 5 (range, 1-11). Almost half of 
all samples (65/138 = 47.1%) were drawn on the second day of therapy. 
A graph of the analyzed imipenem concentrations (n=125) plotted against the 
time after dose is shown in Supplementary Figure 1. These 125 concentrations 
were drawn after 84 individual doses. Following 33 of these doses two or three 
concentrations were taken and after the other 51 doses one concentration was 
drawn. For all PK samples, a creatinine concentration was available in the 24h before 
PK sampling. 
Parametric population pharmacokinetic model 
The parametric popPK analysis using NONMEM showed that the data were best 
described by a model with 2 distribution compartments, BSV on Ke and CKD-EPI-
abs as a covariate on Ke. The parameter estimates of the final model are displayed in 
Table 2. Only BSV on Ke was included (see also Figure 1), because BSV on central 
distribution volume (Vc), rate constant from central to peripheral compartment (Kcp) 
and rate constant from peripheral to central compartment (Kpc) did not significantly 
improve the model (ΔOFV <3.84 and no improvement of GOF plots). Vc, Kcp and Kpc 
are the same for each subject (no BSV was included and therefore no CV% is shown 
in Table 2). Eta-shrinkage was low (14%). No large correlation (>0.95) between 
the parameters was detected [29]. The GOF and VPC plots, displayed in Figure 2a, 
Figure 3a and Supplementary Figure 2a, show a good predictive performance for 
all concentrations, for the time range after dose and for the CKD-EPI-abs range of 
18-190 ml/min (except from an outlier for the 124-141 ml/min bin). The NPC did not 
show points outside boundaries (data not shown). As shown in Table 2, the model-
based parameter estimates were similar to the bootstrap values, indicating stability 
of the model. 
A two-compartment model described the data better than one- or three-
compartment models, according to GOF-plots and OFV increase of 22.99 for a one-
compartment model and 0 for a three-compartment model. The popPK parameters 
of a two-compartment model with logarithmic transformed data were comparable 
to the same model with untransformed data. The GOF plots were improved by 
logarithmic transformation and therefore the following analyses were performed 
with transformed data. An exponential (proportional) error model (see equation 
1) was preferred to a combined error model due to estimation problems with the 
combined model. This confirmed the findings of the untransformed data, where the 
proportional error model had a better performance than the combined error model. 
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Several covariates (as described in Methods section “Covariates”) were tested on Ke, 
the only parameter with BSV. All tested eGFR covariates on Ke resulted in a significant 
OFV decrease (ΔOFV 24.4 until 38.3, p<0.05) compared to the two-compartment 
model without covariates. However, the OFV of the model with CKD-EPI-abs as a 
covariate on Ke was significantly better than the other eGFR models (for example, 
the second best eGFR was CKD-EPI on Ke with an OFV increase of 4.3 compared 
with CKD-EPI-abs, p<0.05). Due to the observation of a maximum of eta in the eta-
eGFR plots, implementation of a maximum Ke value for eGFR values from 150, 120 
and 90 was tested, but this did not further improve the model. None of the tested 
measures of body weight improved the model as a covariate on Ke (ΔOFV<3.84) 
during the univariate analysis. 
Equation 9 describes the calculation of individual Ke (Kei) values in the final NONMEM 
model, using the population parameter estimates for Ke and Ke(cov) from Table 2, 
the individual CKD-EPI-abs value at a certain time point and eη (individual variability). 
Eta (η) is drawn from a normal distribution with a mean of 0 (note equation 9: then 
e0 = 1) and variance ω
2
 (estimated from the data as 0.0354). The corresponding BSV 
for Ke (CV% 19.0%) was calculated from equation 2.     
          
Kei = 0.637 *                             
 0.655 * en         (9)
A plot of the individual Ke against the individual CKD-EPI-abs (n=86) is shown in 
Supplementary Figure 3a. Simulated concentration-time profiles for CKD-EPI-abs 
of 150, 120 and 90 ml/min (n=1000 for each eGFR) are shown in Supplementary 
Figure 4a.  
The median and interquartile range of the untransformed residuals (observed minus 
predicted concentrations) was -0.159 (-0.960 - 1.267) mg/L for the population 
predictions and -0.027 (-0.649 – 0.698) mg/L for the individual predictions. Residual 
plots are shown in Supplementary Figure 5a. 
Nonparametric population pharmacokinetic model 
The nonparametric popPK analysis using Pmetrics resulted in the same model 
structure as the parametric analysis: a model with 2 distribution compartments and 
CKD-EPI-abs as a covariate on the elimination constant Ke. The mean parameter 
estimates of the final model are displayed in Table 2. For example, the mean Kepop 
value is the mean of the support points weighted by population probabilities. This 
is illustrated in Figure 1. Each individual has a Bayesian posterior (i.e. personal or 
individual) set of support points weighted by individual probabilities [6]. No large 
correlation (>0.95) between the parameters was detected. The GOF and VPC plots, 
displayed in Figure 2b, Figure 3b and Supplementary Figure 2b, show a good 
predictive performance for all concentrations, for the time range after dose and 
for the CKD-EPI-abs range of 18-190 ml/min (except from an outlier for the 124-
141 ml/min bin, similar to the parametric model). Similar to the parametric model, 
the NPC did not show points outside boundaries (data not shown). As shown in 
Table 2, the model-based parameter estimates were similar to the bootstrap values, 
indicating stability of the model. 
CKD - EPI - abs
i
119
((
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A two-compartment model described the data better than one- or three-
compartment models, according to GOF-plots and -2LL increase of 26.5 for a one-
compartment model and 0.8 for a three-compartment model. The gamma error 
model was preferred to the lambda model (see equations 3 and 4). The final values 
for C0 and C1 in the assay error polynomial were both 0.05 and C2 and C3 were both 
0 (see equation 5). Parameter boundaries (Ke 0-1.5, V 1-70, Kcp and Kpc 0-1) were set 
based on an IT2B run. 
We evaluated several covariates (as described in Methods section “Covariates”) on 
Ke and V. All tested eGFR covariates on Ke resulted in a significant -2LL decrease 
(Δ-2LL 53.3 until 59.9, p<0.05) compared to the two-compartment model without 
covariates. The -2LL value of the 4 models with the largest -2LL decrease (MDRD, 
MDRD-abs, Jelliffe-abs and CKD-EPI-abs) did not differ significantly from each other. 
The model with CKD-EPI-abs had the lowest bias and imprecision compared to the 
3 other models. Implementation of a maximum Ke value for eGFR values from 150, 
120 or 90 did not improve the model. The univariate analysis resulted in a further six 
significant covariates (p<0.05): TBW, IBW and LBW on Ke (Δ-2LL 4.0 until 8.8) and 
CG, Jelliffe and Jelliffe-abs on V (Δ-2LL 4.6 until 5.5). After backward elimination at 
p<0.001, none of these six covariates remained in the final model. 
Equation 10 describes the calculation of individual Ke values (Kei) in the final Pmetrics 
model. Contrary to the parametric model with equal Ke and Ke(cov) values for each 
individual subject (see equation 9), these values are different for each individual 
subject in the nonparametric model. Kei,med is the weighted median value of the 
Bayesian posterior distribution for Ke in the i
th
 individual, Ke(cov)i,med is the weighted 
median value of the Bayesian posterior distribution for Ke(cov) in the i
th
 individual 
and CKD-EPI-absi is the individual CKD-EPI-abs value at a certain time point. 
           
Kei = Kei,med *                             
Ke(cov)i,med       (10)
A plot of the individual Ke against the individual CKD-EPI-abs (n=86) is shown 
in Supplementary Figure 3b. This plot shows a similar Kei versus CKD-
EPI-abs relationship as the parametric model, although the Kei distribution is 
wider for the nonparametric model. A wider distribution is also shown in the 
simulated concentration-time profiles for CKD-EPI-abs of 150, 120 and 90 ml/min 
(Supplementary Figure 4b).  
The median and interquartile range of the residuals (observed minus predicted 
concentrations) was -0.045 (-0.498 – 1.506) mg/L for the population predictions and 
0.011 (-0.295 – 0.533) mg/L for the individual predictions. Residual plots are shown 
in Supplementary Figure 5b. These are similar to the parametric ones. 
CKD - EPI - abs
i
119
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Figure 1. Distribution of Ke in the NONMEM and Pmetrics popPK models. NONMEM: normal 
distribution (mean 0.637 h-1 and SD 0.121 h-1 (CV 19.0%)). Pmetrics: marginal distribution of 16 
support points with 11 unique values for Ke (weighted mean 0.681 h
-1
 and SD 0.232 h
-1 (CV 34.0%)) 
Table 2. Population parameter estimates.
NONMEM
Final model Bootstrap
Parameter Parameter 
estimate
CV (%) Median 
parameter 
estimate
95%CI 
parameter 
estimate
Median
CV (%)
95%CI 
CV (%)
Vc (L) 29.6 - 29.4 22.9 – 34.4 - -
Kcp (h
-1) 0.166 - 0.169 0.092 – 0.436 - -
Kpc (h
-1) 0.195 - 0.192 0.079 – 0.604 - -
Ke (h
-1) 0.637 19.0 0.634 0.543 – 0.805 18.6 10.5 – 27.4
Ke(cov) 0.655 - 0.665 0.474 – 1.184 - -
Exponential 
error (mg/L)
0.348 - 0.340 0.281 – 0.413 - -
Pmetrics
Final model Bootstrap
Parameter Mean 
parameter 
estimate
CV (%) Median 
parameter 
estimate
95%CI 
parameter 
estimate
Median
CV (%)
95%CI 
CV (%)
Vc (L) 31.1 42.6 35.1 20.1 – 38.3 36.3 3.8 - 62.8
Kcp (h
-1) 0.374 81.2 0.347 0.122 – 0.563 75.2 6.5 - 169.1
Kpc (h
-1) 0.495 72.0 0.387 0.278 – 0.846 90.1 6.2 - 157.6
Ke (h
-1) 0.681 34.0 0.586 0.533 – 0.905 47.0 3.1 - 66.1
Ke(cov) 0.658 55.2 0.791 0.516 – 1.000 38.3 0.0 - 82.6
Gamma 
(error model)
3.40 - - - - -
Vc: central distribution volume, Kcp: rate constant from central to peripheral compartment, Kpc: 
rate constant from peripheral to central compartment, Ke: elimination rate constant, Kecov: 
covariate effect on Ke, CV: coefficient of variation, CI: confidence interval. 
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Figure 2. Goodness-of-fit plots with the observed against the predicted concentrations of 
both models. Solid line: identity (1:1) line. Dotted line: regression line.
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Figure 2a. Goodness-of-fit plots of the final parametric model. The log-transformed 
concentrations are back transformed for an easier comparison with the untransformed 
concentrations in Figure 2b 
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Figure 2b. Goodness-of-fit plots of the final nonparametric model
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Figure 3. Visual Predictive Checks (VPCs) of both models 
Circles: observed concentrations. Upper, middle and lower lines: 95th, 50th and 5th percentile of 
observations. Shaded areas: 95%CI of the corresponding percentiles of predictions.
Figure 3a. VPC of the final parametric model. The log-transformed concentrations are back 
transformed for an easier comparison with the untransformed concentrations in Figure 3b 
Figure 3b. VPC of the final nonparametric model 
Discussion
The structure and parameter estimates of our two independently developed 
parametric and nonparametric popPK models of imipenem in critically ill patients 
treated with imipenem/cilastatin were similar: both included 2 distribution 
compartments and CKD-EPI-abs as a covariate on Ke. Body weight as a covariate 
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was not found to be a significant covariate in either model. Both models described 
imipenem PK well. Two main differences between the models emerged. First, the 
parametric model included between-subject variability (BSV) for Ke only, while the 
nonparametric model included such variability on all popPK parameters. Second, the 
estimated BSV (defined as CV%) for Ke was higher for the nonparametric model 
(34.0% vs 19.0%). The findings of similar parameter estimates but higher BSV for the 
nonparametric model are in line with two previously published studies comparing 
parametric and nonparametric models of other drugs [12, 13]. These BSV differences 
could be explained by the statistics behind the modelling methods. Both models 
have fixed (no BSV) and random (including BSV) parameters. However, while during 
parametric modelling the inclusion of BSV is examined for each popPK parameter, 
all popPK parameters for nonparametric models are in principle random parameters 
while the residual error model is fixed. In addition, while parametric methods assume 
a normal or lognormal distribution of parameters, nonparametric methods make 
no assumption about the parameter distributions, which can cause a wider CI of 
the parameter estimates (e.g. see Figure 1 for Ke, which also clearly shows the 
differences between the two CV% measures, and Supplementary Figure 3). The 
simulated concentration-time profiles in Supplementary Figure 4 indicate that 
the concentrations of the 2.5th percentile are approximately 2-fold lower for the 
nonparametric model. The consequences of this finding (e.g. higher or more frequent 
dosing following the nonparametric model) should be further explored by probability 
of target attainment calculations based on extensive Monte Carlo simulations for 
several dosing regimens [44].
Our finding of 2 distribution compartments is in accordance with other published 
popPK models of imipenem in critically ill patients (all with pneumoniae) [45-47]. 
However, our Vc and clearance (CL = Vc * Ke) values were higher than previously 
described [45-47]. This could be explained by a higher creatinine clearance in our 
population, which could be attributed to augmented renal clearance (ARC) [48, 49]. 
ARC is defined as increased renal elimination of circulating solutes and drugs as 
compared with normal baseline [23] and has been reported in approximately 30-65% 
of critically ill patients [48]. Our Kcp (0.2-0.4) and Kpc (0.2-0.5) values of both models 
were similar to the previously published parametric model [45], but remarkably 
different from the two nonparametric models (Kcp 3-8 and Kpc approximately 9) [46, 
47]. Possibly, these differences could be explained by (unpublished) wider parameter 
boundaries of their nonparametric models. The parameter ranges in nonparametric 
software are strict boundaries wherein the optimal values are sought. To assist 
with optimal setting of parameter ranges in nonparametric popPK, we used the 
parametric IT2B module in Pmetrics to estimate the parameter ranges to pass to 
the nonparametric NPAG module. During parametric modelling with NONMEM, 
the parameter initial estimate is a starting point to search for the optimal value and 
setting limits is not always necessary [29]. This was underlined by the fact that the 
results of our final NONMEM model with only lower boundaries were the same as a 
model with the same upper and lower boundaries as the final Pmetrics model. 
Many types of standard goodness-of-fit plots used for model evaluation are applied 
both in parametric and nonparametric modelling: observed versus population 
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predicted concentrations, observed versus individually predicted concentrations and 
weighted residual (WRES) plots. The observed versus predicted concentration plots 
of our popPK models are comparable. In Pmetrics, the standard layout of these 
plots includes the R2, intercept, slope, bias (mean weighted residual) and imprecision. 
In NONMEM, these measures are not automatically calculated. A residual is the 
difference between an observed and a predicted concentration. Weighted residuals 
are used in WRES plots as well as for the calculation of bias and imprecision. We 
did not show WRES plots nor calculated weighted bias and imprecision for both 
methods because of two reasons. First, the weighting differs between the two 
modelling methods. In NONMEM, the Conditional WRES (CWRES) is the residual 
weighted by the square root of the covariance of a FOCE model [50], while in 
Pmetrics WRES is the residual weighted by the squared error [35]. Second, a weighted 
residual of logarithmic transformed data (in our NONMEM model) is not the same 
as a weighted residual of untransformed data (in our Pmetrics model). We used 
weighted bias and imprecision in Pmetrics only to differentiate between 4 covariate 
models with a -2LL decrease which did not differ significantly from each other. As an 
alternative to weighted bias, we calculated unweighted bias (the unweighted residuals 
of untransformed concentrations), of which the median and interquartile range were 
comparable for both methods. 
The VPCs of both popPK models indicate a sufficient predictive performance. The 
means of the 95th, 50th and 5th percentiles of predictions are comparable for both 
models, but the 95%CI of these percentiles differ for some bins (timeframes) of 
the VPCs. Most remarkably, the 95%CI of the 95th and 50th percentile of the last 
2 bins (4.3-5.8 h after dose) is wider for the nonparametric model. This could be 
explained by a higher estimated BSV of Ke in the nonparametric model, leading to 
a wider distribution of concentrations in the elimination phase. We did not show 
prediction-corrected VPCs (pcVPCs) because this option has been developed for 
parametric methods [51] and has not yet been tested for nonparametric methods. 
In a pcVPC, the variability coming from binning across the independent variable, e.g. 
due to different doses or influential covariates, is removed [51]. The pcVPCs of the 
NONMEM model did not show important differences from the traditional VPCs 
(data not shown).
Both models include CKD-EPI-abs as a covariate on Ke. Two of the three previous 
mentioned published popPK models of imipenem also included renal function as a 
covariate, but other measures were used: 4h creatinine clearance (4h-CLcr) in urine 
[45] and the Cockcroft-Gault equation [47]. Sakka et al. did not find 12h-CLcr in urine 
as a significant covariate [46]. Besides eGFR, also other covariates were included in 
the published models: body weight [45-47], height [46, 47], BSA [46, 47], age [46, 47], 
sex [47] and albumin [45]. In our covariate screening plots, sex, age and height did not 
show a relationship with any PK parameters. Body weight did show a relationship in 
the covariate plots, but inclusion as a covariate did not improve the model. Albumin 
data were not available. BSA was taken into account during eGFR covariate testing. 
We tested both BSA-unadjusted (ml/min) and BSA-adjusted (ml/min/1.73 m2) eGFR 
equations, because the European Medicines Agency [52] and the Kidney Disease 
Improving Global Outcomes (KDIGO) guideline [53] recommends to base dosing on 
92 | Chapter 3.1
absolute instead of BSA-normalized eGFR. The KDIGO [53] recommends using the 
CKD-EPI eGFR equation. This guideline, however, is based on chronic kidney disease, 
while our study population consisted of critically ill patients with a high median 
CKD-EPI eGFR of 116 ml/min/1.73 m2. The correlation between measured CLcr and 
eGFR equations is known to be weak in critically ill patients [23, 54]. Nonetheless, the 
measurement of CLcr (as a surrogate for GFR) is time consuming and not standard 
practice in many ICUs. In daily practice eGFR is also used for dosing drugs with renal 
clearance, although many patients have a renal function that is not in steady state. 
Therefore, we decided to test several eGFR equations to find the most suitable one 
in our population. Minichmayr et al. performed a similar eGFR covariate analysis for 
meropenem in critically ill patients. They found that the Cockcroft-Gault equation 
best described meropenem clearance [55]. We observed a maximum in the BSV-eGFR 
plots. However, implementation of a maximum Ke value for eGFR values from 150, 
120 and 90 did not further improve the model. As already mentioned, the correlation 
between measured CLcr and eGFR equations is weak, but it is also shown that this 
correlation varies over the eGFR range [23]. For example, in a previous study was 
shown that the CKD-EPI equation performed better for measured CLcr <120 ml/min 
than for CLcr > 120 ml/min [23]. We did not confirm this finding in our study (see 
Supplementary Figure 2). This could be explained by a different study population. 
For both modelling approaches, eGFR was implemented as a time-varying covariate 
using a stepwise (discontinuous) approach. The default covariate settings of both 
methods were slightly different (i.e. NOCB without interpolation or LOCF with 
linear interpolation from the last dose before the next covariate value). However, the 
parameter estimates of both final models, developed with the default settings, were 
very similar to the same models using LOCF without interpolation. This is explained 
by the majority (85%) of the patients having reasonably stable CKD-EPI-abs eGFR 
values around PK sampling, according to the KDIGO definition of an eGFR drop or 
rise of less than 25% to the previous value [53]. This stability statement is supported 
by frequent creatinine monitoring. A creatinine concentration in the 24h before 
TDM was available for all PK samples. Due to the stable eGFR values, a continuous 
covariate approach was not necessary. 
We performed our study using the most used parametric (NONMEM) and 
nonparametric (Pmetrics) software. For approximately a decade, a nonparametric 
method also exists in NONMEM and some publications [19, 56-58] regarding the 
evaluation and optimization of this approach are available. However, this method is 
seldom used in clinical practice. The parametric module IT2B in Pmetrics is used to 
estimate parameter ranges to pass to NPAG, but underperformed compared with 
other parametric algorithms [12]. 
One of the limitations of our study is that we used eGFR equations for a critically 
ill population with a high frequency of augmented clearance, while these equations 
are developed for more stable patients with chronic kidney disease. Nonetheless, 
as measured CLcr was unavailable and is also not standard practice in many ICUs, 
we aimed to find the eGFR equation that would best describe imipenem clearance. 
Another drawback is that we could not compare weighted residuals, because the 
weighting is different for both methods and the residuals of untransformed data 
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(used for the nonparametric model) are different from transformed data (used for 
the parametric model). Other limitations are the small number of subjects and the 
absence of an external validation. It would be interesting to compare the predictions 
of both models. 
Conclusions
The general structure and the parameter estimates of both models were comparable. 
The identical covariate results (CKD-EPI-abs on Ke) of the two different modelling 
methods strongly support the findings in this population. The nonparametric model 
included BSV for all parameters while the parametric model only included BSV 
on Ke, and the estimated BSV of Ke was higher in the nonparametric model. The 
consequences of the BSV differences may affect estimated exposure during dosing 
simulations, and this should be further investigated in simulation studies.  
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Supplementary Figure 1. Observed imipenem concentrations (n=125) plotted against the 
time after dose.
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Supplementary Figure 2. Visual Predictive Checks (VPCs) of both models with CKD-EPI-abs 
as the independent variable.
Circles: observed concentrations. Upper, middle and lower lines: 95th, 50th and 5th percentile of 
observations. Shaded areas: 95%CI of the corresponding percentiles of predictions.
Supplementary Figure 2a. VPC of the final parametric model. The log-transformed 
concentrations are back transformed for an easier comparison with the untransformed 
concentrations in Supplementary Figure 2b. 
Supplementary Figure 2b. VPC of the final nonparametric model. 
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Supplementary Figure 3. Individual Ke values plotted against CKD-EPI-abs (n=86) for the 
final parametric (a) and nonparametric models (b). The values of each individual subject (n=26) 
are connected with a solid line. The dotted lines indicate the 10th and 90th percentile of the 
CKD-EPI-abs values. 
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Supplementary Figure 4. Simulated concentration-time profiles for eGFR (CKD-EPI-abs) 
of 150, 120 and 90 ml/min (n=1000 for each eGFR), displayed as the median, 97th and 2.5th 
percentile, for the final parametric (a) and nonparametric models (b). The inserts show the 
simulations at 6h on a linear scale. 
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Supplementary Figure 5. Residual plots
Obs: observed concentration
Pred: population predicted concentration
Ipred: individual predicted concentration
Res: residual (observed minus population predicted concentration)
Ires: individual residual (observed minus individual predicted concentration)
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Supplementary Figure 5a. Residual plots of the final parametric model. The log-transformed 
concentrations are back transformed for an easier comparison with the untransformed 
concentrations in Supplementary Figure 5b.
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Supplementary Figure 5b. Residuals plot of the final nonparametric model.
Chapter 3.2
Validation and simulation of two 
population pharmacokinetic models 
of imipenem
Parametric and nonparametric population pharmacokinetic 
models to assess probability of target attainment of imipenem 
concentrations in critically ill patients 
F. de Velde
B.C.M. de Winter
M.N. Neely
J. Strojil
W.M. Yamada
S. Harbarth
A. Huttner
T. van Gelder
B.C.P. Koch
A.E. Muller
on behalf of Combacte-Net consortium. 
Submitted.
Chapter 4
Optimising the design and analysis of 
clinical trials for antibiotics
Optimising the design and analysis of clinical trials for antibacterials 
against multidrug-resistant organisms: 
a white paper from COMBACTE’s STAT-Net
M.E.A. de Kraker
H. Sommer
F. de Velde
I. Gravestock
E. Weiss
A. McAleenan
S. Nikolakopoulos
O. Amit
T. Ashton
J. Beyersmann
L. Held
A.M. Lovering
A.P. MacGowan
J.W. Mouton
J.F. Timsit
D. Wilson
M. Wolkewitz
E. Bettiol
A. Dane
S. Harbarth
on behalf of Combacte-Net Consortium.
Clinical Infectious Diseases. 2018;67:1922-31.
126 | Chapter 4
Abstract 
Innovations are urgently required for clinical development of antibacterials against 
multidrug-resistant organisms (MDROs). Therefore, COMBACTE STAT-Net (2013-
2017), a European, public-private working group, has reviewed and tested several 
innovative trials designs and analytical methods for randomised clinical trials, which 
has resulted in eight recommendations. The first three focus on pharmacokinetic and 
pharmacodynamic (PK/PD) modelling, emphasizing the pertinence of population-
based PK models, regulatory procedures for the re-assessment of old antibiotics, 
and rigorous quality improvement. Recommendations 4 and 5 address the need for 
more sensitive primary endpoints through the use of rank-based, or time-dependent, 
composite endpoints. Recommendation 6 relates to the applicability of hierarchical 
nested trial designs, while the last two propose the incorporation of historical or 
concomitant trial data through Bayesian methods and/or platform trials. Although 
not all of these recommendations are directly applicable, they provide a solid, 
evidence-based approach to develop new, and established, antibacterials and address 
this public health challenge.
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Introduction
There is a gap between the number of new antibacterials in research and development 
(R&D) and the medical need caused by the increasing prevalence of infections by 
multidrug-resistant organisms (MDROs) [1]. In a 2014 survey [2], pharmaceutical 
industry professionals provided their opinion on the main challenges underlying 
this discrepancy. Most frequently, they indicated the low return on investment for 
antibacterials, followed by the lack of new regulatory pathways for antibacterial 
medicines that address a high unmet medical need, such as novel treatment options 
against MDROs. Importantly, innovative trial designs were seen as an important tool 
to promote R&D efforts for new antibacterials. Since this survey was conducted, 
political awareness of the need to encourage R&D for new antibacterials has risen 
enormously, with regulatory guidance being updated and international harmonization 
efforts underway [3-5]. However, critical to these processes is the need to advance 
and optimize trial design and make more effective use of the available data, so as 
to accelerate antibacterial approval and ensure appropriate use of established 
antibiotics active against MDROs.
Indeed, in the area of MDRO therapeutics where the number of patients with resistant 
infections for each specific indication is generally still rare, large studies are impossible 
or impractical [6]. Within traditional randomized controlled trials (RCTs), outcomes 
for patients with susceptible and resistant infections are combined, and although 
the subset of infections with resistant pathogens is presented separately, sample 
size is often insufficient. As a consequence, assessment of safety and effectiveness 
of new agents against MDROs is challenging, and without novel trial designs, which 
make better use of the available data, progress is difficult. Rex et al. have proposed a 
‘totality-of-evidence’ approach to resolve the impasse [7]; where instead of 2-3 large 
Phase II and III trials, multiple sources of data could contribute to the evidence base 
of the clinical benefit of a new drug, including smaller RCTs. However, this approach 
needs to be supported by robust pharmacokinetic and pharmacodynamic (PK/PD) 
data on optimal dosing of patients and the ability to design, analyze and interpret 
clinical trials as efficiently as possible.
In 2013, the Innovative Medicines Initiative (IMI; www.imi.europa.eu) established 
the Combatting Bacterial Resistance in Europe consortium (COMBACTE; www.
combacte.com) to conduct prospective clinical trials and refine clinical trial 
design for new treatments against MDROs [8]. The specific objective for STAT-
Net (Workpackage 4; WP4) was to deliver strategies that may yield more efficient 
Phase II and III clinical trial programs, and to focus on three pillars: improved PK/PD 
modelling, enhanced endpoints, and innovative trial designs. 
In this white paper, we propose several innovative design and analysis strategies 
for regulatory and pragmatic clinical trials to support the evaluation of new and 
established antibacterials against MDRO infections, and discuss their scientific 
robustness and feasibility. 
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Methods
STAT-Net was initiated in response to the 6th Call for proposals issued by IMI in 
2012 [9]. Subtopic 1A, WP4, specified three research pillars as described above, 
which were aligned with regulatory and scientific challenges at the time of writing. 
SH assembled, through open invitation, a group of experts with strong track 
records in PK/PD, biostatistics, Bayesian statistics, infectious diseases, intensive care 
medicine, epidemiology, and clinical development. Aligned with the IMI public-private 
partnership, pharmaceutical company partners joined to provide additional expertise. 
This group proposed a description of work in line with the original call, which was 
granted by IMI in autumn 2012. 
Between January 2013 and July 2017, systematic reviews, re-analyses of existing 
clinical trial data, and simulations have been carried out. Some of this work has 
already been peer-reviewed and published [10-19]. The final recommendations 
presented here are based on this work, extensive discussions via teleconferences, 
and STAT-Net-specific and COMBACTE-wide meetings, and have been approved by 
all authors. We created an objective scoring system for each recommendation, which 
was approved by all partners (Table 1), and was used to score 1 – alignment with 
the current regulatory framework, 2 – feasibility of technical implementation, like 
the need for specific biostatistical or PK/PD skills 3 – ease of data interpretation, 
4 – ease of practical implementation at the clinical site, and 5 – the strength of 
the evidence base for each recommendation (Table 2). Whenever disagreement 
concerning a recommendation arose, recommendations and scoring was adapted 
until consensus was reached. Based on the average score, recommendations are 
presented as: “strongly recommend” (++++), “recommend” (+++), “strongly suggest” 
(++), or “suggest” (+).
Results
Innovative biostatistical methods for pharmacokinetic and 
pharmacodynamic modelling
Recommendation 1 (study design):  We recommend that Phase II and III clinical trials 
of new antibiotics, particularly those active against MDROs, always apply population PK 
(popPK) models to describe and explain PK variability, optimize dose finding and evaluate 
outcome data relative to exposure.
Antibiotic efficacy, which determines microbiological cure, depends on the in vitro 
potency of the drug (usually expressed as minimal inhibitory concentration, MIC) 
and the in vivo exposure of the microorganism to the drug which relies on the 
concentration-time profile (pharmacokinetics, PK) and the dose. Due to MIC and 
PK variability, dosing optimization for certain patient subgroups is essential to avoid 
poor outcomes from ineffective treatment or resistance selection with too low 
doses, or adverse events with too high doses [20].
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Identification of efficacious dosing regimens based on preclinical PK/PD analyses and 
Phase I and II studies support the dosing rationale in Phase II and III clinical studies [21]. 
An important aspect of preclinical PK/PD analyses is the identification of a dominant 
drug-specific PK/PD index which describes the exposure-response relationship (e.g., 
the percentage of the dosing interval that the free drug concentration remains above 
the MIC, fT>MIC) and the minimal index value that ensures a high probability of 
efficacy (the PK/PD target, e.g., 50% fT>MIC). In Phase I studies, the PK of several 
dosing regimens is explored in healthy volunteers. Subsequently, in Phase II and 
III studies, popPK models can be further developed to describe and explain PK 
variability in the heterogeneous target population [21]. Simulations based on popPK 
models can be used to determine the probability of target attainment (PTA) of 
various dosing regimens in specific subpopulations, and thereby improve efficiency of 
Phase II and III studies. PopPK data, combined with MICs and outcome data, can also 
be used to refine pre-clinical exposure-response relationships and identify clinical-
relevant PK/PD indices and targets.
This recommendation is highly evidence based and in alignment with the current 
regulatory framework (Table 2) [21, 22], however, not yet fully applied for all recently 
approved antibiotics. Another drawback is that evaluation of data is often restricted 
to blood levels, while data for other relevant body sites is important as well, although 
interpretation for these body sites still remains uncertain. This recommendation is 
applicable for all infections including those caused by MDROs (Table 3). 
Recommendation 2 (regulatory procedures):  We recommend an EU-coordinated regulatory 
procedure for re-assessment of old antibiotics and their licensing, particularly those active 
against MDROs, which addresses justification of dosing regimens and exposure-response 
data according to modern PK/PD principles. This should include description of PK/PD targets, 
development of popPK models, and re-assessment of antibacterial spectra.
Many currently used antibiotics have been available clinically for many years, and long 
before current PK/PD principles and popPK modelling programs were employed 
in drug evaluation [20]. PK analyses were based on non-compartmental or simple 
compartmental methods without covariate investigation. PK/PD targets were mostly 
unknown and PTA simulations were not performed. The optimal dosing regimens 
of many old antibiotics therefore remain unknown which makes the probability 
of efficacy attainment uncertain. Also the antibacterial spectrum of old antibiotics 
is often poorly defined as changes in resistance epidemiology have not been 
systematically studied.
Re-analysis of old PK data may support dosing optimization of old antibiotics, 
provided the PD target is or will be established. For example, within the framework 
of STAT-Net, a popPK model using 45-year-old amoxicillin drug concentration data 
was developed and new dosing recommendations were published based on PTA 
simulations [18]. Unfortunately, the retrieval of such old data can be cumbersome. 
Alternatively, new PK studies of old antibiotics can be performed, for example, in 
the EU-project AIDA (www.aida-project.eu). Unfortunately, even though new popPK 
models are being developed, PK/PD targets are still lacking for many old antibiotics 
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[20]. Thus, developing rational dosing recommendations for all old antibiotics can be 
complex.
This recommendation is evidence based (Table 2), but doesn’t align with current 
regulatory approaches as a coordinated redevelopment procedure including updating 
of Summary of Product Characteristics (SmPCs) is currently unavailable [20]. 
However, some studies are performed in EU- and NIH projects (COMBACTEwww.
nih.gov/news-events/news-releases/nih-funds-four-clinical-trials-fight-antibiotic-
resistance), which may provide a suitable basis. This recommendation is applicable 
for all infections including those caused by MDROs (Table 3).
Recommendation 3 (study design):  We recommend that future clinical PK/PD studies provide 
more robust results by a priori determination of the sample size, adjustment for known 
confounders of the exposure-response relationship, assessment of both microbiological and 
patient orientated outcomes, and application of appropriate statistical techniques.
Although clinical PK/PD studies of antibiotics are always performed, their design 
and analysis have had limitations. Consequently, guidance on dosing regimens does 
not always have a strong evidence base, and to maximize the possibility of successful 
clinical outcomes and pathogen eradication, especially in the case of MDROs, more 
robust data are needed.
We conducted a systematic review of clinical PK/PD studies published since 1980 
and which related a calculated PK/PD index to the probability of a clinical or 
microbiological response [17]. After de-duplication, 6,096 records were reviewed 
resulting in 85 articles containing 97 PK/PD analyses being finally included. Only 
three out of 97 studies included a sample size calculation, and as such it cannot be 
determined whether clinical meaningful results would have been detected if present. 
Less than half of the studies included adjusted analysis for known confounders, 
including physiological patient characteristics, infection characteristics, and concurrent 
treatments. About half of the studies focused on clinical response, while the other 
half reported bacteriological response, while in most cases both would be important. 
Clinical response is the most important outcome to the patient, but bacteriological 
response measures the direct effect of the antibiotic. From an analytical perspective, 
only 61 out of 97 studies reported some form of regression, time to event analysis 
or used the Hill/Emax equation to look at the association between PK/PD index and 
outcome. In order to prevent inappropriate interpretation and multiplicity errors 
from analyzing a number of factors in a data dependent way, we recommend that 
pre-approved analysis plans should be implemented. These should ideally be based 
on the recently published regulatory guidance document EMA/CHMP/594085/2015 
[21], which took into consideration the above described work and emphasizes 
application of the most appropriate methods. Further, presentation of confidence 
intervals around stated effects will guard against inappropriate interpretation of 
underpowered analyses. 
This recommendation is based on expert opinion, moderately easy to apply (Table 
2), and is applicable for all infections including those caused by MDROs (Table 3).
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Selection of novel and more sensitive primary outcomes for clinical trials 
Recommendation 4 (study design/analysis):  We recommend using rank-based, composite 
endpoints combining patient-oriented and disease-related endpoints to assess new therapies 
against MDROs. 
At present, an ideal endpoint that would allow assessment of the efficacy of new 
therapies against MDRO is still lacking [15]. Patient-oriented endpoints such as 
mortality or quality of life are robust and directly matter to patients [23]. However, 
they also rely on several other non-infectious, confounding factors. Moreover, they 
require large sample sizes for non-inferiority (NI) testing, with clinically unacceptable 
NI margins [15]. On the other hand, disease-oriented primary endpoints such as 
clinical cure or organ failure free days are more sensitive and require smaller sample 
size, but these are not always unequivocally linked to true patient benefit [15]. 
In this context, composite endpoints appear worthy of further study [15], especially 
if they are easy to use and give appropriate priority to the more clinically important 
events (e.g. mortality). New methods for analyzing composite endpoints have already 
been reported [24, 25], and applied [26, 27]. In a recent Delphi process, 26 experts in 
the field of severe nosocomial pneumonia confirmed that such a composite endpoint 
combining patient-oriented endpoints and disease-related endpoints was expected 
to be the best method for assessing antibacterial efficacy in future clinical trials. 
This could be extended by applying multistate models (recommendation 5a), or a 
hierarchical nested trail design (HNTD) (recommendation 6). 
The development of a rank-based, composite endpoint needs to be planned before 
RCTs start and discussed with regulatory authorities. It is technically feasible to 
apply, but interpretation is complex (Table 2 and Table 3). 
Recommendation 5a (study design/analysis): We strongly suggest, in RCTs dealing with 
MDROs, to apply multistate models to examine a range of time-dependent clinical outcomes 
in the primary analysis to better characterize patients’ disease course. 
FDA and EMA guidelines have suggested the use of different primary endpoints in 
clinical trials evaluating treatment for patients with hospital- or ventilator-associated 
pneumonia (HAP/VAP) that include either a clinical outcome at the TOC visit or 
all-cause mortality at a specific point in time [28]. As discussed above, composite 
endpoints combining these clinical important events could be more informative. On 
top of that, validity could be improved by considering the occurrence of events over 
time, instead of assessing them at a predefined time interval.
If cure and death endpoints are of particular interest, both measures of clinical benefit 
can be simultaneously accounted for in a multistate framework using the co-primary 
endpoint “get cured and stay alive over time”. The application of this type of analysis has 
been illustrated by using data from a recently published trial on HAP/VAP patients 
[14] and can be adapted to more complex disease histories as, for example, patients 
with Clostridium difficile infection [13]. The application of such multistate models 
has the advantage of avoiding common survival biases (which occur if deleting or 
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censoring death outcomes when studying cure), since ignoring time dependency may 
lead to over- or underestimated efficacy. Furthermore, it provides patient-relevant 
information about getting cured and staying alive, instead of providing cure rates and 
mortality rates separately.
This recommendation requires specific statistical expertise, but can be applied to 
many potential MDRO treatment indications both in the design and the analytical 
phase of RCTs (Table 2 and Table 3).
Recommendation 5b (study design/analysis):  We strongly suggest, when applying multistate 
models, to perform statistical significance testing for the probability of being cured and alive 
over the entire treatment process rather than at the end of follow-up. 
Traditionally, the hypothesis tested in RCTs uses the data obtained at the end of 
follow-up (e.g. at the TOC visit). So far, no method has been validated which statistically 
tests NI or superiority for a multistate endpoint demonstrating a treatment effect 
over the complete treatment process instead of merely at the end of follow-up.
We applied an innovative resampling technique to construct one-sided simultaneous 
confidence bands to test the difference in probabilities of being cured and 
alive between study arms [29, 30], which performed well [12]. This provides a 
comprehensive picture of the time-dynamic effect of the entire treatment process 
while preserving the desired alpha level for statistical testing, resulting in a much 
stronger NI or superiority statement.
This recommendation is promising for the analysis of future RCTs, although it 
involves statistical expertise for implementation. Moreover, NI margins are difficult 
to establish given their reliance on historical data of the effects without treatment. 
Discussions with regulatory authorities would be required to agree upon an 
acceptable NI margin for this novel outcome measure (Table 2).
Innovative trial design in the absence of rapid diagnostic tests
Recommendation 6 (study design/analysis):  We strongly suggest that trials aiming to assess 
the clinical benefit of a new therapy against MDRO pathogens should apply a hierarchical 
nested trial design if a priori power calculations indicate feasibility.
Superiority trials for new antibacterials targeting MDROs are, in general, considered 
infeasible [6]. It is usually impossible to select a MDRO subgroup at the time point 
of randomization, since this usually occurs before standard organism susceptibility 
testing is available. Rapid diagnostics would be very useful in this perspective, but 
unfortunately rapid antibiotic susceptibility testing has not yet developed to a level 
which would make application for RCTs feasible. If a new drug against MDROs were 
to be tested among a mixed patient group, with susceptible and MDRO infections, the 
chances of showing superiority is likely low, especially if the proportion of patients 
infected with MDROs is low. Therefore, NI trials have become the standard in this 
area, with limited data about clinical benefit for the MDRO patient subgroup.
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The hierarchical nested trial design (HNTD) [31] is an innovative approach of 
addressing clinical benefit for patients with susceptible infections and patients 
with MDRO infections within one RCT. The HNTD originally suggests power 
calculations to be aligned with inference hierarchy and thus sample size calculations 
will be conducted based on the overall NI testing. In our simulations we observed 
that demonstration of superiority in the MDRO subgroup can become practically 
infeasible if the sample size of this subgroup is small. The power implications of 
designing the trial on the basis of the superiority test in the MDRO subgroup should 
therefore be explored in advance. This is especially important from an ethical point 
of view, as it will indicate the likelihood of success of a RCT for the targeted MDRO 
subgroup, which should be a criterion for patient participation, just like expected 
beneficence for the subgroup of patients with susceptible infection. Nevertheless, 
hierarchical approaches should be considered whenever feasible, as it can provide 
valuable information for both the susceptible and MDRO subgroups. Possibly, a 
combination with rank-based, composite endpoints (recommendation 4) could make 
this approach more powerful.
Application of this recommendation is moderately complex, should be discussed 
with regulatory authorities before application, and requires a large sample of MDRO 
patients (Table 2 and Table 3).
Methods to incorporate historical clinical trial data
Recommendation 7 (study design/analysis):  We strongly suggest that clinical trial 
investigators make use of the multitude of available historical clinical trial data in the design 
and analysis of novel MDRO treatment trials.
As discussed earlier, in most trials it is difficult to prospectively identify a large number 
of patients with MDRO infections and thus adequately power RCTs. Historical data 
from previous studies could be more effectively used to make the preparation and 
conduct of clinical trials more feasible and efficient.
Historical data are already used to help justify NI margins, but they can also be used 
in a Bayesian approach by using pre-existing data to incorporate knowledge about 
possible trial results. Where several trials have been conducted with a similar or 
identical treatment to the control arm of the new trial, a meta-analysis based on 
these data can be performed and a mathematical expression of the prior knowledge 
regarding control efficacy can be constructed. These priors can be interpreted 
as historical control patients, and when used alongside clinical trial patients can 
reduce the number of patients needed in the RCT, or increase the power of a given 
comparison [32, 33]. The new trial can be conducted using a traditional design [34, 
35], or an adaptive design, where the sample size or randomization ratio can be 
adjusted based on interim analyses to optimize power [33, 36].
This methodology highly depends on the quality of historical data, detail of publicly 
available data, and possible time-dependent changes in medical care. It also requires 
extensive communication between the sponsor and regulatory agency to agree on 
the prior distribution and acceptable type I and II error rates in the context of 
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the efficiencies gained with such a design. This recommended methodology is not 
limited to specific endpoints or infection types, so it can be applied in any trial where 
relevant data are available (Table 2 and Table 3).
Recommendation 8 (study design/analysis):  We suggest the use of platform trials to study 
new antibacterial treatments against MDROs.
If no historical data exist (recommendation 7), there are other ways to more efficiently 
improve sample size. In a platform trial investigators focus on the disease rather 
than any particular experimental therapy, and can simultaneously, or subsequently, 
investigate multiple experimental and control treatments, as a way to handle patient 
involvement as effectively as possible.
A key recommendation in the report issued by the President’s Council of Advisors 
on Science and Technology (PCAST) in the United States [37] is the establishment 
of a clinical trials’ infrastructure that would in turn support a “platform trial” for 
antibacterial agents [38’, 39, 40]. While there are notable operational hurdles (for 
example, finding/identifying patients), many of them are germane to the larger 
complexities of implementing clinical trials for antibacterials [37]. Initiating a single 
platform trial in this setting could therefore aid in managing some of these barriers, 
similar to what has already been accomplished in therapy areas such as Oncology 
and Alzheimer’s [41]. The efficiency of such a platform trial is driven by key design 
features. These include use of a shared control and incorporation of Bayesian methods 
to allow use of information across sites of infection and/or from historical data 
(recommendation 7) in one analysis, bearing in mind the general pre-requisites for 
using Bayesian approaches, such as assuring similarity of historical to contemporary 
data [38, 42, 43].
This recommendation requires specific statistical expertise, and there is no real 
world experience yet for antibacterial development, but based on experiences in 
other medical fields it seems a promising alternative (Table 2 and Table 3).
Discussion
Innovations are urgently required in the field of antibacterial development, especially 
for treatments against MDROs. The recommendations provided here could be 
instrumental to advances in this field. Although the proposed recommendations 
would not always be applicable within the same trial, not all of them align with 
current regulatory guidelines, and they differ regarding ease of implementation or 
interpretation, and evidence base, they are all relevant to the debate supporting 
change.
In Table 2, the different recommendations were scored, showing that, in general, 
recommendations for PK/PD studies have the strongest evidence base, and our view 
is that they should be implemented as soon as possible to improve drug dosing in 
RCTs. Bayesian methods, incorporating data from historical controls in new RCTs, 
can be successfully used to reduce the number of patients required for RCTs. They 
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have already been applied to re-analyze clinical trial data, and regulatory applicability 
is promising, provided the historical and contemporary data can be shown to be 
comparable. Rank-based, composite or time-dependent endpoints are another way 
to improve statistical efficiency, and provide more meaningful data at the same time. 
However, technical and practical implementation still present some challenges and a 
regulatory framework to support this approach is still lacking. Our recommendations 
related to HNTDs and platform trials are the least pertinent. Although the HNTD 
approach has clear merit, it generally faces the huge challenge of recruiting sufficient 
patients with MDROs to support a meaningful superiority assessment. Platform 
trials could efficiently provide data for multiple, concurrent or subsequent, control 
arms, by establishment of a common clinical trials infrastructure, but the practical 
implementation is challenging, particularly in gaining commitment at the initiation of 
the platform trial. By increasing RCT efficiency, superiority trials could become more 
feasible, which would be preferable considering the ethical issues associated with NI 
trials [44].
STAT-Net partners are already working on the evaluation and refinement of some of 
the proposed solutions. First, as an extension of recommendation 6, a novel HNTD 
is being evaluated, where an alternative, more sensitive endpoint (statistically) 
is introduced for the subgroup of patients infected by resistant pathogens. Such 
an approach could curtail the required sample size for superiority testing in the 
subgroup. In order to maintain confidence in the clinical benefit, the point estimate 
for the clinical endpoint of interest, as used in the NI assessment for the whole 
sample (i.e., cure rate), should be similar as well. An example of a more statistically 
sensitive endpoint could be the, regulatory approved endpoint of, absolute reduction 
of skin lesions in skin and soft tissue infections. This approach could be especially 
valuable for very rare MDROs.
Secondly, the application of multistate models (recommendation 5) is being studied 
for combined endpoints other than cured and alive, e.g., to be alive and not under 
mechanical ventilation in patients with acute respiratory distress. Study planning for 
more specific multistate endpoints will typically be simulation based [45]. Previous 
studies can be used to define the assumptions needed for these types of simulation 
studies, possibly using only published graphs of outcome probability over time for 
control groups as explained in Allignol et al. [46].
In addition, novel statistical methods will be tested that allow historical control data 
from one single study (as compared to multiple studies, recommendation 7) to be 
utilized in future RCTs [11]. Outcome estimates from a single, previous trial can 
be weighted depending on the similarity to the outcome in the new trial, thereby 
increasing sample size and power with only a limited increase in type I error. This 
may help to demonstrate the totality of evidence to reviewers, by including the 
relevant historical data in a secondary analysis. This new approach can be extended 
to multiple historical studies as well [10], and as such is a promising alternative to the 
methods listed in recommendation 7 since it is more flexible and does not require 
the strong assumptions about heterogeneity and exchangeability.
Finally, efforts to initiate an antibacterial platform trial (recommendation 8) are 
underway in both the European Union, through COMBACTE-Net and PREPARE, and 
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in the United States, through the Antibiotics Resistance Leadership Group (www.
arlg.org), and also globally, through the Wellcome Trust. Additional simulation work 
to understand operating characteristics and further discussions with regulatory 
agencies on a case-by-case basis will be needed in order to continue to progress and 
embed these innovative trials.
The work presented here was bound by the IMI Call text and the subsequent 
description of work. Since 2012, the landscape has changed, and a multitude of 
methodological approaches for accelerated antibacterial development have been 
proposed. Rex et al. have discussed the four-tiered approach to registration, whereby 
required strength of the evidence depends on the severity of the unmet medical 
need, ranging from disease focused double Phase III RCTs to pathogen-focused 
observational studies [7]. Although the current regulatory framework seems more 
open for these alternative routes, acceptance still requires alignment and assessment 
of unmet medical need. For PK/PD data, EMA has recently updated their guidance 
document [21], and sponsors are now encouraged to include and utilize PK/PD 
data in their application for regulatory approval of new antibiotics, although this 
is – unfortunately- not yet fully adopted in all current application dossiers. Clearly, 
these dossiers would need a re-assessment. Additionally a proper framework for the 
re-assessment of old antibiotics is urgently required. Multiple Bayesian applications 
have been proposed as well, of which some would fit logically within the current 
regulatory framework; Bayesian-based meta-analyses could be used to determine 
more appropriate NI margins, while balancing the degree of unmet need and the 
feasibility of the RCT [47]. 
From an ethical point of view, the possible benefit for society should be subordinate 
to the individual risks of participation in research, and should include assessment of 
operational risks of RCTs (e.g. too complex trials stopped due to poor recruitment), 
and scientific rigor (e.g. data validity and power issues). To quote Ruberg et al. ‘Our 
professional challenge is to implement adaptive approaches while maintaining sufficient 
rigor in the design and analysis of clinical development trials and programs without inhibiting 
innovation or delaying the access of needed medications to patients who are waiting.’ [48]. 
Hopefully, these recommendations and their continued evaluation and evolution 
will accelerate antibacterial approval and ensure appropriate use of established 
antibiotics to help those in need as soon and best as possible.
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al
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K
/P
D
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er
ts
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m
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 w
ith
 t
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m
et
ho
do
lo
gy
Ve
ry
 c
om
pl
ex
; r
eq
ui
re
s 
st
at
is
tic
al
 e
xp
er
tis
e 
an
d 
ex
pe
ri
en
ce
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ith
 t
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m
et
ho
do
lo
gy
D
es
ig
n 
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d 
an
al
yt
ic
al
 
m
et
ho
ds
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ca
nt
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pt
at
io
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 s
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d 
cl
in
ic
al
 t
ri
al
 
pr
ot
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s 
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d 
ex
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a 
da
ta
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eq
ui
re
d
T
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s 
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co
m
m
en
da
tio
n 
is
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se
d 
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 e
xp
er
t 
op
in
io
n,
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d/
or
 e
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er
na
l p
an
el
 
co
ns
en
su
s.
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e 
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es
t 
..”
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A
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 d
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ds
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ed
, c
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no
t 
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d 
by
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or
y 
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th
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es
O
nl
y 
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pl
ic
ab
le
 b
y 
st
at
is
tic
ia
ns
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r 
PK
/
PD
 e
xp
er
ts
M
od
er
at
el
y 
co
m
pl
ex
; 
st
at
is
tic
al
 e
xp
er
tis
e 
re
qu
ir
ed
D
es
ig
n 
an
d 
an
al
yt
ic
al
 
m
et
ho
ds
 r
eq
ui
re
 
m
od
er
at
e 
ad
ap
ta
tio
ns
 
of
 s
ta
nd
ar
d 
cl
in
ic
al
 t
ri
al
 
pr
ot
oc
ol
s 
or
 e
xt
ra
 d
at
a 
is
 r
eq
ui
re
d
T
hi
s 
re
co
m
m
en
da
tio
n 
is
 b
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ed
 o
n 
en
co
ur
ag
in
g 
re
su
lts
 fr
om
 s
im
ul
at
io
ns
.
“W
e 
st
ro
ng
ly
 
su
gg
es
t 
...”
++
+
A
da
pt
at
io
ns
 
in
 e
nd
po
in
ts
, 
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ns
ul
ta
tio
n 
w
ith
 r
eg
ul
at
or
y 
au
th
or
iti
es
 r
eq
ui
re
d
A
pp
lic
ab
le
 b
y 
th
os
e 
ex
pe
ri
en
ce
d 
in
 
ap
pl
ie
d 
st
at
is
tic
al
 o
r 
PK
/P
D
 a
na
ly
si
s
M
od
er
at
el
y 
ea
sy
; 
cl
in
ic
al
 t
ri
al
 b
ac
kg
ro
un
d 
re
qu
ir
ed
, b
ut
 n
o 
ne
ed
 fo
r 
a 
st
at
is
tic
al
 
ba
ck
gr
ou
nd
D
es
ig
n 
an
d 
an
al
yt
ic
al
 
m
et
ho
ds
 r
eq
ui
re
 s
m
al
l 
ad
ap
ta
tio
ns
 t
o 
sp
ec
ifi
c 
pa
rt
s 
of
 a
 s
ta
nd
ar
d 
cl
in
ic
al
 t
ri
al
 p
ro
to
co
l 
an
d 
no
 e
xt
ra
 d
at
a 
is
 
re
qu
ir
ed
T
he
re
 is
 fa
ir
 r
es
ea
rc
h-
ba
se
d 
ev
id
en
ce
 
to
 s
up
po
rt
 t
he
 
re
co
m
m
en
da
tio
n;
 
re
-a
na
ly
si
s 
of
 c
lin
ic
al
 
tr
ia
l d
at
a 
ha
s 
pr
ov
id
ed
 
en
co
ur
ag
in
g 
re
su
lts
.
“W
e 
re
co
m
m
en
d 
…
”
++
++
N
o 
ob
st
ac
le
s 
fo
r 
im
pl
em
en
ta
tio
n 
id
en
tifi
ed
, i
n 
lin
e 
w
ith
 c
ur
re
nt
 
re
gu
la
to
ry
 g
ui
de
lin
es
O
nl
y 
ba
si
c 
st
at
is
tic
al
 
or
 P
K
/P
D
 e
xp
er
tis
e 
re
qu
ir
ed
Ea
sy
; n
o 
ne
ed
 fo
r 
a 
st
at
is
tic
al
/c
lin
ic
al
 t
ri
al
 
ba
ck
gr
ou
nd
St
an
da
rd
 c
lin
ic
al
 t
ri
al
 
pr
ot
oc
ol
s 
ca
n 
be
 a
pp
lie
d 
an
d 
no
 e
xt
ra
 d
at
a 
is
 
re
qu
ir
ed
T
he
re
 is
 g
oo
d 
re
se
ar
ch
-
ba
se
d 
ev
id
en
ce
 
to
 s
up
po
rt
 t
he
 
re
co
m
m
en
da
tio
n:
 it
 h
as
 
al
re
ad
y 
be
en
 a
pp
lie
d 
an
d 
te
st
ed
 in
 c
lin
ic
al
 t
ri
al
s.
“W
e 
st
ro
ng
ly
 
re
co
m
m
en
d 
...”
PK
, p
ha
rm
ac
ok
in
et
ic
s; 
PD
, p
ha
rm
ac
od
yn
am
ic
s
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2.
 R
ec
om
m
en
da
tio
ns
 a
nd
 t
he
ir
 c
la
ss
ifi
ca
tio
n 
re
ga
rd
in
g 
cu
rr
en
t 
re
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la
tio
ns
, i
m
pl
em
en
ta
tio
n,
 in
te
rp
re
ta
tio
n,
 a
nd
 e
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de
nc
e 
ba
se
 in
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e 
w
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 T
ab
le
 1
.
R
ec
om
m
en
da
ti
on
s
A
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en
t 
w
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h 
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rr
en
t 
re
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to
ry
 
fr
am
ew
or
k
Ea
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te
ch
ni
ca
l 
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pl
em
en
t-
ta
ti
on
Ea
se
 o
f 
in
te
r-
pr
et
at
io
n
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se
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pr
ac
ti
ca
l 
im
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em
en
t-
ta
ti
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id
en
ce
 
ba
se
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va
ti
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 b
io
st
at
is
ti
ca
l m
et
ho
ds
 fo
r 
ph
ar
m
ac
ok
in
et
ic
 a
nd
 p
ha
rm
ac
od
yn
am
ic
 m
od
el
lin
g
1:
 W
e 
re
co
m
m
en
d 
th
at
 P
ha
se
 II
 a
nd
 II
I c
lin
ic
al
 t
ri
al
s 
of
 n
ew
 a
nt
ib
io
tic
s, 
pa
rt
ic
ul
ar
ly
 t
ho
se
 a
ct
iv
e 
ag
ai
ns
t 
M
D
RO
s, 
al
w
ay
s 
ap
pl
y 
po
pu
la
tio
n 
PK
 m
od
el
s 
to
 
de
sc
ri
be
 a
nd
 e
xp
la
in
 P
K
 v
ar
ia
bi
lit
y, 
op
tim
iz
e 
do
se
 fi
nd
in
g 
an
d 
ev
al
ua
te
 o
ut
co
m
e 
da
ta
 r
el
at
iv
e 
to
 e
xp
os
ur
e.
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
2:
 W
e 
re
co
m
m
en
d 
an
 E
U
-c
oo
rd
in
at
ed
 r
eg
ul
at
or
y 
pr
oc
ed
ur
e 
fo
r 
re
-a
ss
es
sm
en
t 
of
 o
ld
 a
nt
ib
io
tic
s 
an
d 
th
ei
r 
lic
en
si
ng
, p
ar
tic
ul
ar
ly
 t
ho
se
 a
ct
iv
e 
ag
ai
ns
t 
M
D
RO
s, 
w
hi
ch
 a
dd
re
ss
es
 ju
st
ifi
ca
tio
n 
of
 d
os
in
g 
re
gi
m
en
s 
an
d 
ex
po
su
re
-r
es
po
ns
e 
da
ta
 
ac
co
rd
in
g 
to
 m
od
er
n 
PK
/P
D
 p
ri
nc
ip
le
s. 
T
hi
s 
sh
ou
ld
 in
cl
ud
e 
de
sc
ri
pt
io
n 
of
 P
K
/
PD
 t
ar
ge
ts
, d
ev
el
op
m
en
t 
of
 p
op
PK
 m
od
el
s, 
an
d 
re
-a
ss
es
sm
en
t 
of
 a
nt
ib
ac
te
ri
al
 
sp
ec
tr
a.
+
+
+
+
+
+
+
+
+
+
+
+
+
3:
 W
e 
re
co
m
m
en
d 
th
at
 fu
tu
re
 c
lin
ic
al
 P
K
/P
D
 s
tu
di
es
 p
ro
vi
de
 m
or
e 
ro
bu
st
 
re
su
lts
 b
y 
a 
pr
io
ri 
de
te
rm
in
at
io
n 
of
 t
he
 s
am
pl
e 
si
ze
, a
dj
us
tm
en
t 
fo
r 
kn
ow
n 
co
nf
ou
nd
er
s 
of
 t
he
 e
xp
os
ur
e-
re
sp
on
se
 r
el
at
io
ns
hi
p,
 a
ss
es
sm
en
t 
of
 b
ot
h 
m
ic
ro
bi
ol
og
ic
al
 a
nd
 p
at
ie
nt
 o
ri
en
ta
te
d 
ou
tc
om
es
, a
nd
 a
pp
lic
at
io
n 
of
 
ap
pr
op
ri
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e 
st
at
is
tic
al
 t
ec
hn
iq
ue
s.
+
+
+
+
+
+
+
+
+
+
+
+
+
+
Se
le
ct
io
n 
of
 n
ov
el
 a
nd
 m
or
e 
se
ns
it
iv
e 
pr
im
ar
y 
ou
tc
om
es
 fo
r 
cl
in
ic
al
 t
ri
al
s
4:
 W
e 
re
co
m
m
en
d 
us
in
g 
ra
nk
-b
as
ed
, c
om
po
si
te
 e
nd
po
in
ts
 c
om
bi
ni
ng
 p
at
ie
nt
-
or
ie
nt
ed
 a
nd
 d
is
ea
se
-r
el
at
ed
 e
nd
po
in
ts
 t
o 
as
se
ss
 n
ew
 a
nt
ib
ac
te
ri
al
 t
he
ra
pi
es
 
ag
ai
ns
t 
M
D
RO
s.
+
+
+
+
+
+
+
+
+
+
+
+
+
5a
: W
e 
st
ro
ng
ly
 s
ug
ge
st
, i
n 
tr
ia
ls
 d
ea
lin
g 
w
ith
 M
D
RO
s, 
to
 a
pp
ly
 m
ul
tis
ta
te
 
m
od
el
s 
to
 e
xa
m
in
e 
a 
ra
ng
e 
of
 t
im
e-
de
pe
nd
en
t 
cl
in
ic
al
 o
ut
co
m
es
 in
 o
ne
 
pr
im
ar
y 
an
al
ys
is
 t
o 
be
tt
er
 c
ha
ra
ct
er
iz
e 
th
e 
pa
tie
nt
’s 
di
se
as
e 
co
ur
se
.
+
+
+
+
+
+
+
+
+
+
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5b
: W
e 
st
ro
ng
ly
 s
ug
ge
st
, w
he
n 
ap
pl
yi
ng
 m
ul
tis
ta
te
 m
od
el
s, 
to
 p
er
fo
rm
 s
ta
tis
tic
al
 
si
gn
ifi
ca
nc
e 
te
st
in
g 
fo
r 
th
e 
pr
ob
ab
ili
ty
 o
f b
ei
ng
 c
ur
ed
 a
nd
 a
liv
e 
ov
er
 t
he
 e
nt
ir
e 
tr
ea
tm
en
t 
pr
oc
es
s 
ra
th
er
 t
ha
n 
at
 t
he
 e
nd
 o
f f
ol
lo
w
-u
p.
+
+
+
+
+
+
+
+
In
no
va
ti
ve
 t
ri
al
 d
es
ig
n 
in
 t
he
 a
bs
en
ce
 o
f r
ap
id
 d
ia
gn
os
ti
cs
6:
 W
e 
st
ro
ng
ly
 s
ug
ge
st
 t
ha
t 
tr
ia
ls
 a
im
in
g 
to
 a
ss
es
s 
th
e 
cl
in
ic
al
 b
en
efi
t 
of
 a
 n
ew
 
th
er
ap
y 
ag
ai
ns
t 
M
D
RO
 p
at
ho
ge
ns
 s
ho
ul
d 
ap
pl
y 
a 
hi
er
ar
ch
ic
al
 n
es
te
d 
tr
ia
l 
de
si
gn
 if
 a
 p
ri
or
i p
ow
er
 c
al
cu
la
tio
ns
 in
di
ca
te
 fe
as
ib
ili
ty
.
+
+
+
+
+
+
+
+
+
+
M
et
ho
ds
 t
o 
in
co
rp
or
at
e 
hi
st
or
ic
al
 c
lin
ic
al
 t
ri
al
 d
at
a
7:
 W
e 
st
ro
ng
ly
 s
ug
ge
st
 t
ha
t 
cl
in
ic
al
 t
ri
al
 in
ve
st
ig
at
or
s 
m
ak
e 
us
e 
of
 t
he
 m
ul
tit
ud
e 
of
 h
is
to
ri
ca
l c
lin
ic
al
 t
ri
al
 d
at
a 
in
 t
he
 d
es
ig
n 
an
d 
an
al
ys
is
 o
f n
ov
el
 M
D
RO
 
tr
ea
tm
en
t 
tr
ia
ls
.
+
+
+
+
+
+
+
+
+
+
+
+
8:
 W
e 
su
gg
es
t 
th
e 
us
e 
of
 p
la
tfo
rm
 t
ri
al
s 
to
 s
tu
dy
 n
ew
 a
nt
ib
ac
te
ri
al
 t
re
at
m
en
ts
 
ag
ai
ns
t 
M
D
RO
s
+
+
+
+
+
+
+
M
D
RO
, m
ul
ti-
dr
ug
 r
es
is
ta
nt
 o
rg
an
is
m
s; 
PK
, p
ha
rm
ac
ok
in
et
ic
s; 
PD
, p
ha
rm
ac
od
yn
am
ic
s 
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 d
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re
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at
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ha
se
 II
 a
nd
 
III
 c
lin
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 t
ri
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of
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ew
 a
nt
ib
io
tic
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ic
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ar
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 a
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ag
ai
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D
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w
ay
s 
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pl
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po
pu
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PK
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po
pP
K
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m
od
el
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to
 d
es
cr
ib
e 
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d 
ex
pl
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n 
PK
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ri
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ty
, o
pt
im
iz
e 
do
se
 fi
nd
in
g 
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d 
ev
al
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te
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ut
co
m
e 
da
ta
 r
el
at
iv
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to
 
ex
po
su
re
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PK
/P
D
 a
na
ly
se
s 
w
ith
 P
K
 a
nd
 
PK
/P
D
 d
at
a 
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 P
ha
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an
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III
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tu
di
es
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PK
/P
D
 t
ar
ge
t 
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se
d 
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pr
ec
lin
ic
al
 a
nd
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lin
ic
al
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at
a.
A
ll 
in
fe
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ns
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ll
+
 O
pt
im
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ed
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os
in
g, 
in
cr
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si
ng
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ng
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R
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 W
e 
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m
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an
 E
U
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oo
rd
in
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ed
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to
ry
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ro
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ss
es
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 o
ld
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ib
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si
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ic
ul
ar
ly
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ho
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ct
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ag
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t 
M
D
RO
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ss
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 ju
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of
 d
os
in
g 
re
gi
m
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s 
an
d 
ex
po
su
re
-r
es
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e 
da
ta
 
ac
co
rd
in
g 
to
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od
er
n 
PK
/P
D
 p
ri
nc
ip
le
s. 
T
hi
s 
sh
ou
ld
 in
cl
ud
e 
de
sc
ri
pt
io
n 
of
 P
K
/P
D
 
ta
rg
et
s, 
de
ve
lo
pm
en
t 
of
 p
op
PK
 m
od
el
s, 
an
d 
re
-a
ss
es
sm
en
t 
of
 a
nt
ib
ac
te
ri
al
 s
pe
ct
ra
.
PK
/P
D
 a
na
ly
se
s 
w
ith
 P
K
 a
nd
 
PK
/P
D
 d
at
a 
fr
om
 P
ha
se
 I,
 II
, 
an
d 
III
 s
tu
di
es
. 
PK
/P
D
 t
ar
ge
t 
ba
se
d 
on
 
pr
ec
lin
ic
al
 a
nd
 c
lin
ic
al
 d
at
a.
A
ll 
in
fe
ct
io
ns
A
ll
+
 O
pt
im
iz
ed
 d
os
in
g 
an
d 
in
di
ca
tio
ns
 o
f 
ol
d 
an
tib
io
tic
s, 
in
cr
ea
si
ng
 t
he
 li
ke
lih
oo
d 
of
 
de
te
ct
in
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tr
ue
 e
ffi
ca
cy
 in
 R
C
T
s, 
de
cr
ea
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ng
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ih
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d 
of
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m
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N
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r 
al
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en
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w
ith
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or
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N
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g 
re
qu
ir
ed
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bl
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en
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ud
ie
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re
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ir
ed
3:
 W
e 
re
co
m
m
en
d 
th
at
 fu
tu
re
 c
lin
ic
al
 P
K
/
PD
 s
tu
di
es
 p
ro
vi
de
 m
or
e 
ro
bu
st
 r
es
ul
ts
 
by
 a
 p
ri
or
i d
et
er
m
in
at
io
n 
of
 t
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 s
am
pl
e 
si
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en
t 
fo
r 
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n 
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s 
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he
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ur
e-
re
sp
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se
 r
el
at
io
ns
hi
p,
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se
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m
en
t 
of
 b
ot
h 
m
ic
ro
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ol
og
ic
al
 
an
d 
pa
tie
nt
 o
ri
en
ta
te
d 
ou
tc
om
es
, a
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ap
pl
ic
at
io
n 
of
 a
pp
ro
pr
ia
te
 s
ta
tis
tic
al
 
te
ch
ni
qu
es
.
PK
/P
D
 a
na
ly
se
s 
w
ith
 P
K
 a
nd
 
PK
/P
D
 d
at
a 
fr
om
 P
ha
se
 I,
 II
, 
an
d 
III
 s
tu
di
es
.
PK
/P
D
 t
ar
ge
t 
ba
se
d 
on
 
pr
ec
lin
ic
al
 a
nd
 c
lin
ic
al
 d
at
a.
A
ll 
in
fe
ct
io
ns
A
ll
+
 M
or
e 
re
lia
bl
e 
PK
/P
D
 d
at
a, 
op
tim
iz
ed
 
do
si
ng
, i
nc
re
as
in
g 
th
e 
lik
el
ih
oo
d 
of
 d
et
ec
tin
g 
tr
ue
 e
ffi
ca
cy
 in
 R
C
T
s, 
de
cr
ea
si
ng
 t
he
 
lik
el
ih
oo
d 
of
 e
m
er
ge
nc
e 
of
 r
es
is
ta
nc
e
- A
dd
iti
on
al
 p
at
ie
nt
 s
am
pl
in
g 
re
qu
ir
ed
- 
Ex
tr
a 
co
st
s 
fo
r 
R
C
T
 s
po
ns
or
s ta
bl
e 
co
nt
in
ue
s
146 | Chapter 4
R
ec
om
m
en
da
ti
on
 
T
yp
e 
of
 t
ri
al
In
di
ca
ti
on
s
Po
pu
la
ti
on
B
en
efi
ts
 (
+)
 a
nd
 d
is
ad
va
nt
ag
es
 (
-)
Se
le
ct
io
n 
of
 n
ov
el
 a
nd
 m
or
e 
se
ns
it
iv
e 
pr
im
ar
y 
ou
tc
om
es
 fo
r 
cl
in
ic
al
 t
ri
al
s
4:
 W
e 
re
co
m
m
en
d 
us
in
g 
ra
nk
-b
as
ed
, 
co
m
po
si
te
 e
nd
po
in
ts
 c
om
bi
ni
ng
 p
at
ie
nt
-
or
ie
nt
ed
 a
nd
 d
is
ea
se
-r
el
at
ed
 e
nd
po
in
ts
 
to
 a
ss
es
s 
ne
w
 t
he
ra
pi
es
 a
ga
in
st
 M
D
RO
s.
A
ll
A
ll 
in
fe
ct
io
ns
, 
es
pe
ci
al
ly
 
th
os
e 
w
ith
 lo
w
 
m
or
ta
lit
y
A
ll
+
 M
or
e 
m
ea
ni
ng
fu
l, 
an
d 
se
ns
iti
ve
 e
nd
po
in
ts
, 
in
cr
ea
si
ng
 t
he
 li
ke
lih
oo
d 
of
 t
ru
e 
po
si
tiv
e 
fin
di
ng
s 
in
 R
C
T
s
- 
En
dp
oi
nt
s 
co
ul
d 
be
co
m
e 
m
or
e 
su
bj
ec
tiv
e
- 
En
dp
oi
nt
s 
m
ay
 b
e 
m
or
e 
di
ffi
cu
lt 
to
 
in
te
rp
re
t
- 
It
 c
an
 b
e 
di
ffi
cu
lt 
to
 e
st
ab
lis
h 
an
 
ac
ce
pt
ab
le
 N
I o
r 
su
pe
ri
or
ity
 m
ar
gi
n
5a
: W
e 
st
ro
ng
ly
 s
ug
ge
st
, i
n 
tr
ia
ls
 d
ea
lin
g 
w
ith
 M
D
RO
s, 
to
 a
pp
ly
 m
ul
tis
ta
te
 m
od
el
s 
to
 e
xa
m
in
e 
a 
ra
ng
e 
of
 t
im
e-
de
pe
nd
en
t 
cl
in
ic
al
 o
ut
co
m
es
 in
 o
ne
 p
ri
m
ar
y 
an
al
ys
is
 
to
 b
et
te
r 
ch
ar
ac
te
ri
ze
 t
he
 p
at
ie
nt
’s 
di
se
as
e 
co
ur
se
.
A
ll
T
ho
se
 w
ith
 
m
od
er
at
e 
to
 
hi
gh
 m
or
ta
lit
y 
ra
te
s
Po
pu
la
tio
ns
 
w
ith
 
m
od
er
at
e 
to
 h
ig
h 
m
or
ta
lit
y 
ra
te
s
+
 M
or
e 
m
ea
ni
ng
fu
l, 
an
d 
se
ns
iti
ve
 e
nd
po
in
ts
, 
in
cr
ea
si
ng
 t
he
 li
ke
lih
oo
d 
of
 t
ru
e 
po
si
tiv
e 
fin
di
ng
s 
in
 R
C
T
s
- 
C
om
po
si
te
 e
nd
po
in
ts
 m
ay
 b
e 
m
or
e 
di
ffi
cu
lt 
to
 in
te
rp
re
t
- 
It
 c
an
 b
e 
di
ffi
cu
lt 
to
 e
st
ab
lis
h 
an
 
ac
ce
pt
ab
le
 N
I o
r 
su
pe
ri
or
ity
 m
ar
gi
n
In
no
va
ti
ve
 t
ri
al
 d
es
ig
n 
in
 t
he
 a
bs
en
ce
 o
f r
ap
id
 d
ia
gn
os
ti
cs
6:
 W
e 
st
ro
ng
ly
 s
ug
ge
st
 t
ha
t 
tr
ia
ls
 a
im
in
g 
to
 a
ss
es
s 
th
e 
cl
in
ic
al
 b
en
efi
t 
of
 a
 n
ew
 
th
er
ap
y 
ag
ai
ns
t 
M
D
RO
 p
at
ho
ge
ns
 s
ho
ul
d 
ap
pl
y 
a 
hi
er
ar
ch
ic
al
 n
es
te
d 
tr
ia
l d
es
ig
n 
if 
a 
pr
io
ri
 p
ow
er
 c
al
cu
la
tio
ns
 in
di
ca
te
 
fe
as
ib
ili
ty
.
N
on
-in
fe
ri
or
ity
 t
ri
al
s
A
ll
M
D
RO
s
+
 S
ta
tis
tic
al
ly
 s
ou
nd
 r
es
ul
ts
 fo
r 
tr
ea
tm
en
t 
ef
fic
ac
y 
in
 t
he
 M
D
RO
 s
ub
gr
ou
p 
w
ith
ou
t 
th
e 
ne
ed
 fo
r 
ra
pi
d 
di
ag
no
st
ic
s
-L
ar
ge
 s
am
pl
e 
of
 n
on
-M
D
RO
 p
at
ie
nt
s 
re
qu
ir
ed
M
et
ho
ds
 t
o 
in
co
rp
or
at
e 
hi
st
or
ic
al
 c
lin
ic
al
 t
ri
al
 d
at
a
7:
 W
e 
st
ro
ng
ly
 s
ug
ge
st
 t
ha
t 
cl
in
ic
al
 t
ri
al
 
in
ve
st
ig
at
or
s 
m
ak
e 
us
e 
of
 t
he
 m
ul
tit
ud
e 
of
 a
va
ila
bl
e 
hi
st
or
ic
al
 c
lin
ic
al
 t
ri
al
 d
at
a 
in
 
th
e 
de
si
gn
 a
nd
 a
na
ly
si
s 
of
 n
ov
el
 M
D
RO
 
tr
ea
tm
en
t 
tr
ia
ls
.
A
ll
A
ll
A
ll
+
 R
C
T
s 
ca
n 
in
cl
ud
e 
a 
lo
w
er
 n
um
be
r 
of
 
pa
tie
nt
s, 
bu
t 
re
m
ai
n 
po
w
er
ed
, a
nd
 e
xi
st
in
g 
ev
id
en
ce
 is
 e
ffi
ci
en
tly
 u
se
d
- 
In
cr
ea
se
d 
ty
pe
 I 
er
ro
r
- 
N
ee
d 
fo
r 
hi
st
or
ic
al
 R
C
T
 d
at
a, 
w
hi
ch
 m
ay
 
be
 d
iffi
cu
lt 
to
 o
bt
ai
n
ta
bl
e 
co
nt
in
ue
s
147Optimising the design and analysis of clinical trials for antibiotics |
4
R
ec
om
m
en
da
ti
on
 
T
yp
e 
of
 t
ri
al
In
di
ca
ti
on
s
Po
pu
la
ti
on
B
en
efi
ts
 (
+)
 a
nd
 d
is
ad
va
nt
ag
es
 (
-)
8:
 W
e 
su
gg
es
t 
th
e 
us
e 
of
 p
la
tfo
rm
 t
ri
al
s 
to
 
st
ud
y 
ne
w
 a
nt
ib
ac
te
ri
al
 t
re
at
m
en
ts
 a
ga
in
st
 
M
D
RO
s.
A
ll
A
ll
A
ll
+
 In
cr
ea
si
ng
 t
he
 e
ffi
ci
en
cy
 o
f R
C
T
s 
by
 u
si
ng
 
th
e 
sa
m
e 
pa
tie
nt
s 
fo
r 
m
ul
tip
le
 R
C
T
s
- 
La
rg
e 
da
ta
ba
se
 a
nd
 h
ig
h 
w
or
kl
oa
d,
 w
hi
ch
 
m
ay
 n
ot
 b
e 
ut
ili
ze
d 
ev
en
tu
al
ly
- 
Po
te
nt
ia
l c
on
fli
ct
s 
be
tw
ee
n 
di
ffe
re
nt
 s
tu
dy
 
sp
on
so
rs
 a
nd
/o
r 
co
m
pa
ni
es

Chapter 5
Clinical applications of population 
pharmacokinetic models of antibiotics: 
challenges and examples
Based on: Clinical applications of population pharmacokinetic 
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Clinical applications of population PK models
Three main clinical applications of population pharmacokinetic (popPK) models can 
be specified for antibiotics: 1) dosing evaluation of old antibiotics, 2) setting clinical 
breakpoints and 3) therapeutic drug monitoring (TDM). This thesis is mainly focused 
on dosing evaluation of old antibiotics. However, many challenges regarding the 
interpretation of popPK models used for dosing evaluation are also applicable for 
the other clinical applications. 
The most important challenges are summarized in Table 1 and further clarified 
in the text below the table. At first, the role of popPK models in setting clinical 
breakpoints and in TDM are explained in the two paragraphs below. 
Setting clinical breakpoints
The European committee on antimicrobial susceptibility testing (EUCAST) provides 
species-related and PK/PD (non-species related) clinical breakpoints. The EUCAST 
procedure for setting PK/PD breakpoints includes Monte Carlo simulations using 
population PK models to estimate exposure of an antimicrobial agent in the target 
patient population for commonly used dosing regimens [1]. Following the simulations, 
the probability of target attainment (PTA) is determined for different PK/PD targets. 
Subsequently, the PK/PD target is plotted as a function of the minimal inhibitory 
concentration (MIC) for the mean of the population and 95% and 99% CI estimates 
(corresponding to 97.5% and 99.5% PTA). EUCAST uses the MIC values resulting 
from both PTAs to determine a PK/PD breakpoint [1]. 
Therapeutic drug monitoring (TDM)
Therapeutic drug monitoring is the measurement of drug concentrations to 
optimize dosing regimens for individual patients with the objective to maximize 
efficacy and minimize toxicity [2]. Criteria for a drug to be appropriate for TDM 
are: large between-subject variability, small between-occasion variability, defined 
concentration-effect relationship, small therapeutic range, available analysis method 
and no clearly defined clinical parameter that allows dose adjustments (e.g. glucose 
or INR levels) [3].
TDM can be applied by evaluating if the drug concentrations are in the therapeutic 
range, but in case of deviating concentrations, or when the therapeutic target is not 
just a concentration but e.g. an AUC, it is difficult to provide a dosing recommendation 
manually. A more robust approach to individualize dosing by TDM is the maximum 
a posteriori probability (MAP) Bayesian fitting procedure [4], which is implemented 
in various TDM software programs [5, 6]. The library of these TDM software tools 
include population parameters, SD’s and covariates based on population PK models. 
Several TDM computer tools are available. In 2012, a review of 12 software tools 
was published [5]; they differ in the number of drugs offered in the library (from 2 
151Clinical applications of popPK models of antibiotics |
5
to 180). Eight of these programs provide the option to add new drug models. Other 
differences are the availability of MAP Bayesian dosage adaptation (10/12 tools) 
and the proposal of a priori dosage regimens based on certain covariates (9/12 
tools). The authors of the review recommend that most TDM software tools can be 
improved, more specifically the interface, user friendliness, data storage capability 
and report generation.
TDM is applied to many antibiotic classes. For aminoglycosides (e.g. gentamicin, 
tobramycin and amikacin) and glycopeptides (e.g. vancomycin and teicoplanin), TDM 
has become standard clinical practice to balance efficacy and toxicity [7, 8]. For 
other groups, such as beta-lactams and fluoroquinolones, TDM is not yet commonly 
employed [7, 8]. The most important reasons that TDM is not commonly used for all 
antibiotic classes are unclear therapeutic targets, the lack of clinical outcome studies 
and the unavailability of an assay in the hospital [7-13].  
Table 1. Challenges per clinical application of population PK models. The degree of importance 
is scored with ++ (highly important), + (important), - (not applicable). The most important 
challenges are further clarified in the text.
Challenges Clinical applications of population PK models
Dosing 
evaluation of 
old antibiotics
Setting clinical 
breakpoints
Therapeutic 
drug 
monitoring
1. PK/PD targets ++ ++ ++
2. Protein binding + ++ ++
3. Site of measurement + + +
4. Clinical validation ++ + ++
5. PTA interpretation ++ ++ -
6. Population PK model selection + + ++
7. Assay availability + + ++
8. MIC accuracy and variation + + ++
Challenge 1: PK/PD targets
The optimal PK/PD target value is still not clearly defined for all antibiotics [14, 15], in 
part because this depends on its clinical indication or use. Preclinical derived PK/PD 
target values differ from clinical derived values in critically ill patients [6]. Currently, 
there is a trend towards the use of more conservative targets for critically ill patients 
than for the less critically ill. However, it may be possible that this assumption is the 
consequence of variation in MIC measurements [16]. More research in this area is 
clearly required. 
For dosing evaluation of old antibiotics, some authors use two or more targets and 
give different dosing recommendations depending on the target [17]. For example, a 
review about gentamicin [18] showed that the chosen targets in 7 simulation studies 
in adults varied between Cmax ≥ 8 mg/L, Cmax >10 mg/L, Cmax = 22 mg/L, Cmax/MIC > 8, 
Cmax/MIC ≥ 10, AUC24 70-120 mg*h/L and AUC48 > 140 mg*h/L.
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Challenge 2: protein binding
PK/PD indices and targets are (almost) always defined as free (unbound) concentrations 
whereas many assays measure total (unbound and protein bound) concentrations [19, 
20]. However, protein binding is often highly variable and hypoalbuminemia occurs 
frequently in critically ill patients [21, 22], which might lead to unreliable outcomes 
if a free concentration is calculated using a literature value for protein binding. In 
addition, protein binding can be concentration dependent and even nonlinear [23-25]. 
Challenge 3: site of measurement
Most PK/PD targets are based on blood levels. However, other body sites may be 
important as well, although the interpretation for these body sites still remains 
uncertain [26]. If there is a good correlation between plasma levels and body 
site levels this is not a major problem, as this is just a shift in target values. If the 
correlation is less predictable this may become a major issue [27]. For instance in the 
very obese patients, tissue concentrations can be much lower than expected [28].
Challenge 4: clinical validation of new dosing recommendations
Clinical validation of new dosing recommendations is often lacking. It is desirable 
that future clinical validation studies not only focus on target achievement, but also 
relate the exposure to clinical outcomes. 
A recent review about the PK/PD of gentamicin and other aminoglycosides [18] found 
that only 1 study prospectively evaluated model-based dosing recommendations to 
see what exposure actually was achieved in clinically practice [29]. 
Another example of a dosing recommendation which was hardly prospectively 
validated, is ciprofloxacin. Ciprofloxacin is a frequently prescribed fluoroquinolone. 
The pharmacodynamic target of AUC0-24/MIC >125 (or fAUC0-24/MIC >100) for 
Pseudomonas aeruginosa is well established in in vitro, animal and clinical studies [30-
32]. According to the manufacturer, for most indications, the recommended dosing 
regimen of intravenous ciprofloxacin is 400 mg twice or three times daily in patients 
with normal renal function [33, 34], which implies that the dosing frequency can be 
chosen by the prescribing physician. However, an increasing number of simulation 
studies using population PK models show that a dosing regimen of 1200 mg/day is 
necessary to attain the pharmacodynamic target of AUC0-24/MIC >125 (or 100 for 
unbound drug) for Gram-negative pathogens with an MIC ≥ 0.5 mg/L [32, 35-38]. 
A major drawback of these studies is that the dosing recommendations of 400 mg 
q8h for MICs ≥ 0.5 mg/L were based on simulations and not prospectively validated. 
The majority of the study population received a daily dose of maximally 800 mg/
day. Despite the fact that these studies resulted in the same conclusion, the study 
designs were remarkable different. Some study populations were only ICU patients 
[35, 37] while other study populations also included general ward patients [32, 36, 
38]. Some studies reduced the dose in patients with impaired renal function, each 
using a different dosing algorithm [32, 36, 38], while in other studies dose reduction 
was not applied [35, 37]. Translation of these recommendations to clinical practice is 
therefore difficult. Even the EMA and FDA provide different dosing recommendations 
for ciprofloxacin in patients with impaired renal function [33, 39].
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Challenge 4: clinical validation of TDM
Despite the fact that TDM is used extensively in clinical practice, there is a paucity of 
prospective studies on the influence of TDM on clinical outcomes [7, 8, 11-13]. Also 
for antibiotics which are already in TDM programs, prospective studies are sparse [2]. 
Two prospective controlled studies about aminoglycoside TDM using Bayesian 
software showed that TDM significantly reduced nephrotoxicity, hospitalization and 
costs [40, 41]. However, these two studies were performed before the introduction 
of extended-interval dosing of aminoglycosides and might not reflect the current 
practice.
For vancomycin, two prospective controlled studies showed that TDM significantly 
reduced nephrotoxicity [42, 43]. 
A prospective controlled study including amikacin, ciprofloxacin, levofloxacin, 
ceftazidime and cefotaxime showed that TDM improved the probability of a good 
clinical outcome and pathogen eradication [44]. In this study, Bayesian software was used 
only for amikacin and the two fluoroquinolones, but not for the two beta-lactams [44].
Another prospective beta-lactam TDM study didn’t use Bayesian software to adjust 
dosing, but manually adjusted the frequency or infusion time [45]. Dosing was adjusted 
if the trough or steady state unbound concentration was below 4-5x MIC or above 
10x MIC, which happened in 74.2% of the patients [45]. A main drawback of this study 
was the calculation of free concentrations using measured total concentrations and 
literature values for protein binding, while protein binding is often highly variable 
in critically ill patients [21]. Another limitation was the unavailability of MICs for 
a major part of the study population. By using ECOFFs (EUCAST epidemiological 
cut-off value) when a pathogen was isolated but no MIC available, or a MIC based 
on local epidemiology information of a potential pathogen (when no pathogen was 
isolated), a worst case scenario was applied and dosing adjustments might have been 
unnecessary [16]. In 2018, a prospective Dutch study evaluating a Bayesian TDM 
software program of beta-lactams has begun (the DOLPHIN study [46]).
Challenge 5: PTA interpretation
PTA interpretation is not standardized. Used PTA acceptance levels vary between 
90-100% and are sometimes not even mentioned. However, it is important to realize 
that a PTA of 90% means that 10% of the patients do not attain the target for a specific 
MIC, which implicates that the probability for successful treatment is diminished. For 
new antimicrobials, the EMA indicates a PTA of 90% for dose selection [26].
The chosen MICs for the dosing recommendations should always be weighed against 
the internationally published MIC clinical breakpoints. The EUCAST uses the MIC 
values based on PTA’s of 97.5% and 99% for setting breakpoints [1]. 
Challenge 6: population PK model selection
An important aspect of reliable TDM programs is the choice of a population PK model 
which must be suitable for the patient population for which TDM is performed. Neef 
and colleagues presented a case of vancomycin MAP Bayesian adjustment where 
4 different population PK models resulted in 4 strikingly different dosing schemes 
recommendations [47], see the vancomycin example below. Another study evaluated 
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different population PK models for amikacin and also showed significant differences 
in model performance (results not shown here) [48]. 
Challenge 6: example 
This case [47] describes a 3-week-old neonate (3.6 kg, 50 cm, serum creatinine 25 
µmol/L) receiving vancomycin 70 mg every 12 h with an infusion duration of 2 h. 
Two levels were drawn before and after the third dose. Figure 1 shows the TDM 
performance of 4 models (presented in Table 2) for 4 tested dosing regimens. It is clear 
that model D has the worst fit of the measured levels. The other models have better 
fits, but model A predicts very high levels, probably due to absence of clearance in 
the model parameters. The conclusion of the authors is that model B best fit the data. 
Challenge 7: assay availability
Obviously, the availability of an assay is a limiting condition for TDM. However, the 
availability of assays differs per antibiotic and also per hospital. Most hospitals have 
assays for aminoglycosides and vancomycin [47], but assays for beta-lactams and 
fluoroquinolones are less common [19, 49]. Possible reasons preventing institutions 
to provide TDM could be the absence of a prospective clinical outcome study or the 
requirement of a chromatographic method instead of an immunoassay [49]. 
Challenge 8: MIC accuracy and variation
For dose adjustment of antibiotics based on TDM, both the measure of the 
concentration of the drug itself and the MIC of the pathogen responsible for the 
infection are necessary. However, most institutions use a single MIC determination 
which is inappropriate and can potentially cause underdosing of patients [16]. The 
accuracy and variation of MIC measurements must be carefully considered during 
this process [16].
Table 2. PK models of vancomycin, used in the TDM software presented in Figure 1 [47].
Kelm: metabolic elimination rate constant, Kelr: renal elimination rate constant, V1: volume of 
distribution central compartment, K12: distribution rate constant from central to peripheral 
compartment, K21: distribution rate constant from peripheral to central compartment, PNA: 
postnatal age (days), KKGT: Dutch Association for Quality Assessment in TDM and Clinical 
Toxicology, AHZ: Central Pharmacy of The Hague Hospitals. Reprinted with permission from 
Therapeutic Drug Monitoring [47].
 Model Kelm 
(h-1)
Kelr
(h-1 (ml/min)-1)
V1 
(L/kg)
K12 
(h-1)
K21 
(h-1)
A: Neonate < 15 PNA 0.457 ± 
0.022
- 0.46 ± 
0.23
1.5 ± 
0.75
2.6 ± 
1.3
B: Neonate > 15 PNA 0.053 ± 
0.025
0.003 ± 
0.021
0.41 ± 
0.21
1.88 ± 
1.21
3.6 ± 
2.0
C: KKGT pop model 0.01429 ± 
0.00286
0.00327 ± 
0.00109
0.21 ± 
0.042
1.12 ± 
0.028
0.48 ± 
0.12
D: Neonate AHZ 0.0086 ± 
0.0009
0.0022 ± 
0.0002
0.633 ± 
0.060
1.4357 ± 
0.1400
2.5619 ± 
0.2500
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Fitting the model to the data will provide the
individualized pharmacokinetic parameters. One reason why
different MAP Bayesian estimators with the same underlying
structural pharmacokinetic model (eg, a two-compartment
model with first order elimination) can give different
individualized parameters is related to different precision of
the model parameters. This example illustrates that the choice
of a particular model in TDM has a major impact on the
recommended dosing scheme.
CONCLUSION
Software and population model validation studies are
scarce in literature, especially for old drugs. In the process of
TDM the final dose recommendation might be dependent from
the analytical performance of the calibrators or the a priori
chosen PK-model. As a quality assessment institute, the
KKGT learned much from these cases.
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FIGURE 5. Vancomycin case displayed using four different population models: A, Model vancomycin neonate , 15 pna; B, Model
vancomycin neonate . 15 pna; C, Model vancomycin kkgt-pop; D, Model vancomycin neonate AHZ.
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Figure 1. TDM performance of 4 population models A-D (details displayed in Table 2) for 4 
tested dosing regimens for each model: 1) 50 mg/24 h continuous infusion, 2) 100 mg/24 h 
continuous infusion, 3) 25 mg/12h, 4) 10 mg/24h. Reprinted with permission from Therapeutic 
Drug Monitoring [47].
Summary and perspectives 
There is n bund nce f published population PK models hich are used to evaluate 
dosing regimens, implemented in TDM software programs or used to set clinical 
breakpoints. These applications can be helpful to optimize the efficacy-toxicity 
balance of antibiotics, but have some limitations and knowledge gaps for which future 
research is needed.  
PK/PD targets
More clarity about the optimal PK/PD target value of some antibiotics for 
specific clinical indications is required. Without a clear PK/PD target value, dosing 
recommendations from modelling and simulation studies are difficult to interpret 
and individualised dosing using TDM is hard to implement. 
Assays
Obviously, an assay to measure antibiotic concentrations is essential to provide input 
for population PK models and to use them in clinical practice. It is important to 
measure unbound concentrations of antibiotics with a large variability in protein 
binding. Currently, assays for plasma concentrations are sufficient for clinical use 
because most current PK/PD target values are based on the concentrations in the 
central compartment, although the concentration at the infection site might also be 
important. Research on this topic is ongoing.
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Population PK modelling and simulation
For reliable individual dosing recommendations in TDM programs as well as general 
dosing recommendations for specific patient groups, the choice of a population 
PK model suitable for that population is crucial. The used PTA acceptance levels in 
published dosing recommendations should be carefully considered. 
PBPK (Physiologically Based PK) modelling methods [13] and joined clinical PK and 
PD modelling methods [11] are newer modelling methods which need to be further 
explored.
Clinical validation 
It is imperative that the beneficial effects of dosing individualisation using TDM 
software be more prospectively studied. MIC accuracy and variation should be 
carefully considered during this process [16]. 
Interpretation of population PK modelling studies
Little knowledge of PK/PD and modelling prevents a good understanding of 
dosing recommendations resulting from modelling and simulation studies, clinical 
breakpoints and TDM. Therefore, good education on these topics is essential to 
improve antibiotic dosing in clinical practice.
Conclusions
Population PK models are extensively used in clinical practice to optimize antibiotic 
dosing. However, more clarity about PK/PD targets values, more clinical evaluation 
studies of model-based dosing recommendations and more clinical outcome studies 
of TDM are required.
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Optimizing antibiotic therapy is necessary in a world of increasing antimicrobial 
resistance and few new antibiotics coming into the market. Population pharmacokinetic 
(PK) models describe the behaviour of a drug in a body and can be used to improve 
dosing with the objective to maximize antibiotic efficacy and minimize resistance and 
toxicity. Figure 1 gives an overview of the different roles of population PK models 
in optimizing antibiotic therapy: by dosing (posology) evaluation, setting breakpoints 
and therapeutic drug monitoring. 
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Figure 1. The roles of population PK models in optimizing antibiotic therapy. Reprinted from 
De Velde et al [1]. 
This thesis is mainly focused on dosing evaluation of old antibiotics, as their dosing 
was developed in a period when PK/PD principles were largely unknown with less 
sophisticated PK methods than currently available. Several examples of dosing 
evaluation of old antibiotics using population PK modelling are included in this thesis. 
Additionally, the population PK modelling itself was evaluated by comparing population 
PK approaches and assessing modelling-related challenges. Recommendations on the 
(re)development of old and new antibiotics, following from the work conducted in 
this thesis, were included in a white paper of the STAT-Net group of the COMBACTE 
consortium.  
This chapter summarizes and discusses the findings of the research performed in 
this thesis. 
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Amoxicillin and clavulanic acid
In Chapter 2.1, the population pharmacokinetics of oral amoxicillin in healthy 
volunteers was described. Simulations using the population PK model were 
performed to compare the probability of target attainment (PTA) of current dosing 
regimens for a target of 40% fT>MIC (percentage of the dosing interval that the 
free concentration remains above the minimal inhibitory concentration). The main 
finding was a saturable (non-linear) absorption rate with increasing amoxicillin doses. 
The simulations showed that high doses as well as twice daily regimens are less 
favourable than regimens with lower doses and higher frequency. For example, the 
PTA and therefore the breakpoint of amoxicillin 875 mg twice daily was lower than 
the 500 mg three-times daily regimen. The main conclusion was that the current 
view of interchangeability of these regimens should therefore be reconsidered, 
because they are now considered to be equally effective in the summary of product 
characteristics (SmPC) [2].   
A population PK model of oral clavulanic acid was described in Chapter 2.2 using 
the same phase I trial data as in Chapter 2.1. The population PK analysis revealed 
that clavulanic acid concentrations were not only highly variable between patients, 
but also varied between the three daily doses per patient, despite that the food 
intake was the same around each dose. The population PK model showed that the 
bioavailability and absorption rate decreased over the day. For the simulations using 
the population PK model, both %fT>Ct and fAUC were calculated because the PK/
PD index and target were (and are) still unknown for clavulanic acid combined with 
amoxicillin. A recent paper about clavulanic acid combined with ceftibuten in a murine 
model reported that the PK/PD index %fT>Ct with a threshold concentration (Ct) 
of 0.5 mg/L best correlated with efficacy and that 20% fT>0.5mg/L was correlated 
with the static endpoint [3]. Our simulations in Chapter 2.2 showed that 20% 
fT>0,5mg/L was achieved with 125 mg three times daily by 95% of the population. 
However, as few information about the PK/PD targets of beta-lactamase inhibitors 
is available, it is unknown if the clavulanic acid-ceftibuten results can be extrapolated 
to clavulanic acid-amoxicillin. When the new evidence about the target becomes 
available, our population PK model can be used to further evaluate the current dosing 
regimens to optimize efficacy and prevent underdosing. More research regarding the 
target of clavulanic acid is clearly required. We did not find any significant effect of 
the amoxicillin dose on clavulanic acid PK during population PK modelling, but the 
literature of the interaction between both compounds is not conclusive. Recent 
reviews [4, 5] indicate that also for other combinations of beta-lactams and beta-
lactamase inhibitors, the interactions are not clear. Investigating these interactions 
becomes even more important because new combinations with old beta-lactams and 
new beta-lactamase inhibitors are increasingly studied [6]. Studying these interactions 
is also included in the EMA guideline on PK/PD of antimicrobials [7]. 
Chapter 2.3 included a smaller PK study of intravenous amoxicillin/clavulanic acid in 
patients with and without renal impairment. In all patients, the amoxicillin target of 40% 
fT>MIC for MIC 8 mg/L was achieved, concluding that amoxicillin 1000 mg four times 
daily is sufficient in both populations. However, the %fT>MIC was significantly higher 
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in the renally impaired patients due to prolonged half-lives, which raised the question 
whether their dosing is not unnecessary high. More research is necessary to determine 
the upper amoxicillin concentration limit. Additionally, after the clavulanic acid target 
becomes clear, the clavulanic acid dosing in renal impairment should be reassessed.
We used a PK/PD target of 40% fT>MIC in both amoxicillin studies, similar to the 
target in the amoxicillin EUCAST rationale document [8] and in the EMA background 
documentation on harmonizing the amoxicillin/clavulanic acid SmPC [9]. Importantly, 
this target is primarily based on Streptococcus pneumoniae and Haemophilus influenzae 
in patients with otitis media and on preclinical studies with Enterobacterales [8, 10]. 
Amoxicillin (or another penicillin) exposure-response relationships for Enterococcus 
species, as well as clinical studies on Enterobacterales, are currently unknown. In 
absence of a better alternative, the 40% fT>MIC target is also used for Enterococcus 
species and Enterobacterales [11]. It is important to realize that this is an extrapolation 
from other microbiological species and primarily derived from one indication. More 
research on exposure-response relationships of amoxicillin is clearly required to 
further optimize dosing: not only for the monotherapy, but also for the combination 
with clavulanic acid.  
Imipenem
In Chapter 3.1, a parametric and a nonparametric population PK model were 
described for imipenem in critically ill patients. Both models had the same structure 
and the included covariate (absolute CKD-EPI eGFR on Ke) was identical. The 
parameter estimates were comparable except for the estimated between-subject 
variability, which was higher in the nonparametric model. The consequences of this 
finding were further explored by simulations using both population PK models, which 
were performed for three dosing regimens and three eGFRs (90, 120 and 150 ml/
min). The simulations and PTA’s for 50% fT>MIC and 100% fT>MIC were described 
in Chapter 3.2. Half of the PTA results were similar for both models, while for the 
other half those of the nonparametric model resulted in lower MICs. These different 
PTA results may lead to different dosing advices, e.g. decreased dosing following the 
parametric model and increased dosing following the nonparametric model. This 
finding was explained by the higher estimated between-subject variability of the 
nonparametric model. The simulations of both models indicated that 1000 mg four 
times daily is suitable to reach MICs of 2 mg/L in critically ill patients with eGFRs 
of 90-120 ml/min, using the 50% fT>MIC target. However, for MICs of 2 mg/L and 
an eGFR of 150 ml/min, and for MICs of 4 mg/L, dosing recommendations could 
not be given due to largely different PTA values per model (e.g. 1000 mg q6h, eGFR 
90 ml/min, MIC 4 mg/L: PTA 90% using the parametric model and 63% using the 
nonparametric model). More research on the differences between both modelling 
methods and associated simulations is clearly needed. Besides the simulations, 
Chapter 3.2 also included an external validation of both population PK models. 
The external predictive performance of both models was adequate for subjects with 
high eGFRs but insufficient for low eGFRs. This was explained by a lack of subjects 
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with renal impairment in the modelling population. Due to this finding, the previous 
mentioned simulations were only performed for eGFRs higher than 90 ml/min. This 
finding emphasizes the importance of external validation of population PK models 
to confirm or preclude the use of a certain population PK model with the objective 
to optimize dosing for a specific population. 
The two PK/PD targets (50% and 100% fT>MIC) for the imipenem simulations 
were based on the findings of a large prospective study on beta-lactam exposure-
relationships in an ICU population [12]. The dosing recommendations following from 
our imipenem study were based on the 50% fT>MIC target because the regression 
analysis of the original study indicated that an elevated target of 100% fT>MIC might 
not be necessary in this particular ICU population. The imipenem PK/PD targets 
in EUCAST and EMA documents vary between 30-40% fT>MIC (EMA background 
documentation on harmonizing the imipenem SmPC [13]) and 40-50% fT>MIC 
(EUCAST imipenem rationale document [14]), although these are not developed 
for ICU patients which might need higher targets [15]. Other imipenem simulation 
studies in ICU patients used targets of 20-100% fT>MIC [16-18], but they did not 
analyse exposure-relationships. Similar to our conclusions of the amoxicillin study, 
we recommend that more research on imipenem exposure-relationships is needed 
to further optimize dosing. 
White paper on (re)development of new and old 
antibiotics 
As a member of the STAT-Net group of the European COMBACTE consortium, we 
contributed to two recommendations on evaluation of new and old antibiotics in 
STAT-Net’s white paper (included in Chapter 4). A third recommendation of the 
white paper was written by other STAT-Net members than the Dutch team, but is 
also PK/PD related and therefore highly relevant for this thesis. 
Recommendation 1: We recommend that phase II and III clinical trials of new antibiotics, 
particularly those active against MDROs, always apply population PK models to describe 
and explain PK variability, optimize dose finding, and evaluate outcome data relative to 
exposure.
The first recommendation is in alignment with current EMA guidelines [7] and FDA 
guidance’s [19]. However, a complete pharmacometric analysis with population PK 
modelling, evaluation of exposure-response relationships and PTA simulations is not 
yet fully applied for all recently approved antibiotics. This was again mentioned in a 
recent minireview resulting from an NIH workshop [20] and very clearly illustrated 
by Paul Ambrose with 4 examples of antibiotic development failures due to PK/PD 
shortcomings [21]. 
Recommendation 2: We recommend a EU–coordinated regulatory procedure for 
reassessment of old antibiotics and their licensing, particularly those active against MDROs, 
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which addresses justification of dosing regimens and exposure-response data according to 
modern PK/PD principles. This should include description of PK/PD targets, development of 
population PK models, and reassessment of antibacterial spectra.
Many antibiotics were approved long before PK/PD principles were known and 
sophisticated population PK modelling approaches existed, and their dosing 
regimens may therefore not be optimal. Reanalysis of old PK data (such as our work 
on amoxicillin in Chapter 2.1 and clavulanic acid in Chapter 2.2) or organizing 
new PK studies for old drugs can be performed to investigate PK variability and 
exposure. However, as PK/PD targets for old drugs are often still lacking (such as 
for clavulanic acid), it can be cumbersome to formulate dosing recommendations. 
Future research should focus on this knowledge gap. A second problem is that a 
coordinated redevelopment programme is currently unavailable, although some EU 
and NIH projects are set up [22]. The Committee for Medicinal Products for Human 
Use (CHMP) of the EMA performs “article 30 referrals” to harmonise indications, 
posology and contra-indications in European SmPC’s [9, 13, 23]. For amoxicillin, 
clavulanic acid and imipenem, referrals are available, but these were not included in 
the respective chapters in this thesis. Therefore, the posology and PK/PD information 
in the referrals of amoxicillin, amoxicillin/clavulanic acid and imipenem are discussed 
below. 
For amoxicillin (both oral and intravenous), the assessment report of the article 30 
referral procedure was published in 2015 [23]. Their recommendation to dose three 
times daily (TID) matches with the conclusion of our amoxicillin study in Chapter 
2.1. However, despite that the vast majority of the clinical trials was conducted with 
the TID regimen, the referral document states that twice daily (BID) dosing can be 
still an option in patient groups in which TID dosing may give compliance problems. 
The BID regimen as an alternative for TID dosing remained therefore in the SmPC. 
Based on our results in Chapter 2.1, we would recommend to remove BID dosing 
as an alternative for TID dosing from the SmPC. We are specifically concerned about 
BID dosing in patients with compliance problems, because the effect of one missed 
dose has even more effect with BID dosing compared to more frequent regimens. 
It was defined that the harmonised dosing recommendations were based on the 
doses studied in clinical trials and supported by PK/PD data, but, unfortunately, very 
few details about the PK/PD data are given (e.g. no PK/PD targets and unclear if 
population PK methods were used). Remarkably, section 5.2 about PK properties 
in the SmPC only includes Cmax, Tmax, AUC, t1/2 and urine recovery, while trough 
levels and fT>MIC values are missing but clearly more relevant. The posology for 
renally impaired patients was only based on small studies from 1975-1979 [24-26] 
without assessing trough levels or %fT>MIC.  
The article 30 referral documents for amoxicillin/clavulanic acid (both oral and 
intravenous) were published in 2009 [9]. The amoxicillin PK/PD target (T>MIC 
40%) is mentioned in the combination referral, although it is unclear if free or total 
concentrations are meant. The breakpoints for oral amoxicillin are higher than 
those calculated with our population PK model: 250/125mg TID 1 mg/L versus 0.25 
mg/L, 500/125mg TID 2 mg/L versus 0.5 mg/L, 875/125 mg TID 2-4 mg/L versus 
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1 mg/L, possibly due to a lower PTA cut-off value (not specified in the referral). 
For renally impaired patients, the 4:1 (500/125 mg) regimen is recommended based 
on therapeutic clavulanic acid concentrations, although it is unclear which target 
concentrations are meant as they were not mentioned. 
For imipenem, the referral documents were published in 2011 [13]. Dosing was 
evaluated using data of clinical trials as well as by Monte Carlo simulations based 
on a population PK model (NONMEM). The described PTA’s were higher than our 
findings due to a lower PK/PD target (fT>MIC 40% vs. fT>MIC 50%) and because 
no ICU patients were included, who have often a higher distribution and thus lower 
antibiotic concentrations. However, the referral’s conclusions were comparable to 
our NONMEM model for patients with normal renal function: 500 mg four times 
daily (QID) and 1000 mg TID have similar drug exposure and 1000 mg QID is 
recommended for very severe infections and less susceptible pathogens (i.e. MIC 
4 mg/L). For renally impaired patients, the posology in the referral was based on 
a study with 17 patients, but it is unclear if population PK methods were used. 
In 2018, the marketing authorisation holder performed another population PK 
analysis (NONMEM) for imipenem using data of the new drug imipenem/cilastatin/
relebactam [27]. Dosing regimens in renal insufficiency were updated in the SmPC of 
imipenem/cilastatin based on model simulations and a lower target of fT>MIC 30%.
The main conclusion about these referrals is that population PK analyses are 
occasionally performed to optimize dosing and the PK/PD evidence in the underlying 
documents is often unclear. Of course, the objective of article 30 referral procedures 
is to harmonise SmPC’s across Europe, and not to redevelop the old drugs. A 
coordinated redevelopment procedure for old antibiotics is still necessary. 
Recommendation 3: We recommend that future clinical PK/PD studies provide more robust 
results by a priori determination of the sample size, adjustment for known confounders of 
the exposure-response relationship, assessment of both microbiological and patient-oriented 
outcomes, and application of appropriate statistical techniques.
The third recommendation of the white paper was based on a draft review about 
PK/PD targets, both prepared by STAT-Net members from Bristol (UK). Recently, 
this review has been published [28]. For beta-lactams, they included 20 clinical PK/
PD studies, precluding all studies that did not measure MICs for all patients. Of note, 
half of these 20 studies did not perform or report statistical analysis. The majority 
(7) of the remaining 10 studies investigated cephalosporines, while penicillins (1) and 
carbapenems (2) were much less frequently reported. The current EMA guideline on 
PK/PD of antibiotics [7] “does not attempt to provide detailed guidance on issues 
such as methodologies for modelling and simulation”. However, the results of this 
review [28] indicate again that coordinated reassessment of PK/PD targets is needed 
to justify antibiotic dosing.
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Challenges of population PK models in clinical practise 
While this thesis was mainly focused on dosing evaluation of old antibiotics using 
population PK models, these models are also used to set clinical breakpoints and 
in therapeutic drug monitoring (TDM) software. We summarized challenges of 
population PK models in clinical practise in a review (Chapter 5). Main challenges 
were knowledge gaps regarding PK/PD targets for all antibiotics, clinical evaluation 
studies of model-based dosing recommendations and clinical outcome studies of 
TDM.
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Introduction
In this chapter, general perspectives for future research and practical recommen-
dations for clinicians to assess population PK models are described.
General perspectives for future research
The following 4 general perspectives for future research were established, following 
from the work performed in this thesis and supported by recently published literature.
1. Reassessment of PK/PD targets for effectivity, toxicity and resistance
PK/PD targets of old antibiotics should be reassessed because proper exposure-
response studies are lacking for many of these drugs [1, 2].There should not only 
be a focus on targets for effectivity, but also for toxicity (see Chapter 2.3) and 
resistance. Special attention should be given on the differences between beta-lactam 
groups (i.e. penicillins, cephalosporins, carbapenems [3]), targets of beta-lactamase 
inhibitors [4, 5] and special populations such as ICU patients [6]. Additionally, the 
differences in targets between prophylactic and therapeutic indications should be 
further examined. 
A coordinated regulatory procedure for reassessment of the dosing of old antibiotics, 
including refining of PK/PD targets, is highly needed. Preferably, private funding at a 
European level should be used to set up such a project [7].   
2. Development of population PK models for beta-lactam/beta-
lactamase inhibitor (BL/BLI) combinations
Although we could not find evidence for an interaction between amoxicillin and 
clavulanic acid (Chapter 2.2), the influence of the interaction between the two 
compounds is not yet clear for this and other combinations [4, 5]. Given the 
redevelopment of old beta-lactams as a combination with new beta-lactamase 
inhibitors [8], this topic is increasingly important and should be further investigated. 
The EMA guideline on PK/PD of antimicrobials [9] instructs to develop population 
PK models for BL/BLI combinations to support dosing simulations. 
A recent review on semi-mechanistic PK/PD models of antibiotic drug combinations, 
based on in vitro experiments, identified 13 publications of which 1 BL/BLI combination 
[10]. No publications of PK/PD antibiotic interaction models based on clinical data 
could be found [10].
3. Further exploring PK/PD modelling approaches
Chapter 3 illustrated the similarities and differences between a parametric and a 
nonparametric model developed with the same data. Main difference was a higher 
between-subject variability in the nonparametric model. Currently, most population 
PK models are developed with parametric modelling approaches. One should be 
aware that the between-subject variability could be lower than estimated with a 
nonparametric model. The differences between parametric and nonparametric 
modelling needs to be further investigated. 
Although population PK modelling is currently the cornerstone of the pharmacometric 
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framework, other pharmacometric approaches are also increasingly used during drug 
(re)development. Quantitative Systems Pharmacology (QSP) and Physiologically 
Based PK (PBPK) models integrate drug physiochemical and human physiological 
parameters into mathematical models [11, 12]. Key challenge of these models is the 
estimation of numerous physiological parameters. Recently, EMA and FDA guidelines 
on PBPK modelling have been published [13, 14]. 
4. Improvement of validation and evaluation of population PK models
The importance of an external validation of a population PK model has been shown 
in the imipenem study described in Chapter 3.2. Additionally, a model should be 
prospectively clinically evaluated [15]. Preferably, a prospective evaluation is not only 
focused on target achievement, but also on clinical outcome. However, there are 
few prospective studies evaluating the effects of TDM (using population PK models) 
or dosing strategies (based on these models) on clinical outcomes, as described in 
Chapter 5 and in other recent papers [16]. An important aspect in these studies 
is the use of measured MICs. In the often referenced DALI-study [17], for only 
34% of the patients an actual MIC was available and for the rest of the patients an 
assumption was necessary (which is often a worst case scenario). Fortunately, more 
recent studies do include actual MICs [18]. However, the use of a MIC obtained by a 
single determination is considered inappropriate and MIC variation should be taken 
in account [19, 20]. 
Practical recommendations for clinicians to assess population PK 
models
There is an abundance of published population PK models which are used to 
evaluate dosing regimens, implemented in TDM software programs or used to 
set clinical breakpoints. These applications can be helpful to optimize the efficacy-
toxicity balance of antibiotics, but have some limitations and knowledge gaps. 
For reliable individual dosing recommendations in TDM programs as well as safe 
implementation of general dosing recommendations for specific patient groups, the 
choice of a population PK model suitable for that population is crucial. Therefore, 
the following recommendations to assess population PK models were composed for 
clinicians. When one is reading a paper about a population PK model and considering 
to implement this model in the local TDM software and/or to use the dosing 
recommendations in the hospital, the following aspects are recommended to assess:
1. The modelling population should be as similar as possible to the local 
population. Models based on ICU patients should not be used for non-ICU 
patients, and vice versa. 
2. An external validation of the population PK model and a prospective 
evaluation of dosing strategies or TDM should be performed to make sure that 
model-based dosing recommendations are robust.  
3. The sample size of the populations used for modelling, validation and evaluation 
should be adequate. The sample size for modelling and validation depends on 
the number of subjects as well as the number of PK samples (per patient and 
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per time point) [21, 22]. Sparse PK sampling at few timepoints can be a problem 
when the number of patients is low. Sample size calculations of TDM evaluation 
studies result in general in a few hundreds of subjects [23-26].
4. The used PK/PD target should be suitable for population and indication.
5. The used PTA acceptance level should be considered, although unfortunately 
not always mentioned in publications. The EMA guideline on PK/PD in 
antimicrobial development recommends a PTA > 90% for dose selection [9], 
while the EUCAST uses PTA > 97.5% for breakpoint setting [27]. It is important 
to realize that with a 90% level, 1 of 10 patients will not achieve therapeutic 
concentrations. 
6. The used population PK approach should be assessed. Results of nonparametric 
models can show higher between-subject variability compared to parametric 
models.
7. In case of eGFR covariates: the used eGFR equation should be assessed and one 
should be aware of differences because they are not completely interchangeable. 
8. The use of measured MICs should be checked. When EUCAST cut-off values 
(ECOFFs) are included instead of measured MICs, this may be a worst case 
scenario with possibly low PTAs. In case of measured MICs, accuracy and 
variation should be carefully considered [19]. 
9. The used assay and the measurement of total or free concentrations should 
be assessed. Analysis of free concentrations may be more appropriate in case of 
high protein binding and/or a high variation in protein binding. 
Overall, good education regarding interpretation of population PK studies and 
MIC-based dosing is essential to improve antibiotic dosing in clinical practice. 
Little knowledge of PK/PD and modelling prevents a good understanding of 
dosing recommendations resulting from modelling and simulation studies, clinical 
breakpoints and TDM. 
Conclusions of this thesis
This thesis studied the dosing evaluation of old beta-lactam antibiotics using 
population PK models. The amoxicillin/clavulanic acid results revealed highly relevant 
PK issues that were not found during the original phase I studies. Amoxicillin high dose 
twice daily regimens are less favourable than regimens with lower doses and higher 
frequencies, contrary to the SmPC that qualifies these regimens as interchangeable. 
The imipenem results provided more insight to the similarities and differences 
between parametric and nonparametric modelling approaches. PTA’s calculated 
from simulations using parametric population PK models might be higher than those 
from nonparametric models; the truth is probably somewhere in between. Practical 
recommendations for clinicians to assess population PK models were formulated.
The following general perspectives for future research were established:
1. Reassessment of antibacterial PK/PD targets for effectivity, toxicity and 
resistance
2. Development of population PK models for beta-lactam/beta-lactamase inhibitor 
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combinations
3. Further exploring PK/PD modelling approaches
4. Improvement of validation and evaluation of population PK models
In conclusion, given the global problem of increasing antibacterial resistance, a 
coordinated redevelopment procedure for dosing optimization of old antibiotics using 
PK/PD principles is urgently needed, with a particular priority to the reassessment 
of PK/PD targets. 
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Infectieziekten, bacteriën en resistentie
Infectieziekten worden veroorzaakt door ziekteverwekkers zoals bacteriën, virussen, 
schimmels of parasieten. Antibiotica worden gebruikt voor de behandeling van 
infectieziekten die door bacteriën worden veroorzaakt. Helaas kunnen bacteriën 
resistent worden voor antibiotica waardoor deze niet meer goed de infectie kunnen 
bestrijden. Antibacteriële resistentie is wereldwijd steeds groter wordend probleem 
door veelvuldig en onjuist gebruik van antibiotica. Voor de behandeling van resistente 
bacteriën zijn nieuwe antibiotica of hogere doseringen van oude antibiotica nodig. 
Er zijn echter weinig nieuwe antibiotica op de markt gekomen de afgelopen jaren. 
Achteraf gezien bleek dat voor sommige antibiotica in de onderzoeksfase te lage 
doseringen zijn gebruikt, waardoor deze niet effectief genoeg waren om de infectie 
te bestrijden. Daarnaast is het een bekend probleem dat er voor veel geneesmiddelen 
slechts één dosisadvies beschikbaar is voor een grote groep mensen terwijl er veel 
variatie is binnen die groep, waardoor deze vaste dosis bij sommige mensen leidt tot te 
lage geneesmiddelconcentraties in het lichaam en bij andere mensen juist tot te hoge 
concentraties. 
Het toenemende resistentieprobleem en de problemen bij de ontwikkeling van nieuwe 
antibiotica laten zien dat het belangrijk is om de doseringen van oude en nieuwe antibiotica 
te optimaliseren. Voor de optimalisatie van doseringen kunnen farmacokinetische en 
farmacodynamische (PK/PD) studies worden gebruikt. Farmacokinetiek (PK) beschrijft 
wat het lichaam doet met een geneesmiddel en omvat de processen absorptie, verdeling, 
metabolisme en uitscheiding. Farmacodynamiek (PD) beschrijft wat het geneesmiddel 
doet met het lichaam; in het geval van antibiotica wordt beschreven wat dit middel 
doet met de bacteriën in het lichaam (bijvoorbeeld het remmen van bacteriële 
groei). Populatie PK modellen beschrijven de concentraties van het geneesmiddel in 
een bepaalde populatie en verklaren de verschillen tussen individuele concentraties. 
Dosisevaluatie van antibiotica kan plaatsvinden door simulaties van deze populatie PK 
modellen te combineren met PD effectmaten. De toepassing van deze modellen wordt 
in de huidige internationale richtlijnen aangeraden voor dosisoptimalisatie tijdens de 
ontwikkeling van nieuwe antibiotica, maar ze zijn niet of nauwelijks gebruikt tijdens 
de ontwikkeling van oude antibiotica decennia geleden omdat deze populatie PK 
methoden en de huidige PK/PD kennis toen nog niet bestonden.
Het voornaamste doel van dit proefschrift was de evaluatie van de juistheid van 
doseringen van oude antibiotica door het ontwikkelen van populatie PK modellen. Ook 
zijn twee methoden voor het maken van populatie PK modellen met elkaar vergeleken, 
namelijk parametrische en non-parametrische technieken. Daarnaast zijn uitdagingen 
bij het proces van dosisevaluatie met behulp van populatie PK modellen geïdentificeerd 
en aanbevelingen voor het gebruik van deze modellen tijdens geneesmiddelontwikkeling 
en in de klinische praktijk opgesteld. 
Amoxicilline en clavulaanzuur
Hoofdstuk 2 bevat drie PK/PD studies naar amoxicilline en clavulaanzuur. Amoxicilline 
is een penicilline en behoort tot de groep van beta-lactam antibiotica. Clavulaanzuur 
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is een beta-lactamase remmer. Beta-lactamases zijn enzymen die bacteriën resistent 
maken tegen beta-lactam antibiotica. Amoxicilline wordt gecombineerd met 
clavulaanzuur bij infecties met beta-lactamase producerende bacteriën, maar kan 
ook alleen worden toegediend. Beide middelen zijn al meer dan 30 jaar beschikbaar 
en hun doseringen zijn destijds ontworpen zonder het gebruik van populatie PK 
modellen. In het kader van dit proefschrift zijn populatie PK modellen ontwikkeld 
voor orale amoxicilline (Hoofdstuk 2.1) en clavulaanzuur (Hoofdstuk 2.2) in gezonde 
proefpersonen die amoxicilline/clavulaanzuur tabletten kregen. Voor amoxicilline werd 
gevonden dat de absorptie verzadigbaar was met toenemende doseringen. Vervolgens 
zijn verschillende amoxicilline doseringen onderzocht met behulp van simulaties van 
het model, waarmee werd berekend wat de waarschijnlijkheid van het bereiken van de 
PK/PD streefwaarde was. Als PK/PD streefwaarde werd in deze studie 40% fT>MIC 
gebruikt, wat inhoudt dat de niet eiwitgebonden geneesmiddelconcentratie boven 
een bepaalde MIC (minimaal remmende concentratie van het antibioticum, bepaald 
in het microbiologisch laboratorium) moet liggen gedurende minimaal 40% van het 
doseerinterval. Bij het bereiken van deze PK/PD streefwaarde, die in eerdere studies 
is bepaald, is er een hoge waarschijnlijkheid van succesvolle behandeling. Voor een 
hoge effectiviteit van beta-lactam antibiotica, zoals amoxicilline, is het belangrijk om 
frequent te doseren gedurende de dag. Dit blijkt ook uit de belangrijkste conclusie van 
deze studie, namelijk dat twee maal daags 875 mg niet uitwisselbaar is met drie maal 
daags 500 mg, in tegenstelling tot wat in de bijsluiter van amoxicilline/clavulaanzuur 
wordt genoemd. Voor clavulaanzuur werd gevonden dat de clavulaanzuur absorptie 
gedurende de dag afnam, waardoor concentraties in de ochtend hoger waren dan in 
de avond. Er konden helaas geen doseeradviezen worden opgesteld voor clavulaanzuur, 
aangezien (nog steeds) onbekend is wat de PK/PD streefwaarde is voor een hoge 
waarschijnlijkheid van succesvolle behandeling. 
Hoofdstuk 2.3 beschreef de farmacokinetiek van intraveneuze amoxicilline in 
patiënten die behandeld werden met amoxicilline/clavulaanzuur infusen. Dit onderzoek 
werd gedaan om de amoxicilline dosering te evalueren voor zowel patiënten met 
verminderde nierfunctie als patiënten met normale nierfunctie. Met vier maal daags 
1000 mg amoxicilline werd de PK/PD streefwaarde van 40% fT>MIC behaald voor beide 
patiëntengroepen. In patiënten met een verminderde nierfunctie waren de amoxicilline 
concentraties echter veel hoger dan in patiënten met een normale nierfunctie. Op 
dit moment wordt alleen een ondergrens van amoxicilline concentraties (fT>MIC) 
gehanteerd, maar het is onbekend wat de bovengrens is. Hier dient meer onderzoek 
naar te worden verricht. 
Imipenem
Hoofdstuk 3 gaat over het intraveneuze beta-lactam antibioticum imipenem, dat 
beschikbaar is sinds de jaren 80. In Hoofdstuk 3.1 werd de ontwikkeling van en 
vergelijking tussen een parametrisch en een non-parametrisch populatie PK model van 
imipenem in kritisch zieke patiënten (opgenomen op de intensive care) beschreven. 
Deze vergelijking werd gedaan omdat er weinig bekend is over de verschillen tussen 
beide methoden. Parametrische populatie PK methoden gaan uit van een bekende 
verdeling van populatie parameters, terwijl non-parametrische methoden geen 
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aanname doen over deze verdeling. Bij de twee imipenem modellen zijn geen verschillen 
gevonden in structuur en covariaten. De parameter schattingen waren vergelijkbaar 
met uitzondering van de interindividuele variabiliteit, die hoger was voor het non-
parametrische model. In Hoofdstuk 3.2 zijn deze modellen vervolgens gevalideerd 
met een tweede database en tevens zijn ze gebruikt voor simulaties ter evaluatie van 
verschillende doseringen. De externe validatie liet zien dat de twee modellen geschikt 
waren voor patiënten met een goede nierfunctie, maar dat ze niet geschikt waren 
voor patiënten met een verminderde nierfunctie. Dit kon verklaard worden omdat 
de modellen waren gebouwd met weinig patiënten met een verminderde nierfunctie. 
De doseringssimulaties werden vervolgens alleen uitgevoerd voor patiënten met een 
goede nierfunctie. Vijftig procent van deze doseringssimulaties gaf dezelfde resultaten 
voor beide modellen, terwijl de andere helft verschillend was. Deze verschillende 
resultaten leidden tot andere doseeradviezen, waarbij volgens het non-parametrische 
model hoger gedoseerd moest worden dan voor het parametrische model. Dit werd 
verklaard door een hogere interindividuele variabiliteit van het non-parametrische 
model. 
Aanbevelingen voor de (her)ontwikkeling van antibiotica
Als deelnemer aan het Europese consortium COMBACTE (Combatting Bacterial 
Resistance), heeft de auteur van dit proefschrift bijgedragen aan een publicatie met 
aanbevelingen voor ontwerp en analysestrategieën om nieuwe en oude antibiotica te 
evalueren (Hoofdstuk 4). De twee PK/PD aanbevelingen opgesteld door de auteur van 
dit proefschrift waren: 
1) dat altijd populatie PK modellen moeten worden gebruikt tijdens klinisch 
onderzoek met antibiotica om PK variabiliteit te verklaren, doseringen te 
optimaliseren en de concentratie-effect relaties te evalueren, en
2) dat een Europese procedure moet worden opgezet voor de herontwikkeling van 
oude antibiotica met als doel de optimalisatie van doseringen met populatie PK 
modellen, de evaluatie van concentratie-effect relaties en voor het vaststellen van 
PK/PD streefwaarden. 
In het kader van dit proefschrift is de onderbouwing van de doseringen in de bijsluiters 
van amoxicilline, amoxicilline/clavulaanzuur en imipenem nader bekeken. Ondanks dat 
deze bijsluiters recent nog zijn herzien, bleek dat deze doseringen niet altijd waren 
gebaseerd op populatie PK modellen en dat de gehanteerde PK/PD streefwaarden 
vaak onduidelijk waren. 
Gebruik van populatie PK modellen in de klinische praktijk
Populatie PK modellen worden niet alleen gebruikt tijdens geneesmiddelenonderzoek, 
maar ook in de klinische praktijk. Naast evaluatie van algemene doseerstrategieën 
(wat dit proefschrift voornamelijk behandelt), worden de modellen ook gebruikt voor 
het vaststellen van klinische breekpunten (die worden gebruikt in microbiologische 
laboratoria) en voor het geven van individuele doseeradviezen op basis van gemeten 
concentraties in het bloed. In Hoofdstuk 5 werden diverse uitdagingen bij het gebruik 
van deze modellen in de klinische praktijk beschreven. De belangrijkste uitdaging is 
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gebrek aan (duidelijke) PK/PD streefwaarden, klinische studies ter evaluatie van 
populatie PK model gebaseerde doseerstrategieën en klinische studies ter evaluatie 
van individuele doseeradviezen op basis van gemeten concentraties in het bloed.
Aanbevelingen voor het gebruik van populatie PK modellen in de klinische 
praktijk
Na een samenvattende discussie in Hoofdstuk 6, worden in Hoofdstuk 7 
aanbevelingen gegeven voor apothekers, artsen en anderen die populatie PK 
modellen uit de literatuur gebruiken voor dosisoptimalisatie van antibiotica in de 
klinische praktijk:
1) De populatie die gebruikt is voor het bouwen van het model dient zo veel 
mogelijk gelijk te zijn aan de lokale populatie waarvoor het model beoogd is.
2) Een externe validatie van het model en een prospectieve evaluatie van de 
dosisadviezen dienen te zijn uitgevoerd om te verifiëren of het model robuust is. 
3) Het aantal patiënten en het aantal monsters per patiënt, gebruikt om het model 
te bouwen, moeten voldoende hoog zijn. 
4) De gebruikte PK/PD streefwaarde moet geschikt zijn voor de populatie en de 
indicatie.  
5) De gebruikte afkapwaarde voor de waarschijnlijkheid van het bereiken van deze 
PK/PD streefwaarde moet hoog genoeg zijn. 
6) De gebruikte populatie PK methode moet worden beoordeeld. Non-
parametrische modellen kunnen een hogere interindividuele variabiliteit laten 
zien dan parametrische modellen, wat kan leiden tot andere doseeradviezen. 
7) In het geval dat nierfunctie een covariaat is, moet de gebruikte nierfunctie 
formule worden beoordeeld. Deze formules zijn niet altijd goed onderling 
uitwisselbaar. 
8) De methode voor het vaststellen van MICs moet worden beoordeeld. Bij 
gemeten MICs moeten de juistheid en variatie worden bekeken. Bij populatie 
MICs moet rekening worden gehouden met een onderschatting van de 
waarschijnlijkheid van het bereiken van de PK/PD streefwaarde. 
9) De gebruikte analysemethode en de meting van totale of alleen ongebonden 
concentraties moet worden beoordeeld. 
Aanbevelingen voor vervolgonderzoek
De volgende aanbevelingen voor vervolgonderzoek werden opgesteld:
1) Herbeoordeling van PK/PD streefwaarden voor effectiviteit, toxiciteit en 
resistentie van antibiotica, bij voorkeur door middel van een Europees 
gecoördineerde procedure. 
2) Ontwikkeling van populatie PK modellen voor combinaties van beta-lactam 
antibiotica met beta-lactamase remmers. 
3) Meer onderzoek naar de verschillen tussen de diverse methoden voor het 
ontwikkelen van PK/PD modellen, zoals  parametrische en nonparametrische 
populatie PK methoden. 
4) Verbetering van validatie en evaluatie van populatie PK modellen. 
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Conclusies van dit proefschrift
In dit proefschrift zijn diverse voorbeelden van dosisevaluatie van oude beta-lactam 
antibiotica met behulp van populatie PK modellen opgenomen. De amoxicilline/
clavulaanzuur studies lieten relevante PK informatie zien die niet tijdens de 
geneesmiddelontwikkeling waren opgemerkt. Ons onderzoek liet zien dat twee 
maal daags een hoge dosis amoxicilline minder gunstig is dan drie maal daags een 
lagere dosis, in tegenstelling tot de bijsluiter die beide als evenwaardig beschouwt. 
De imipenem studies hebben meer inzicht gegeven in de gelijkenissen en verschillen 
tussen parametrische en nonparametrische populatie PK methoden. Sommige 
verschillen leidden tot andere doseeradviezen, waarbij volgens het non-parametrische 
model hoger gedoseerd moest worden dan volgens het parametrische model. 
Aanbevelingen voor het beoordelen van populatie PK modellen in de literatuur en 
voor vervolgonderzoek zijn opgesteld. 
Gezien het wereldwijde probleem van antibacteriële resistentie en het gebrek aan 
nieuwe antibiotica, is een gecoördineerde procedure voor de herontwikkeling van 
oude antibiotica dringend nodig, waarbij de herbeoordeling van PK/PD streefwaarden 
prioriteit zou moeten hebben.
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kan niemand anders bedenken die dit beter had kunnen doen. 
Prof.dr. Knibbe, prof.dr. Spriet en prof.dr. Verbon, hartelijk dank voor het beoordelen 
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Prof.dr. Guchelaar, dr. van Hest en dr. de Winter, veel dank voor het plaatsnemen in 
de grote commissie op 14 oktober. 
Alle modellers van het wekelijkse nonmem overleg (Brenda, Louise, Linda, Rixt, Johan, 
Anouk, Birgit, Stijn, Sabine, Willem Jan, Sanne) wil ik bedanken voor hun hulp bij het 
bouwen van de modellen. Brenda: bedankt voor je geduld tijdens het beantwoorden 
van al mijn waarom vragen. Je hebt me samen met Linda en Rixt enorm verrast 
met een vrijgezellenfeestje in Lissabon tijdens het PAGE congres. Ook aan PAGE in 
Chersonissos en IATDMCT in Kyoto bewaar ik mooie herinneringen met jullie en 
anderen.
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Prof.dr. Neely, dear Michael, it was such a pleasure to visit your lab in the spring of 
2017. Thank you very much for the hospitality and all scientific discussions. Prof.dr. 
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